{
  "responseHeader":{
    "status":0,
    "QTime":8,
    "params":{
      "q":"(Background: head and neck squamous cell carcinoma OR HNSCC OR Doc_title: head and neck squamous cell carcinoma OR HNSCC) AND (Background: CDKN2A OR \"ARF\" OR \"MLM\" OR \"P14\" OR \"P16\" OR \"P19\" OR \"CMM2\" OR \"INK4\" OR \"MTS1\" OR \"TP16\" OR \"CDK4I\" OR \"CDKN2\" OR \"INK4A\" OR \"MTS-1\" OR \"P14ARF\" OR \"P19ARF\" OR \"P16INK4\" OR \"P16INK4A\" OR \"P16-INK4A\" OR Doc_title: CDKN2A OR \"ARF\" OR \"MLM\" OR \"P14\" OR \"P16\" OR \"P19\" OR \"CMM2\" OR \"INK4\" OR \"MTS1\" OR \"TP16\" OR \"CDK4I\" OR \"CDKN2\" OR \"INK4A\" OR \"MTS-1\" OR \"P14ARF\" OR \"P19ARF\" OR \"P16INK4\" OR \"P16INK4A\" OR \"P16-INK4A\")"}},
  "response":{"numFound":786,"start":0,"docs":[
      {
        "Meeting_name":" Conditional mouse and zebrafish models of INK4-mediated tumor suppression reveal ARF-independent regulation of cellular senescence",
        "Background":"['The INK4b-ARF-INK4a locus on human chromosome 9p21 is a hot spot genomic region that undergoes frequent inactivation or deletion in a wide spectrum of human cancers. The locus encodes three cell cycle inhibitory proteins', ' p15INK4b encoded by CDKN2b, p16INK4a encoded by CDKN2a and p14ARF (p19Arf in mice) encoded by an alternative reading frame (ARF) of CDKN2a. We have recently identified a homologous INK4 genomic locus in zebrafish that is surprisingly devoid of ARF sequences, and encodes a single zebrafish ink4ab gene that functions to activate stress-induced senescence. Therefore, evolution of the mammalian INK4 locus to include multiple tumor suppressors sharing regulatory features could attribute to stronger mechanisms of tumor suppression in these longer-lived vertebrates. Oxidative and/or oncogenic stress provokes cellular senescence involving the retinoblastoma (Rb) and ARF/p53 pathways, leading to silencing of growth-promoting genes by methylation of histone H3 lysine 9 (H3K9me) with the histone methyltransferase Suv39h1. We found that ink4ab deficient zebrafish had deregulated Rb signaling and senescence responses, and reduced suv39h1 expression levels that led to poor overall survival. Ink4ab deficient zebrafish had increased lymphocyte proliferation, splenomegaly, and developed multiple spontaneous tumors including metastatic melanoma, osteosarcoma, hepatocellular adenoma, leukemias and myelodysplastic disorders. Moreover, zebrafish heterozygous for both p53 and ink4ab mutations displayed significantly higher tumor incidence compared to p53 heterozygotes with wild-type ink4ab, indicating that ink4ab haploinsufficiency promotes tumorigenesis. To this end, the combined deficiency of ink4ab and p53 accelerates tumor latency, likely by reversing cellular senescence responses. To further examine ARF-independent senescence regulatory roles of INK4 products in a mammalian model, we have generated conditional mice deficient for all three INK4 open reading frames in the adult hematopoietic system. Within seven months, homozygous Ink4a/Ink4b/ARF-/- mice exhibited marked splenomegaly and developed spontaneous tumors, including leukemias and soft tissue sarcomas. Peripheral blood, splenic and bone marrow analyses of homozygous mutant mice showed deregulated lymphocyte development, uncontrolled proliferation, apoptosis and Suv39h1-dependent senescence when compared to heterozygous and wild type mice. These results identify ARF-independent and Suv39h1-dependent senescence regulatory and tumor suppressor mechanisms whose inactivation permits tumor formation in response to oncogenic and/or oxidative stress. Our models offer the opportunity to reveal novel paradigms for promoting cellular senescence as an alternative strategy for cancer prevention and therapy.']",
        "Doc_id":"AACR_2015-1264",
        "Doc_title":" Conditional mouse and zebrafish models of INK4-mediated tumor suppression reveal ARF-independent regulation of cellular senescence",
        "_version_":1606188979097436160},
      {
        "Meeting_name":" Functional analysis of a chimera of p16 and ARF",
        "Background":"['Adults in the US are now 28 times more likely to develop melanoma than 75 years ago. Among other genetic abnormalities, mutations in the INK4a locus on chromosome 9p21 are prominent in melanoma and can be found in nearly 50% of familial cases. Two independent tumor suppressors which are transcribed from the INK4a locus, p16 (CDKN2A) and ARF (p14ARF), share common exons 2 and 3 but are translated in unique reading frames. p16 causes cell cycle and growth arrest in the G1 phase by binding cyclin-dependent kinases 4 and 6 (CDK4/6), thereby displacing Cyclin D1 and inhibiting the enzymes. ARF, meanwhile, causes cell cycle and growth arrest in the G1 and G2/M phases by binding MDM2, in turn stabilizing p53. Mutations in melanoma often affect one or both genes, suggesting p16 and ARF may play equally important roles in tumor suppression. We report a 2 bp deletion, 1 bp insertion (CC to T) in exon 2 of p16/ARF found in a melanoma cell line that alters the reading frames of both genes and creates unique proteins. One transcript initiates from the ARF promoter and codes for the first 94 amino acids of ARF before switching to the reading frame of p16 to code for another 75 residues. We named the resulting protein chimera ARF (chARF). The other transcript initiates from the p16 promoter, codes for the first 80 amino acids of p16, then switches to a non-p16/non-ARF reading frame to code for an additional 63 residues. We called this protein p16-Alternate Carboxyl Terminus (p16-ACT). Based on sequence, we hypothesized that chARF could function both as ARF and p16 since it contains the MDM2 binding domain of ARF as well as most of the CDK4/6 binding domain of p16. Meanwhile, we hypothesized that p16-ACT would have no function since it is missing most of the CDK4/6 binding region of p16. To assess the function of these proteins, we overexpressed both mutant and wild-type proteins in the p16/ARF-inactivated tumor cell line U2OS. In CDK4 immunoprecipitation assays, chARF bound CDK4, but unlike wild-type p16, did not displace Cyclin D1. p16-ACT neither bound CDK4 nor displaced Cyclin D1. chARF expression strongly activated the p53/p21 pathway and arrested U2OS cells in the G1 and G2/M phases of the cell cycle in a manner identical to wild-type ARF. p16-ACT, however, had no noticeable effect on cell cycle distribution. Finally, we looked at cell proliferation and found that chARF expression suppressed monolayer cell growth and colony formation in U2OS cells by 75-85%, similar to wild-type ARF. p16-ACT expression had a small suppressive effect on colony formation, but no effect on monolayer growth. We conclude that chARF functions as wild-type ARF but neither chARF nor p16-ACT function as wild-type p16.']",
        "Doc_id":"AACR_2013-5202",
        "Doc_title":" Functional analysis of a chimera of p16 and ARF",
        "_version_":1606188983626235904},
      {
        "Meeting_name":" Concurrent mutation of CDKN2A and TP53 loci in primary keratinocytes.",
        "Background":"['Concurrent inactivation of the p16Ink4a and p53 tumor suppressors, often through mutation of CDKN2A and TP53, is frequent in early development of head and neck squamous cell carcinoma (HNSCC) and other cancers. The role of this early combined inactivation, and the oncogenic drivers that subsequently lead to tumor development, are poorly defined. To characterize the precancerous role of concurrently mutated CDKN2A and TP53, we combined a number of recent advances to disrupt both loci in primary cells. First, we grew primary keratinocytes in medium conditioned by irradiated J2-3T3 cells and containing an inhibitor of ROCK kinases, conditions that greatly extend their normally limited proliferative potential. Second, we transfected primary keratinocytes with plasmid vectors expressing both Cas9 and sets of guide RNAs targeting specific regions of CDKN2A and TP53. We targeted either or both of the p14Arf and p16Ink4a protein products of CDKN2A for knockout (KO), together with either TP53 KO or a TP53 point mutation (R248Q protein product), two major categories of genetic alterations of p53 in HNSCC. Third, we evaluated use of nutlin-3, an inhibitor of p53-MDM2 interaction, to try to select against cells that still contained wild-type p53. We assessed KO efficiency by PCR of genomic DNA; the TP53 point mutation introduced a SauA3i site into TP53. Two weeks of nutlin-3 treatment led to a 3 fold increase in p53 KO efficiency versus untreated cells (50% versus 14%). p16Ink4a KO efficiencies were enhanced 2 to 14 fold after nutlin-3 treatment, depending on the specific Cas9/guide-RNA constructs used. In cells transfected to produce p53 R248Q, 14% of PCR products amplifying the mutated region after nutlin-3 exposure showed Sau3Ai digestion, whereas no Sau3Ai digestion was detected in untreated cells. This result suggests that up to 14% of nutlin-3 treated keratinocytes had integrated the mutated donor oligo sequence. We similarly enrich for mutated keratinocytes having p14Arf-specific or combined CDKN2A KO along with TP53 KO or mutation. Combined transfection to generate concurrent CDKN2A and TP53 mutations under conditions that allow extended proliferation in culture, followed by selection for successful TP53 mutation with nutlin-3, will facilitate identification of keratinocyte clones with bi-allelic knockout genotypes. This panel of keratinocytes with concurrent CDKN2A and TP53 mutations will help delineate the roles of these genes in early cancer development and will allow screening for the oncogenic drivers required for tumor development and metastasis, with emphasis on discovering more effective and specific druggable targets for improving treatment.']",
        "Doc_id":"AACR_2017-2575",
        "Doc_title":" Concurrent mutation of CDKN2A and TP53 loci in primary keratinocytes.",
        "_version_":1606189033885532160},
      {
        "Meeting_name":" ARF regulates the stability of p16 protein via REG-dependent proteasome degradation",
        "Background":"['The cell cycle regulatory gene INK4A-ARF (CDKN2A) has two alternative transcripts that produce entirely different proteins, namely p14ARF and p16, which have complementary functions as regulators of p53 and pRB tumor suppressor pathways, respectively. The unusual organization of INK4A-ARF has long led to speculation of a need for coordinated regulation of p14ARF and p16. We now show that p14ARF (ARF) regulates the stability of p16 protein in human cancer cell lines, as well as in mouse embryonic fibroblasts (MEFs). In particular, ARF promotes rapid degradation of p16 protein, which is mediated by the proteasome and, more specifically, by interaction of ARF with one of its subunits, REG. Furthermore, this ARF-dependent destabilization of p16 can be abrogated by knock-down of REG or by pharmacological blockade of its nuclear export. Thus our findings have uncovered a novel crosstalk of two key tumor suppressors mediated by a REG-dependent mechanism.']",
        "Doc_id":"AACR_2014-1575",
        "Doc_title":" ARF regulates the stability of p16 protein via REG-dependent proteasome degradation",
        "_version_":1606188986003357696},
      {
        "Meeting_name":" Ink4a/Arf locus drives gastric tumorigenesis through induction of parietal cell loss",
        "Background":"['Background', ' Cancer development is often preceded by the appearance of preneoplastic lesions. In gastric carcinogenesis, chronic inflammation and histopathologic progression of the stomach epithelium lead to the development of metaplasia and eventually adenocarcinoma. Spasmolytic polypeptide-expressing metaplasia (SPEM) is one of the preneoplastic lesions in the stomach and is triggered by the loss of parietal cells that secrete gastric acid. The Ink4a/Arf locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p19(ARF) in mice. However, little is known regarding the role of these proteins encoded by the INK4a/ARF locus in gastric tumorigenesis.Methods', ' To evaluate the functional role of Ink4a/Arf locus, we crossed mouse gastric cancer modelK19-Wnt1/C2mE mice with Ink4a/Arf (-/-) mouse and generated Ink4a/Arf (-/-) K19-Wnt1/C2mE mice and evaluated the effect of deletion of Ink4a/Arf locus on the parietal cell loss and formation of SPEM and gastric tumor. Results', ' In K19-Wnt1/C2mE mice, accumulation of reactive oxygen species (ROS) and the increase of p19 expression were observed in gastric epithelium along with the parietal cells loss leading to SPEM development. However, the parietal cells loss followed by formation of SPEM and gastric tumor were drastically suppressed in Ink4a/Arf (-/-) K19-Wnt1/C2mE mice. Furthermore, treatment of tamoxifen, an inducer of parietal cells loss, in Ink4a/Arf (-/-) mice revealed that deletion of Ink4a/Arf locus suppresses parietal cells loss in mice. Conclusion', ' These results suggest that activation of p19(ARF) tumor suppressor protein by ROS accumulation paradoxically play a key role in the parietal cells loss leading to gastric tumorigenesis.']",
        "Doc_id":"AACR_2014-65",
        "Doc_title":" Ink4a/Arf locus drives gastric tumorigenesis through induction of parietal cell loss",
        "_version_":1606188987002650625},
      {
        "Meeting_name":" CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis",
        "Background":"['Background', ' HPV infection is associated with high p16 expression and relatively good prognosis in head and neck cancers. Analysis of CDKN2A, the gene that encodes the p16 tumor suppressor protein, may further elucidate the association between HPV status and prognosis in head and neck squamous cell carcinomas (HNSCCs). We aimed to identify whether CDKN2A copy number loss was associated with poor survival in HNSCCs stratified by HPV status. Methods', ' We analyzed The Cancer Genome Atlas (TCGA) head and neck cancer data, integrating genomic measurements with clinical metadata. Patients 85 years old or younger with a primary tumor in the oral cavity, oropharynx, hypopharynx, or larynx were included. Defining CDKN2A copy number loss as a relative log2 copy number ratio <0.6, CDKN2A mRNA and p16 protein expression levels were compared to confirm significant differences in gene transcription and translation between the copy number loss and non-copy number loss patient groups. Overall survival (OS) and disease-free survival (DFS) were evaluated to characterize prognostic differences between genomic groups. Results', ' 397 patients negative for HPV (HPV) and 91 patients positive for HPV (HPV+) HNSCC were identified. 139 HPV patients and 9 HPV+ patients demonstrated CDKN2A copy number loss. The CDKN2A copy number loss group expressed significantly lower levels of CDKN2A mRNA and p16 protein than did the non-copy number loss group in both HPV+ and HPV disease. Median OS for HPV patients with and without CDKN2A copy number loss was 21.8 months and 46.0 months (P = 0.02). Median DFS was 12.0 and 19.4 months respectively (P < 0.05). Median OS for HPV+ patients with and without CDKN2A copy number loss was 12.7 months and 57.4 months (P = 0.004) and median DFS was 7.0 and 36.6 months respectively (P = 0.02). Conclusions', ' CDKN2A copy number loss was associated with low CDKN2A mRNA and p16 protein expression, with poor prognosis in terms of disease-free and overall survival.']",
        "Doc_id":"ASCO_187826-199",
        "Doc_title":" CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis",
        "_version_":1606189000282865665},
      {
        "Meeting_name":" Molecular profiles of head and neck cancer tumorgrafts",
        "Background":"['Purpose', ' We have developed a primary tumorgraft system of squamous cell carcinoma of the head and neck with relevance for investigating mechanisms of therapeutic resistance, understanding differential responses to standard therapy in HPV-positive and HPV-negative cancers, and testing novel therapeutics. To better understand the power, limitations and relevance of our tumorgraft system, we have initiated molecular characterization of these tumors. Methods', ' Patients with newly diagnosed or recurrent HNSCC were consented for donation of tumor at the time of surgery. Tumor tissue was obtained, washed in antibiotic rich media, manually disaggregated, and subcutaneously implanted into mice (NOD.Cg-Prkdc scid Il2rgtm1Wjl/SzJ) for initial tumorgraft establishment. Subsequent mouse-to-mouse passages were performed and formalin-fixed/paraffin embedded as well as flash frozen tissue was harvested for subsequent molecular analyses. Expression of p16(Ink4a), p53, pRB, and EGFR was assessed by immunohistochemistry(IHC). HPV status and subtype was assessed using MY09/MY11 and GP5/GP6 degenerate nested polymerase chain reaction and Sanger sequencing. Transcriptionally active HPV infection was assessed by qRT-PCR for the HPV oncogenes E6 and E7. Mutation status of p53 was assessed by PCR-based exon amplification and Sanger sequencing. Results', ' To date, thirty primary tumorgrafts have been established with robust growth in eighteen (60%). p16(INK4A) expression was identified in approximately one-third. The majority of HPV-positive tumorgrafts contained HPV-16 and were transcriptionally active by mRNA expression profiling. HPV-positive tumors showed low p53 and RB expression by IHC. As anticipated, mutations in p53 were seen more frequently in HPV-negative tumors. Conclusions', ' These primary human tumorgrafts represent a diverse range of head and neck cancers. Both HPV-positive tumors and HPV-negative tumors have been successfully propagated with a diverse range of molecular characteristics. These primary tumorgrafts will provide a valuable platform for testing novel therapeutics as well as radiation and chemotherapy response profiles.']",
        "Doc_id":"AACR_2012-2352",
        "Doc_title":" Molecular profiles of head and neck cancer tumorgrafts",
        "_version_":1606189032261287936},
      {
        "Meeting_name":" Significance of p16 in site-specific HPV-positive and HPV-negative HNSCC",
        "Background":"['Expression of p16INK4A (p16+ve) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinoma (HNSCC), however, p16-positivityis not limited to HPV-positive (HPV+ve) tumors and therefore, not a perfect surrogate for HPV. Also, p16+ve status has a strong relationship with survival and treatment outcomes in HNSCC, which is best documented for the oropharyngeal site (OP); non-OP sites such as the oral cavity (OC), larynx, and hypopharynx (HP) are understudied. The goal of this study was to evaluate p16 in the context of HPV and examine p16 survival outcomes in HPV+ve and HPV-negative (HPV-ve) site-specific HNSCC. The cohort of 80 primary HNSCC consisted of 10 HPV16+ve and 10 HPV16-ve cases each for four sites', \" OC, OP, larynx and HP. Expression of p16 was significantly different across sites (p<0.001), being more frequent in OP (65%) than in non-OP sites (13%). The frequency of p16 expression was different (p=0.031) between Caucasian Americans (CA, 38%) and African Americans (AA, 16%) similar to HPV (CA 65% vs AA 37%, p=0.013). p16+ve patients had improved survival for all sites combined and for the OP subgroup (similar to HPV+ve cases). However, subgroups defined by both HPV and p16, indicate that patients with p16-negative (-ve)/HPV-ve status had the worst survival for all sites combined as well as for OP. Cohorts with larger representations of non-OP sites examining multiple molecular markers will be key to deciphering and dissecting out p16's role as a useful prognostic indicator when assessed in combination with HPV status\"]",
        "Doc_id":"AACR_2012-722",
        "Doc_title":" Significance of p16 in site-specific HPV-positive and HPV-negative HNSCC",
        "_version_":1606188973181370368},
      {
        "Meeting_name":" Loss of cellular senescence checkpoint functions reveals the oncogene characteristics of Notch1 in squamous cell carcinomas",
        "Background":"['Introduction', ' Notch signaling regulates cell fates that are dependent upon the CSL transcription factor. Both tumor suppressor and oncogenic roles of Notch have been implicated in the pathogenesis of squamous cell carcinomas (SCCs). We investigated the functional consequences of Notch activation in head and neck as well as esophageal SCCs (HNSCC and ESCC). Methods', ' Primary tumor tissues annotated with known clinical outcomes were analyzed. Human esophageal cells immortalized with telomerase or human papilloma virus E6/E7 genes, their derivatives expressing mutant p53 and ESCC cell lines were stably transduced with ICN1, an active form of Notch1 in a regulatable manner (Tet-On system). Notch was inhibited by dominant negative mastermind-like1 (DNMAML1), a genetic pan-Notch inhibitor or -secretase inhibitors (GSI). 8xCSL-luciferase reporter was used to assess Notch-mediated transcriptional activity. RNA interference was done targeting either CSL or p16INK4A. Senescence was determined by cell growth inhibition and senescence-associated -galactosidase assays. Cell growth was tested in soft agar and immunodeficient mice. Gene expression was determined by quantitative RT-PCR, Western blotting and immunohistochemistry (IHC). Results', ' In primary tumors, the active form of Notch1 (ICN1Val1744) was detected as intense nuclear staining of tumor cells in the invasive fronts in 29% of HNSCC (n=17) and 56% of ESCC (n=171). Nuclear ICN1Val1744 was significantly associated with a poor 5-year survival in postsurgical ESCC patients (n=115). In culture, ICN1 induced cellular senescence through CSL-dependent p16INK4A induction, which was antagonized by DNMAML1 or knockdown of either CSL or p16INK4A. Moreover, ICN1 failed to induce senescence in immortalized cells expressing E6/E7 or ESCC cells with a deleted INK4 locus. However, p53 mutation did not prevent ICN1-induced senescence. In soft agar and xenograft transplantation, ICN1 stimulated colony formation and tumor growth of ESCC cells that negated senescence. Histology revealed an increased number of less-differentiated tumor cells upon ICN1 induction. Moreover, GSI treatment of mice with xenografted ESCC cells resulted in tumor necrosis. Conclusions', ' These data indicate that Notch activation contributes to disease progression in ESCC. While ICN1 induces senescence, loss of p16INK4A-mediated senescence checkpoint point functions may be required in ICN1-mediated malignant transformation, thus providing a novel mechanistic insight into how Notch signaling may contribute to the pathogenesis of SCCs.']",
        "Doc_id":"AACR_2012-70",
        "Doc_title":" Loss of cellular senescence checkpoint functions reveals the oncogene characteristics of Notch1 in squamous cell carcinomas",
        "_version_":1606188990195564544},
      {
        "Meeting_name":" Tumor suppressor functions of the zebrafish ink4ab",
        "Background":"['The human INK4b-ARF-INK4a genetic locus encodes two closely related members of the INK4 family of cyclin dependent kinase inhibitors, p15INK4b and p16INK4a regulating RB phosphorylation and subsequently cell proliferation, and a p53 stabilizer, known as ARF. All of the three products play a pivotal role in tumor suppression and are frequently deleted or inactivated in a wide spectrum of human cancers. Despite the critical role of the mammalian INK4b-ARF-INK4a locus in tumor suppression, its counterpart in zebrafish has not yet been characterized. Zebrafish is an advantageous vertebrate to model human cancers, specifically because of the high fecundity, the ease of performing high-throughput screens, and the genetic conservation with mammals. We identified a syntenic zebrafish ink4ab locus that consists of a single gene orthologous to both mammalian CDKN2a (INK4A) and CDKN2b (INK4B), and functions to activate senescence in response to oxidative stress. Utilizing morpholino targeted knockdown and zebrafish mutants for the ink4ab gene, we have developed a zebrafish model for tumorigenesis. We demonstrate that the zebrafish ink4ab gene functions as a tumor suppressor by controlling cell cycle regulation under stress. Senescence was activated by oxidative stress in wild type embryos but not in embryos with ink4ab deficiency when examined with a whole embryo senescence-associated beta-galactosidase (SA--gal) assay. Surprisingly, we find that ink4ab deficient embryos also display significantly higher levels of apoptosis than controls. We determined that the apoptosis associated with ink4ab deficiency is p53-dependent. Furthermore, ink4ab deficiency led to significantly lower survival rates, both overall and upon radiation. Ink4ab deficient zebrafish had splenomegaly, increased lymphocyte proliferation, and developed spontaneous tumors including metastatic melanoma, osteosarcoma, leukemia and myelodysplastic disorders. Thus, the zebrafish ink4ab protein functions as a tumor suppressor similarly to the human p15INK4B and p16INK4A. To study the upstream control of zebrafish ink4ab expression, we investigated the orchestrated regulation by the Bmi-1 oncogene, and identified bmi-1a as a repressor of ink4ab expression. Zebrafish heterozygous for both p53 and ink4ab mutations displayed significantly higher tumor incidence compared to p53 heterozygotes with wild-type ink4ab, indicating that ink4ab haploinsufficiency promotes tumorigenesis. To this end, the combined deficiency of ink4ab and p53 accelerates the latency and broadens the tumor spectrum including the formation of retinoblastoma. Collectively, the zebrafish ink4ab model of tumor suppression provides a platform to perform large-scale screens for small molecules that modulate tumorigenesis in the ink4ab deficient fish, and permit defining the genetic pathways of CDKN2a- and CDKN2b-mediated tumor suppression.']",
        "Doc_id":"AACR_2013-1581",
        "Doc_title":" Tumor suppressor functions of the zebrafish ink4ab",
        "_version_":1606189000633090048},
      {
        "Meeting_name":" A key role for ARF in drug resistance in invasive bladder cancer",
        "Background":"['Although most superficial bladder cancers can be removed transurethrally with excellent prognosis, clinical outcome is much more problematic for patients with muscle-invasive disease. Indeed, invasive bladder cancer is a major clinical challenge since it is highly associated with postoperative recurrence and metastasis. Current treatments for those lethal forms of bladder cancer include systemic chemotherapy and molecular targeted therapy; however, survival is poor since most patients develop resistance to the drugs within a short timeframe. Clearly, there is a need to identify novel therapeutic options for invasive bladder cancer as well as a greater understanding of the molecular mechanisms of drug resistance. We have been investigating mechanisms of drug resistance using genetically-engineered mouse models of invasive bladder cancer based on the combinatorial deletion of p53 and Pten in bladder epithelium. p53 and PTEN are frequently inactivated in human bladder cancers, particularly those with poor prognosis. Indeed, allograft tumors established from these mice responded initially to the treatment with cisplatin, docetaxel, or rapamycin but eventually developed resistance. We have observed that these p53; PTEN deficient tumors express robust levels of p19Arf, while targeted deletion of Arf retards the aquisition of resistance following drug treatment. The significance of this expression was further suggested by analysis of a published gene expression profile of human bladder cancers which revealed that high Arf expression is an independent predictor of poor survival of invasive bladder cancer patients. Furthermore, following drug treatment in the mouse model, the Arf-positive, compared to the Arf-negative, tumors were significantly enriched in extracellular matrix/integrin signaling gene signature consistent with activation of downstream PI3K-mTOR pathway, suggesting that a model for drug resistance is via PI3K pathway activation. We have observed similar results in human bladder cancer cell lines either following knock-down of p14Arf in J82 cells that express endogenous p14Arf or following forced expression of p14Arf in ARF-negative UMUC3 human bladder cancer cells, and in both cases it was coincident with deregulated activation of PI3K-mTOR pathway. Thus, we propose that Arf confers drug resistance on bladder cancer by activating PI3K-mTOR pathway, highlighting a potential therapeutic target for advanced invasive bladder cancer patients.']",
        "Doc_id":"AACR_2012-802",
        "Doc_title":" A key role for ARF in drug resistance in invasive bladder cancer",
        "_version_":1606189030193496065},
      {
        "Meeting_name":" The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC) is a rare lethal human malignancy with no effective therapy. It is critical to identify new therapeutic strategies for NHSCC. Deregulation of CDKN2A (p16) or CCND1 (cyclin D1) occurs commonly in HNSCC and induces sustained cyclin-dependent kinase (CDK) 4/6 activation. The selective CDK4/6 inhibitor, LY2835219 inhibited CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induced cell cycle arrest and growth inhibition. In an animal xenograft model of HNSCC, LY2835219 treatment led to reduced tumor growth. However, because single-agent treatment with LY2835219 showed a limited effect in HNSCC, a combinational strategy is necessary for effective therapy. At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR. The combination of LY2835219 with mTOR inhibitor was found to be more effective than either drug alone in vitro and in vivo. Taken together, our findings suggest that a combination treatment with LY2835219 and mTOR inhibitor is a promising therapeutic approach for HNSCC.']",
        "Doc_id":"AACR_2016-2837",
        "Doc_title":" The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma",
        "_version_":1606189022343856128},
      {
        "Meeting_name":" Loss of LZAP inactivates p53 in head and neck cancer and regulates sensitivity of cells to DNA damage in the p53-dependent manner.",
        "Background":"['We previously reported that tumor suppressor LZAP is lost in a portion of head and neck squamous cell carcinomas and that LZAP inhibits NF-kB, while activating p53 in ARF-dependent and -independent fashions. The ability of LZAP to regulate p53 in the absence of ARF has been largely unexplored. Here, we show that LZAP depletion diminished expression of mutant and wild-type p53 protein. LZAP activity toward p53 was independent of ARF and the known p53 regulators, Wip1 and HDM2. Loss of LZAP decreased p53 translation and destabilized p53 protein due, at least partially, to increased nucleolin expression. Knockdown of LZAP abrogated p53 stabilization induced by ionizing radiation, and LZAP depletion protected wild-type p53 cells from radiation or chemotherapeutic agents, while rendering cells expressing mutant or no p53 more sensitive. In human HNSCC, LZAP levels correlated with p53 levels, and remarkably, tumors with low LZ were less likely to have p53 mutations. These data suggest that loss of LZAP represents a novel mechanism of p53 inactivation in human cancer. Given these findings, inhibition of LZAP activity toward p53 for patients with tumors harboring p53 mutations may represent a therapeutic strategy to simultaneously sensitize tumors while protecting normal tissues from radiation or chemotherapy.']",
        "Doc_id":"AACR_2013-1587",
        "Doc_title":" Loss of LZAP inactivates p53 in head and neck cancer and regulates sensitivity of cells to DNA damage in the p53-dependent manner.",
        "_version_":1606188976582950912},
      {
        "Meeting_name":" Regulation of p16Ink4a - Rb pathway by Cyclin D1- Dmp1 interaction",
        "Background":"['Cyclin D1 is a crucial regulator in mammalian cell cycle that binds to and activates CDK4/6, which is an kinase that drives cells to enter S phase. It has an important oncogenic role in breast cancer because the CCND1 gene is amplified in 15% of cases and its protein expression is elevated in up to 50% of cases. Previous studies demonstrate that cyclin D1 overexpression can cause pRb hyper-phosphorylation and therefore induce cell hyperproliferation, which can result in the development of mammary adenocarcinoma. In addition, cyclin D1 is found to contribute to tumorigenesis by affecting the activity of transcriptional factors via physical interaction. One of the affected transcriptional factors is called Dmp1, which acts as a tumor suppressor when receiving oncogenic signals. It activates Arf by binding to its promoter region, therefore causing Arf, p53-dependent cell cycle arrest in normal cells. Our recent study in MMTV-neu mice showed that loss of Dmp1 significantly accelerates mammary carcinogenesis. Although both Dmp1 and cyclin D1 play vital roles in breast cancer prevention and development respectively, the biological functions and significance of Dmp1-cyclin D1 interaction remains to be explored. To identify the impact of their interaction on the activation of p16Ink4a/ p19Arf promoters induced by cyclin D1, MEFs were overexpressed cyclin D1 and we found the endogenous p16Ink4a and p19Arf transcripts were increased up to 7 fold. However, their transcription level was not affected in Dmp1-null MEFs. Moreover, cyclin D1 mutant 142-253 that cannot bind to Dmp1could not fully activate the p16Ink4a/p19Arf promoters, indicating the activation of p16Ink4a/p19Arf promoters by cyclin D1 is dependent on Dmp1, and loss of Dmp1-cyclin D1 interaction will attenuate this effect. To identify the potential regulation of p16Ink4a by Dmp1, we performed EMSA and luciferase reporter assay, and we found that Dmp1 activates the p16Ink4a promoter by directly binding to its promoter. Moreover, the p16Ink4a mRNA and protein level were increased upon Dmp1 overexpression. The above results suggest that Dmp1 is a physiological regulator of p16Ink4a. To explore the effect of Dmp1 on Cdk4 kinase activity, 293T cells were overexpressed cyclin D1 alone or together with Dmp1, and we found there was less cyclin D1 associated with CDK4 after CDK4 immunoprecipitation. As a consequence, pRb phosphorylation was decreased in CDK4 kinase assay. These results suggest that Dmp1 decreases CDK4 kinase activity by impairing cyclin D1-CDK4 interaction. Taken together, our data suggest that Dmp1 decreases pRb phosphorylation in two ways', ' one is to directly bind to and activate p16INK4a, and the other one is to block the CDK4 kinase activity by binding to cyclin D1. In addition, cyclin D1-Dmp1 interaction is indispensible in activation of p16Ink4a/p19Arf promoters induced by cyclin D1.']",
        "Doc_id":"AACR_2012-2052",
        "Doc_title":" Regulation of p16Ink4a - Rb pathway by Cyclin D1- Dmp1 interaction",
        "_version_":1606189002588684289},
      {
        "Meeting_name":" Characterization of the differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas and correlation with patient outcome.",
        "Background":"['Background. CDKN2A inactivation has been reported to be a frequent event in head and neck squamous cell carcinomas that correlates with worse patient outcome. The differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas (OTSCC) have been poorly characterised. We sought to determine the frequency of potential mechanisms of CDKN2A inactivation in OTSCC and explore their impact on patient outcome.Material and methods. We investigated a cohort of 134 OTSCC patients treated between 2002 to 2008 with combinations of surgery, radiotherapy and chemotherapy, who have been comprehensively annotated for patient/tumour characteristics and outcome. 134 formalin fixed paraffin embedded blocks representative of primary tumours prior to treatment were collected. DNA was extracted from 115 patient blocks and a tissue microarray was made representing 123 patient samples. We assessed p16/CDKN2A expression by immunohistochemistry (IHC), promoter methylation status by methylation-sensitive high resolution melting, mutation status by Sanger sequencing, gene copy number variation by fluorescence in-situ hybridisation and correlated each of these with patient outcome.Results. The majority of OTSCC demonstrated loss of p16 expression (107/118, 90.7%), assessed by IHC. The frequency of CDKN2A inactivating mutations was 20.3% (21/103), homozygous CDKN2A loss was 4.1% (7/98), hemizygous CDKN2A loss 30.6% (30/98), and CDKN2A promoter methylation >10% was 17.7% (20/113). 34/107(31.8%) p16 IHC negative tumours had no evidence of CDKN2A mutation, copy number variation or promoter methylation identified. Of eleven p16 IHC positive patients, only two demonstrated evidence of HPV type 16 and 33 on PCR. No correlation was identified between any of the mechanisms of CDKN2A inactivation and clinicopathological features. Smoking status and age did not influence the frequency of any mechanism of CDKN2A inactivation or patient outcome. There was a non-significant trend for worse outcome for p16 IHC negative patients versus IHC positive patients (HR=0.65, 95% CI=0.23-1.79, p=0.40). No significant relationship between mechanisms of p16 inactivation and patient outcome were found.Conclusion. Loss of p16 is a frequent event in oral tongue squamous cell carcinomas that can occur through gene copy number variation, mutation, promoter methylation or through other unidentified mechanisms. We identified no correlation between mechanisms of p16 loss and clinicopathological characteristics or patient outcome.']",
        "Doc_id":"AACR_2013-4693",
        "Doc_title":" Characterization of the differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas and correlation with patient outcome.",
        "_version_":1606189008473292800},
      {
        "Meeting_name":" Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.",
        "Background":"['Background', ' Despite recent improved understanding of cancer, the 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) remains relatively unchanged. It is critical to identify new therapeutic strategies for NHSCC. Deregulation of CDKN2A (p16) or CCND1 (cyclin D1) occurs commonly in HNSCC and induces sustained cyclin-dependent kinase (CDK) 4/6 activation. In addition, HNSCC is characterized by persistent activation of the AKT/mTOR pathway that triggers a signaling cascade of cell proliferation and survival. Methods', ' HNSCC cell lines were tested for the CDK4/6 inhibitor LY2835219, alone and in combination with mTOR inhibitor, both in vitro and in vivo. Results', ' The selective CDK4/6 inhibitor, LY2835219 inhibited CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induced cell cycle arrest and growth inhibition. In an animal xenograft model of HNSCC, LY2835219 treatment led to reduced tumor growth. However, because single-agent treatment with LY2835219 showed a limited effect in HNSCC, a combinational strategy is necessary for effective therapy. At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR. The combination of LY2835219 with mTOR inhibitor was found to be more effective than either drug alone in vitro and in vivo. Conclusions', ' Taken together, our findings suggest that a combinational treatment with LY2835219 and mTOR inhibitor is a promising therapeutic approach for HNSCC.']",
        "Doc_id":"ASCO_164735-176",
        "Doc_title":" Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.",
        "_version_":1606189013374337024},
      {
        "Meeting_name":" P16INK4a over-expression sensitizes HPV(-) HNSCC to radiation through down-regulation of USP7",
        "Background":"['Background', ' Head and neck squamous cell carcinoma (HNSCC) tumorigenesis induced by human papillomavirus (HPV) shows a greater clinical response to radiation therapy when compared to HPV negative patients. The underlying mechanism for this more favorable outcome is unknown, but the presumption is that DNA repair response must play a large role. P16INK4a is a known surrogate marker for HPV positivity; however the relationship between radiation sensitivity and P16INK4a has not been completely elucidated in this context. Ubiquitin specific protease 7 (USP7), also known as HAUSP, is a deubiquitylating enzyme that cleaves ubiquitin from substrates to stabilize target proteins. USP7 overexpression is a predictor of poor prognosis in lung carcinomas and correlates with disease progression and lower survival in gliomas. More recent studies have shown USP7 has a role in the stability of DNA damage response proteins such as RNF168, BRCA1 and Chk1; and USP7 knockdown has been shown to radio-sensitize breast cancer cells to radiation. We have investigated the possible role of USP7 in the radio-response of HNSCC cells in the context of HPV status.Methods', ' Four HPV(+) and four HPV(-) HNSCC were chosen for this study. The radio-response was determined by clonogenic survival assay. P16INK4a overexpression was generated using lentivirus. Western blot analysis was used for visualizing protein expression. The Cancer Genome Atlas was interrogated to examine the relationship between USP7 and clinical outcome.Results', ' Our data suggest P16INK4a negatively regulates USP7 and leads to the more radiosensitive phenotype associated with HPV(+)HNSCC. Radio-resistant HPV(-) HNSCC cell lines show higher levels of USP7 than HPV(+) lines and over-expression of P16INK4a in HPV(-) HN5 cells leads to down-regulation of USP7 and radio-sensitization. Conversely, P16INK4a siRNA knockdown in HPV(+) UMSCC-47 shows an increase of USP7 protein expression and radio-resistance. P22077, an inhibitor of USP7 activity, was also shown to radiosensitize a HPV(-) cell line. This shows proof of principle that inhibiting USP7 can be a viable approach to sensitizing HPV(-) HNSCC to radiation. USP7 overexpression was also associated with poorer overall survival in HNSCC.Conclusion', ' These results suggest that USP7 may be a marker of clinical radioresistance in HNSCC and that its inhibition has the potential to improve the treatment outcome of patients with HPV(-) HNSCC when combined with radiotherapy.']",
        "Doc_id":"AACR_2016-1652",
        "Doc_title":" P16INK4a over-expression sensitizes HPV(-) HNSCC to radiation through down-regulation of USP7",
        "_version_":1606189000621555712},
      {
        "Meeting_name":" Association of p16 and pEGFR expression with high-risk HPV in head and neck squamous cell carcinoma.",
        "Background":"['Background', '    A study was conducted to evaluate the hrHPV status, phosphorylated EGFR (pEGFR) and P-16 expression of tumor tissues of patients with Head and Neck Squamous Cell Carcinoma (HNSCC).   Methods', '    In 140 HNSCC formalin fixed paraffin embedded tumor tissues, qPCR performed to detect hrHPV (16,18,31,39,45,51,52,68) and immunohistochemistery performed to evaluate P-16 and pEGFR expression (0= negative, positive=1,2,3).  Results', '    Seventy out of 140 samples (50%) were positive for hrHPV, HPV16 (n=16), HPV18 (n=48), HPV51 (n=5), HPV31 (1). HPV positivity/negativity was compared to p16 (0,1,2,3) values and a significant association (Chi-Sq=7.65, p=0.0057) was found.  A similar analysis correlating HPV with pEGFR showed no significant association (p=0.216).  A multiple logistic regression was used to investigate the joint association between p16 and pEGFR on HPV status.  After an analysis indicated no interaction between the two factors we fit the no interaction model.  The results were highly significant for p16 (p=0.002) and nearly significant but in the unexpected direction for pEGFR (p=0.074).  Conclusions', '    In tumor tissues of patients with HNSCC, hrHPV is associated with P-16 expression, and there might be an independent association between hrHPV and pEGFR.']",
        "Doc_id":"ASCO_76670-102",
        "Doc_title":" Association of p16 and pEGFR expression with high-risk HPV in head and neck squamous cell carcinoma.",
        "_version_":1606188992440565760},
      {
        "Meeting_name":" Phase I/IIa study of therapeutic p16INK4a vaccination in patients with HPV-associated cancers.",
        "Background":"['Background', '  Therapeutic strategies specifically targeting HPV-associated cancers are lacking. The cellular protein p16INK4a is strongly overexpressed in HPV-associated cancers, while in normal tissues p16INK4a expression is barely detectable. Therefore targeting of p16INK4a by vaccination could represent an interesting immune therapeutic approach for patients with HPV-associated cancers. We performed a phase I/IIa trial to monitor toxicity and immunogenicity of p16INK4avaccination (Vicoryx).  Methods', '  Patients with advanced p16INK4a-overexpressing, HPV DNA-positive cancer (anogenital region, head and neck) were included after completion of standard treatment. The protocolcomprised a total of 12 subcutaneous injections of a synthetic p16INK4 peptide mixed with Montanide ISA-51 VG in weekly intervals. Objectives of the trial were clinical safety and changes of humoral and cellular immune responses against the p16INK4apeptide. T cell responses were monitored by interferon-gamma ELISpot and antibodies by ELISA from peripheral blood.  Results', '  Phase I is completed with 10 patients, phase IIa is ongoing with 14 patients recruited of 16 planned. No toxicity was observed during and after vaccination that was regarded as related to vaccination with the auto-antigen p16INK4a in any of the patients. While pre-existing baseline T cell and antibody responses against the p16INK4a peptide were rare, p16INK4a-reactive T cells and antibodies were successfully induced in 8 of 16 patients analyzed to date. So far one head and neck cancer patient with lung metastases completed the entire study protocol with stable disease for now 18 months after the last vaccination. The remaining 9 patients of phase I had progressive disease.  Conclusions', '  This is the first study demonstrating that p16INK4a peptide vaccination is safe and well tolerated and that immune responses against p16INK4a can be induced by p16INK4a peptide vaccination and are not accompanied by clinical autoimmune symptoms. Further trials will be designed to assess whether this approach may be an adjuvant therapeutic strategy for patients with HPV-associated cancers. Clinical trial information', ' NCT01462838.']",
        "Doc_id":"ASCO_133734-144",
        "Doc_title":" Phase I/IIa study of therapeutic p16INK4a vaccination in patients with HPV-associated cancers.",
        "_version_":1606188980873723904},
      {
        "Meeting_name":" Characterization of HPV-positive head and neck cancer cell lines as preclinical models for targeted therapy",
        "Background":"['Background', 'Head and neck squamous cell carcinoma (HNSCC) is the 6th most frequently diagnosed non-skin cancer in the world. Risk factors associated with HNSCC include smoking, alcohol use and human papillomavirus (HPV) infection. With the decline in tobacco use, there has been an increase in the incidence of HPV-associated head and neck cancers. Our increased understanding of the mutational landscape demonstrates that HPV-positive and HPV-negative HNSCC are molecularly distinct. Additionally, patients with HPV-positive tumors respond better to therapy and have better prognosis overall. However, there are no targeted therapies for HPV+ HNSCC. Human cell lines can serve as preclinical models for studying cancer progression and identifying possible therapeutic targets. Our aim was to determine if HNSCC tumors and cell lines derived from head and neck tumors display similar proteomic profiles. Methods', ' Reverse phase protein array (RPPA) analysis was performed on 66 HNSCC cell lines. The HPV-status of these cell lines was determined by quantitative and reverse transcriptase polymerase chain reaction (PCR). Results', ' Real-time PCR analysis confirmed that 9 of the 66 cell lines were HPV-positive. Differential expression of 156 proteins was analyzed and proteomic pathway scores were determined by t-test in HPV-positive and HPV-negative HNSCC cell lines. We identified significant proteomic differences between HPV-positive and negative HNSCC cell lines. As observed in HPV-positive head and neck tumors, the clinical biomarker p16 was overexpressed in HPV-positive cell lines (p-value <0.0001). Furthermore, the expression of other cell cycle proteins p21 (p-value <0.0001) is lower in HPV-positive cell lines while cyclin E1 (p-value <0.03) and pRb (p-value <0.0001) are higher in HPV-positive cell lines. Similar to RPPA profiles of HNSCC tumors, HPV-positive cell lines show less epithelial to mesenchymal transition as indicated by lower levels of fibronectin and N-cadherin. When compared to HNSCC tumors, we also observed dysregulated expression of receptor tyrosine kinases such as epidermal growth factor receptor (EGFR). In comparison to HNSCC tumors, cell lines share similar trends in proteomic profiles. Conclusion', ' Our findings suggest that HNSCC cell lines are suitable preclinical models for the discovery of pathways activated in HPV-positive HNSCC and identification of possible targets for new therapeutic strategies.']",
        "Doc_id":"AACR_2015-1826",
        "Doc_title":" Characterization of HPV-positive head and neck cancer cell lines as preclinical models for targeted therapy",
        "_version_":1606189025911111680},
      {
        "Meeting_name":" Prognostic significance of nuclear factor kappa B expression in human papillomavirus-associated oropharyngeal cancer",
        "Background":"['Nuclear factor kappa B (NFB) has been implicated in the development of head and neck squamous cell carcinoma (HNSCC) from premalignant changes to tumor progression and recurrence. However, the prognostic significance of cytoplasmic or nuclear localization of NFB expression in human papillomavirus (HPV)-associated HNSCC has not been investigated largely due to limited patient samples. We hypothesized that cytoplasmic and/or nuclear expression of NFB may be a poor prognostic factor for tumor recurrence and overall survival (OS) regardless of p16 status. We conducted a retrospective study with archival formalin-fixed paraffin-embedded tumor biopsies collected from 188 patients with oropharyngeal SCC between October 1994 and February 2008 from Emory University Department of Pathology. Median follow-up was 21.7 and 58.0 months for p16- and p16+ patients, correspondingly. Tumors were evaluated for p16 expression (a surrogate marker for HPV) by immunohistochemistry (IHC). Cytoplasmic expression of NFBp65 by IHC or total expression combining cytoplasmic and nuclear localization were significantly greater in p16- patients (N=58) than p16+ patients (N=130), p<0.05. High cytoplasmic expression of NFBp65 was significantly associated with poor OS (p=0.0276) and the total expression was associated with recurrence (p=0.0081) by log rank test, whereas nuclear NFBp65 displayed weak association. Positive nuclear expression significantly correlated with smoking history (p=0.025). In conclusion, p16+ and low total NFBp65 expression is associated with the best while p16- and high total NFBp65 is associated with the worst OS in this patient cohort (Table I). (The study was supported by Head and Neck SPORE Grant P50CA128613).']",
        "Doc_id":"AACR_2012-4498",
        "Doc_title":" Prognostic significance of nuclear factor kappa B expression in human papillomavirus-associated oropharyngeal cancer",
        "_version_":1606189019108999168},
      {
        "Meeting_name":" ERCC1, p16, and ki-67 immunohistochemichal expression as predictive and prognostic markers in head and neck squamous cell carcinoma treated with platin-based induction chemotherapy",
        "Background":"['Background', '    Head and neck squamous cell carcinoma (HNSCC) treatment had undergone important changes, in particular due to the organ preservation and the advent of chemotherapy, particularly using platinum. The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and has been associated with resistance to platinum-based chemotherapy. The purpose of this study was to evaluate the role of ERCC1expression with p16 and Ki-67 as predictive markers in the response to platin-based induction chemotherapy and as prognostic markers in patients with HNSCC.  Methods', '    208 patients treated from 2000 to 2006 by an induction chemotherapy regimen for HNSCC were included retrospectively. ERCC1 (8F1 and FL297 clone), p16 and Ki-67 staining were performed on paraffin-embedded tumor tissue collected before chemotherapy. We assessed response to treatment, progression-free survival (PFS) and overall survival (OS).  Results', '    Respectively, 68% (142/208 patients) and 81.5% (163/200 patients) of HNSCC showed low expression of 8F1 and FL297 ERCC1. No correlation was found between the two clones (p=0.1). There was no correlation between the expression of 8F1 ERCC1, FL297 ERCC1 and Ki-67 and the response to induction chemotherapy, OS or PFS. However, in the subgroup of 129 patients treated with induction cisplatin-5FU chemotherapy, a low expression of 8F1 ERCC1 was significantly associated with a better response (p=0.027). Over expression of p16, found in 34.5% of cancers of the oropharynx was significantly correlated with a better OS (p=0.0007) and a better PFS (p = 0.01).  Conclusions', '   These results suggest that ERCC1 expression might be a useful predictive marker of HNSCC in patients treated by cisplatin-based chemotherapy. The 8F1 ERCC1 clone appears to be the best for immunohistochemical analysis; clone FL297 did not show any association with treatment response and survival. Independently, our study confirms the prognostic value of the over expression of p16 in carcinoma of the oropharynx.']",
        "Doc_id":"ASCO_93161-114",
        "Doc_title":" ERCC1, p16, and ki-67 immunohistochemichal expression as predictive and prognostic markers in head and neck squamous cell carcinoma treated with platin-based induction chemotherapy",
        "_version_":1606188973016743936},
      {
        "Meeting_name":" p16 expression and its prognostic impact in HNSCC pts in Belm-Brazil.",
        "Background":"['Background', ' p16 protein overexpression is a surrogate marker of oncogenic human papillomavirus (HPV) infection and a prognostic marker in head and neck squamous cell carcinoma (HNSCC) patients (pts). Here we aim to study p16 expression and its prognostic impact in HNSCC pts in Belm, Northern Brazil. Methods', ' Pts with locally advanced HNSCC treated between 2009-2012 at reference cancer center, Hospital Ophir Loyola, were included in this retrospective analysis. p16 expression was evaluated by immunohistochemistry (mouse monoclonal E6H4) and p16 was considered to be overexpressed when strong and diffuse nuclear and cytoplasmic staining was detected in at least 70% of tumor cells. Survival curves were estimated using the Kaplan-Meier method and compared with log-rank test. Univariable and multivariable hazard ratios (HRs) were estimated using the Cox proportional model. Results', ' 80 pts, 68 men/12 women, median age 59.5 y (28-89), staged as III (31%) and IV (69%), 88% smokers were studied. Primary sites were 19 oral cavity, 18 oropharynx, 12 hypopharynx and 31 larynx. p16 overexpression (p16+) was detected in 21 patients (26 %), predominantly in oral cavity (42%) and oropharyngeal (44%) tumors. Laryngeal tumors had significantly lower overexpression (6.45%, p 0.0001). Median follow-up was 20 months (1-73). 5-year overall survival rate for all sites was 38% in p16(+) pts versus 25% in those p16-negative (HR 0.4; 95%CI 0.49-0.9; p 0.02). Among oral cavity and oropharyngeal pts, p16+ pts also presented better 5-year OS outcomes', ' 49% vs. 18% (HR 0.49; 95%CI 0.26-0.92; p 0.02) and 42% vs. 18% (HR 0.27; 95%CI 0.07-1.0; p 0.05), respectively. Conclusions', ' p16 overexpression was frequent in these HNSCC pts and presented a favorable impact in terms of overall survival.']",
        "Doc_id":"ASCO_167398-176",
        "Doc_title":" p16 expression and its prognostic impact in HNSCC pts in Belm-Brazil.",
        "_version_":1606189034918379520},
      {
        "Meeting_name":" Biomarkers of HPV in head and neck squamous cell carcinoma",
        "Background":"['Human papillomavirus (HPV) is an accepted cause of head and neck squamous cell carcinoma (HNSCC) and patients with HPV-associated disease have a favorable prognosis. Currently there is no general guidance on the most appropriate biomarkers for clinical assessment of HPV. We measured DNA-based and serological markers in a single population-based study to assess their associations with disease outcome and to determine the most relevant biomarker for clinical use. HPV16 serology was determined using an immunoassay for the capsid protein L1, and multiplex serology based on the capsid protein L1 and the early oncoproteins E6/E7 for 488 patients. Immunohistochemical detection of p16 expression in tumors was performed in a subset of 233 cases, and we used two different methods to assess the presence of HPV16 DNA in a subset of 179 cases tumors. Seropositivity for the E6 and E7 proteins (individually) was significantly associated with enhanced survival (HRE6 or HRE7=0.3, 95%CI=0.2-0.5). Neither the presence of HPV16 DNA or p16 overexpression was associated with significant enhanced overall survival (HRDNA=0.8, 95%CI=0.5-1.3; HRp16=0.8, 95%CI=0.5-1.4). However the combination of HPV positive DNA and E6/E7 serology was associated with similarly enhanced overall survival (HRDNA+/E6+/E7+=0.1, 95%CI=0.01-0.6), while E6/E7 seronegative patients with evidence of HPV in tumor DNA did not show any evidence of favorable survival (HRDNA+/E6-/E7-=1.2, 95%CI = 0.7-2.2). Further, the combination of p16 staining and early gene seropositivity showed a favorable survival (HRp16+/E6+/E7+=0.3, 95%CI=0.1-0.9), while those who were p16 positive and early gene seronegative had significantly increased hazard of death (HRp16+/E6-/E7-=2.1, 95%CI=1.1-4.2). Determination of only HPV16 DNA status or p16 immunostaining is not an effective prognostic biomarker for HNSCC. However the combination of measurement of HPV16 DNA and p16 immunostaining with E6/E7 antibodies has high predictive clinical value, strongly suggesting that a combined biomarker approach is necessary for the assessment of the prognosis of HNSCC patients.']",
        "Doc_id":"AACR_2012-4497",
        "Doc_title":" Biomarkers of HPV in head and neck squamous cell carcinoma",
        "_version_":1606189023060033536},
      {
        "Meeting_name":" Cellular p16 localization and survival outcomes in head and neck cancer.",
        "Background":"['Background', '  Head and neck squamous cell carcinoma (HNSCC) constitutes approximately 3-5 percent of all cancers. Recent data suggest an increasing incidence rate among younger people who are often non-smokers and non-drinkers, which are believed to be caused by human papillomavirus (HPV) infection.  HPV positive tumors are typically found in the oropharynx and have better response to treatment and better disease outcome despite more advanced nodal stages. Therefore, HPV-positive HNSCCs represent a unique clinical subgroup with a separate tumor entity.   Methods', '  Patients treated for HNSCC from 2002 to 2006 at UNC hospitals and had banked tissue available were eligible for this study. Tissue microarrays (TMA) were generated in triplicate. Immunohistochemical (IHC) staining for p16 was performed and scored separately for nuclear staining and cytoplasmic staining. Human papilloma virus (HPV) staining was also carried out using monoclonal antibody E6H4. P16 expression, HPV status and other clinical features were correlated with progression-free (PFS) and overall survival (OS).  Results', '  135 patients had sufficient sample for this analysis. Median age of diagnosis was 57 years (range 20-82), with 68.9% males, 8.9% never smokers and 32.6 % never drinkers. 3 year OS rate and PFS rate was 63.0% and 54.1% respectively. Based on the p16 staining score, patients were divided into three groups', ' high nuclear any cytoplasmic staining group (HNAC), low nuclear low cytoplasmic staining group (LNLC) and low nuclear high cytoplasmic staining group (LNHC). HNAC and LNLC groups had significantly better overall survival than LNHC groups with hazard ratios of 0.01 and 0.37 respectively, after controlling for other factors, including HPV status. HNAC and LNLC groups also had better progression-free survival than LNHC group, although not significantly. A similar trend was observed in an independent patient population with comparable magnitude of effect.  Conclusions', '  Different p16 protein localization suggested different survival outcomes', ' high nuclear p16 staining is an indication of better survival while high cytoplasmic p16 staining signals poor survival outcome; and this effect is beyond the effect of HPV infection.']",
        "Doc_id":"ASCO_81533-102",
        "Doc_title":" Cellular p16 localization and survival outcomes in head and neck cancer.",
        "_version_":1606189031201177600},
      {
        "Meeting_name":" Correlation of PD-L1 expression and HPV status among primary and metastasized HNSCC tumors",
        "Background":"['Dysregulation of the immune checkpoints has been identified as one of the mechanisms tumor cells employ for immune escape. Human papillomavirus (HPV) plays an important role in the etiology of one subset of Head and Neck Squamous Cell Carcinomas (HNSCC). Recent studies reported that PD-1/PD-L1 pathway may be correlated with HPV-associated HNSCC. The degree of PD-L1 expression has been reported to be increased in those patients with HPV-positive disease. Also, PD-L1 expression in HNSCC was observed in the primary, recurrent, and metastatic disease setting. However, the clinicopathological implications associated with PD-L1 in HNSCC, as well as in disease metastasis, remain largely unclear.Using immunohistochemistry (IHC) and In situ hybridization (ISH) on VENTANA BenchMark ULTRA automated stainers, 40 cases of HNSCC, with matching primary and metastatic cancer stages, were evaluated for expression of PD-L1, p16, a surrogate marker of transforming HPV infections, and presence of HPV. Formalin-fixed paraffin-embedded tumor samples were subjected to PD-L1- and p16-IHC as well as HPV-ISH. A potential association between PD-L1 expression and HPV status among primary tumors and matched metastases was analyzed.Our data show that expression of PD-L1 or p16 is concordant in the majority of HNSCC primary vs metastatic tumor cases tested. Agreement rate of p16 expression among 40 case pairs of primary vs metastatic tumor was 88.2% with a 95% Confidence Interval (CI) of (73.4-95.3). PD-L1 expression was 76.9% (61.7-87.4) concordant among the 40 case pairs. Agreement rate between PD-L1 and p16 was 77.1% (61.0-87.9) in primary cases and 51.3% (35.9-66.6) in metastatic cases. No obvious association between PD-L1 and p16 expression was observed.']",
        "Doc_id":"AACR_2016-477",
        "Doc_title":" Correlation of PD-L1 expression and HPV status among primary and metastasized HNSCC tumors",
        "_version_":1606189008972414976},
      {
        "Meeting_name":" Analysis of KRAS variant in a cohort of resected HPV negative HNSCC.",
        "Background":"['Background', ' A single nucleotide polymorphism in let-7 complementary site 6 (LCS-6) of the KRAS 3UTR reduces KRAS inhibition by the let-7 family of miRNA. It is associated with increased risk and greater proliferation of NSCLC tumors, and poor outcomes in ovarian cancers. It is also associated with platinum resistance in head and neck squamous cell carcinoma (HNSCC). The excision repair cross-complementing group 1 enzyme (ERCC1) plays an important role in nucleotide excision repair and double strand break repair, also affecting platinum resistance. We measured ERCC1 expression and KRAS LCS-6 variant status as prognostic markers for HNSCC outcome in a series of p16 negative tumors.']",
        "Doc_id":"AACR_2017-4732",
        "Doc_title":" Analysis of KRAS variant in a cohort of resected HPV negative HNSCC.",
        "_version_":1606189017781501952},
      {
        "Meeting_name":" Targeting the Hedgehog pathway to inhibit osteosarcoma growth through dual effects on tumor and microenvironment cells.",
        "Background":"['In addition to serving crucial roles in bone development, Hedgehog (Hh) signaling contributes to the development and progression of many cancers, making it an attractive candidate for treatment of bone-resident cancers. Recent data suggest that Hh-targeted agents exert pluripotent effects on host bone microenvironment cells through both cell-intrinsic and paracrine mechanisms, interrupting the vicious cycle of tumor cell, osteoblast (OB), osteoclast (OC), and bone marrow stromal cell (BMSC) interactions in bone metastatic breast cancers. Here, reciprocal stimulation between tumor cells and bone cells enhance both tumor growth and bone pathology. Similarly, development of osteosarcoma (OS), the most common primary bone cancer, is strongly influenced by conditions within surrounding microenvironment providing additional points for therapeutic intervention.The 5-year survival rate for metastatic OS is under 30%, highlighting the need for novel and targeted treatments. We have demonstrated that mice deficient in the tumor suppressor ARF (p19ARF; p14ARF in humans) have enhanced rates of bone turnover, mimicking the adolescent growth period in which OS is prevalent. By crossing Arf-/- mice with those expressing Tax, an HTLV-1 oncogene that results in osteolytic tumors, we developed a model of high penetrant spontaneous OS that recapitulates many aspects of human disease. Here, suppression of bone turnover with the bisphosphonate zoledronic acid prevented the development of OS, suggesting that enhanced OC activity may stimulate OS growth. In agreement, we found that Tax+Arf-/- OS had increased RANKL-to-OPG ratios resulting in increased osteoclastogenic ability. Compared to normal osteoblasts and mesenchymal stem cell precursors, Tax+Arf-/- OS cells have increased expression of Hh pathway genes and exhibit increased susceptibility to Hh inhibitors (SMO antagonists). In particular, Tax+Arf-/- OS cells express high levels of the Hh ligands Sonic (SHH) and Indian (IHH), suggesting they may stimulate surrounding cells in a paracrine fashion. Notably, BMSC derived from non-tumor bearing Tax+Arf-/- mice also exhibit increased expression of pro-tumorigenic factors (including IL-6 and IGF), generating a fertile soil. SHH or conditioned media from Tax+Arf-/- OS cells enhanced OC activity and BMSC cell production of pro-tumorigenic growth factors. Furthermore, the increased OB and OC differentiation and activity present in Tax+Arf-/- cells could be abrogated with SMO inhibitors. We have established an OS cell line from Tax+Arf-/- mice (TAN) with the ability to form mineralized tumors upon intratibial injection. Using this model, we hypothesize that treatment with SMO antagonists will decrease OS growth due to both tumor cytotoxic effects and direct effects on host bone microenvironment cells that abrogate the pro-tumor microenvironment.']",
        "Doc_id":"AACR_2013-1624",
        "Doc_title":" Targeting the Hedgehog pathway to inhibit osteosarcoma growth through dual effects on tumor and microenvironment cells.",
        "_version_":1606189003179032577},
      {
        "Meeting_name":" Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas.",
        "Background":"['Background', ' Head and neck squamous cell carcinoma (HNSCC) is one of the leading causes of cancer death in the United States and Worldwide. Most cancers are tobacco-related, although an increasing number of tumors are found in nonsmokers in association with the human papilloma virus (HPV).Methods', ' The Cancer Genome Atlas (TCGA) is conducting DNA, RNA and miRNA sequencing along with DNA copy number profiling, quantification of mRNA expression, promoter methylation, and reverse-phase protein arrays on surgically resected samples from previously untreated patients with HNSCC. We report for the first time the results for 279 HNSCC samples for whom complete data are available.Results', ' The demographics of 279 patients enrolled in the study documented a median age of 61 years (range', ' 19-90); 27% female, and history of tobacco smoking in 80%. Over 30 sites of significant somatic copy number alteration (SCNA) were identified, most of which were shared with recently reported alterations in lung squamous cell carcinoma. However, some notable SCNA were absent in HNSCC', ' PDGFRA amplification and deletion of FOXP. Similarly, SCNA were compared between HPV + and HPV - tumors identifying numerous differences, including a paucity of receptor tyrosine kinase alterations in HPV + tumors and novel deletions in chromosome 11q and 14q. Exome sequencing revealed at least 15 significantly mutated genes at the False Discovery Rate (FDR) of <0.01, including', ' CDKN2A, TP53, PIK3CA, FAT1, MLL2, TGFBR2, HLA-A, NOTCH1, HRAS, NFE2L2, and CASP8. Consideration of differences between HPV + and HPV - tumors suggested differences which included nearly universal alteration of TP53 and frequent p16 mutations in HPV - tumors. By contrast, few TP53 or CDKN2A mutations were observed in HPV + samples. Strikingly, a large number of co-occurring genomic alterations were observed. For example, mutations of HRAS were observed nearly universally in combination with either CASP8 or FAT1. All three of these mutations were absent in HPV + patients. mRNA expression profiling revealed four distinct expression subtypes, each one enriched with distinct SCNA and mutational profiles', ' classical, basal, mesenchymal, and atypical. Deep sequencing by multiple platforms allowed for a detailed accounting of the role of HPV in alterations of the cancer genomes of HNSCC patients, including integration sites, disruption of tumor suppressor genes, and more complex rearrangements. Potential therapeutic targets for clinical trials with currently available drugs will be discussed.Conclusions', ' HNSCC is a heterogeneous tumor which displays distinctive patterns of somatic alteration potentially amenable to molecularly targeted therapies. We document for the first time using TCGA data, the role of an oncogenic virus in the human cancer genome. Results presented on behalf of TCGA.']",
        "Doc_id":"AACR_2013-1117",
        "Doc_title":" Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas.",
        "_version_":1606189017363120128},
      {
        "Meeting_name":" p16INK4A negatively regulates Leptin through miR-141 and miR-146b-5p in breast stromal adipocytes",
        "Background":"['Obesity, a disease linked to increased number of adipocytes in various tissues, is increasingly recognized as a risk factor for the development of breast cancer. Obesity has been reported to be associated with the occurrence of larger, more advanced tumors and aggressive cancer pathological features, including lymph node metastasis, advanced tumor stage, and high grade. Accumulating recent evidence highlights the tumor-surrounding adipose tissue as a key component of breast cancer progression. However, the molecular basis of adipocyte-related breast carcinogenesis remains elusive. To shed light on this important phenomenon, we investigated the autocrine and paracrine roles of the tumor suppressor p16 INK4A protein in adipocytes. We have found that down-regulation of p16INK4A by specific shRNA in breast adipocytes enhanced their migration/invasion abilities and increased the expression/secretion levels of various adipokines including leptin. In addition, we have shown that p16INK4A protein inhibits the pro-carcinogenic effects of breast stromal adipocytes in vitro and in tumor xenografts through repressing the expression/secretion of Leptin. Indeed, p16INK4A suppresses Leptin at the mRNA level. This effect is mediated trough miR-141 and miR-146b-5p, which inhibits Leptin expression through a specific sequence at the Leptin 3UTR. In addition, we present clear evidence that down-regulation of p16INK4A is sufficient to trans-activate breast stromal adipocytes, which promote epithelial-to-mesenchymal-transition in normal breast luminal cells in a leptin-dependent manner.These results provide the first indication that p16INK4A and miR-141 and miR-146b-5p represses Leptin and its procarcinogenic effects in breast stromal adipocytes. This indicates that p16 pathway has non-cell-autonomous tumor suppressor function.']",
        "Doc_id":"AACR_2016-757",
        "Doc_title":" p16INK4A negatively regulates Leptin through miR-141 and miR-146b-5p in breast stromal adipocytes",
        "_version_":1606188985873334272},
      {
        "Meeting_name":" CpG hypermethylation of p16 and BDNF associate with distant metastasis and survival of head and neck squamous cell carcinoma",
        "Background":"[\"Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world, and is highly mortal due to tumor recurrence and metastasis. Invasion of tumor cells into lymph nodes is one of the characters of regional metastasis and DNA hypermethylation is characterized in all types of human cancers. We therefore assessed whether epigenetic modification of DNA methylation is correlated to HNSCC metastasis, and evaluated the potential clinical implications of DNA methylation-based biomarker. Methylation array (Illumina infinium beadsarray) was applied to profile aberrant methylated CpG loci in HNSCC with lymph node invasiveness. Fourteen HNSCC tumors and two normal oral tissues were included.  value, the indicator of methylation status of each tested CpG locus, was derived with normalization. A cluster of 111 CpG loci was selected based on the difference between the mean  value of HNSCC tumors with and without regional metastasis (metz minus non-metz  0.2 or  0.2). Hierarchical diagram revealed distinct methylation signature was observed between tumors with or without regional metastasis. Ingenuity pathway analysis showed that the major diseases associated were neurological disorder and endocrine system disorder; and the top canonical pathway was Huntington's disease signaling. Of the top aberrant hypermethylated alleles, p16 and brain-derived neurotrophic factor (BDNF) were selected for further investigation on clinical implication. The methylation status of p16 (n=107) and BDNF (n=88) in HNSCC tumors was assayed by methylation-specific PCR. The primer sequences of both alleles were adopted from published report. Statistic analysis (t-test, 2 or Fisher's exact, logistic regress, Kaplan-Meier survival, and Cox regression) was performed using SPSS. Hypermethylation of p16 or BDNF were not associated with stage, metastasis at diagnosis, and differentiation. Hypermethylation of p16 was significantly associated with age (p=0.008, t-test) and lymph node invasion (p=0.021, 2-test), in contrast to distant metastasis of follow-up (p=0.061, 2-test). However, hypermethylation of BDNF was associated with distant metastasis of follow-up (odds ratio\", ' 4.96, 95% CI', ' 1.28-18.87, p=0.002), and combination with p16 improved the prediction (odds ratio', ' 10.31, 95% CI', ' 1.68-62.5, p=0.012). Hypermethylation of BDNF was associated with poor survival of patients (odds ratio', ' 2.80, 95% CI', ' 1.17-6.71, p=0.021), and hypermethylation of both alleles increased the risk (odds ratio', ' 3.81, 95% CI', ' 1.71-8.49, p=0.001). Together, our data suggest hypermethylation of p16 and BDNF may be potential biomarker associate with poor prognosis of HNSCC. The results also show the association of p16 and BDNF in gain of metastatic properties, which warrants further investigation.']",
        "Doc_id":"AACR_2012-4038",
        "Doc_title":" CpG hypermethylation of p16 and BDNF associate with distant metastasis and survival of head and neck squamous cell carcinoma",
        "_version_":1606189008695590912},
      {
        "Meeting_name":" TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects",
        "Background":"['Objective', ' Patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to radiotherapy and higher overall survival rates than do patients with HPV-negative HNSCC, but the mechanisms underlying this phenomenon are unknown. P16 is used as a surrogate marker for HPV infection. Our goal was to examine the role of p16 in HPV-related favorable treatment outcomes and to investigate the mechanisms by which p16 may regulate radiosensitivity.Methods', ' HNSCC cells and xenografts were used. P16-overexpressing (HPV/p16-negative HN5 and UMSCC-1) and p16 shRNA knockdown (HPV/p16-positive UMSCC-47 and UCPI-SCC154) cells, TRIP12 shRNA or siRNA knockdown (HPV/p16-negative HN5 and Fadu) cells were generated. The effects of p16 or TRIP12 on HNSCC cell radiosensitivity were determined by clonogenic cell survival. The effects of p16 on tumor xenografts (HPV/p16-negative HN5 and HPV/p16-positive UMSCC-47) radioresponse were evaluated by tumor growth delay assays. DNA double-strand breaks (DSBs) were assessed by immunofluorescence analysis of 53BP1 foci; DSB levels were determined by neutral comet assay; western blotting was used to evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene expression was examined by real-time polymerase chain reaction (PCR); and data from The Cancer Genome Atlas HNSCC project were analyzed.Results', \" P16 expression led to downregulation of TRIP12 protein both in vitro and in vivo via decreasing TRIP12 protein's half life, which in turn led to increased RNF168 levels and subsequently repressed DNA damage repair, represented by increased 53BP1 foci and neutral comet moment tails at 24 hours after irradiation. As a result, p16 expression enhanced radioresponsiveness both in vitro and in vivo. Inhibition of TRIP12 expression led to radiosensitization through repressed DNA damage repair, represented by decreased BRCA1 foci at 1 and 5 hours after irradiation; and increased neutral comet moment tails at 24 hours after irradiation. Furthermore, overexpression of TRIP12 was associated with poor survival in patients with HPV-positive HNSCC.Conclusions\", ' The findings of our study reveal that p16 participates in radiosensitization through influencing DNA damage repair. P16 downregulates TRIP12 protein expression via post-translational regulation. Inhibition of TRIP12 sensitized HNSCC cells via prohibition of DNA damage repair. These findings support the rationale of blocking TRIP12 signaling to improve radiotherapy outcomes.']",
        "Doc_id":"AACR_2016-1661",
        "Doc_title":" TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects",
        "_version_":1606188973930053632},
      {
        "Meeting_name":" Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.",
        "Background":"['Background', ' Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for both lung metastases and secondary primary cancers of the lung. Given the histopathologic similarity between these two lesions, distinguishing metastasis from a second primary lung SCC is often based on clinical grounds. Resection of oligometastatic HNSCC lesions may be associated with favorable prognosis, although this remains controversial. We demonstrate the potential of a commercially available genomic platform to resolve this clinical dilemma. Methods', ' A 64-year-old 20 pack-year former smoking male with history of HPV-associated oropharyngeal (OP) cancer 4 years prior presented with an asymptomatic 4.5 cm right hilar mass on surveillance images. Following surgical resection, the patient was referred for adjuvant chemotherapy for pT2aN1 (stage IIB) presumed lung SCC. To settle concerns this was a late recurrence of HNSCC, the primary OP and resected lung tumors were subjected to histopathologic analysis, p16 immunohistochemistry, in situ hybridization (ISH) for HPV 16/18 DNA, and tumor NGS via FoundationOne. Results', ' Both tumors showed poor differentiation, had strong nuclear and cytoplasmic p16 staining, and were positive for integrated HPV 16/18 by ISH. Comprehensive genomic profiling (CGP) by NGS for both specimens (OP, lung) reported the same somatic mutation in CYLD (K664*; c.1990 A > T) as the sole genomic alteration; moreover, the OP and lung specimens shared 11 of 12 variants of uncertain significance, confirming metastasis from the original OP. The CYLD mutation, present in 6% of HPV-associated HNSCC, results in C-terminal truncation and disruption of CYLD deubiquitinase activity, and is associated with NFB pathway activation. No chemotherapy was given, and PET/CT imaging 4 months after resection showed no evidence of disease. Conclusions', ' This is the first report of CGP by NGS to confirm the etiology of secondary squamous lung tumors in patients with HNSCC. In such cases, CGP applied to both primary and subsequent tumors may serve as a fingerprint for distinguishing SCC origin. The role of metastasectomy for treatment deserves additional evaluation.']",
        "Doc_id":"ASCO_166052-176",
        "Doc_title":" Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.",
        "_version_":1606189007255896064},
      {
        "Meeting_name":" An internal ribosomal entry site in the 5-untranslated region of p16INK4a mRNA provides a novel mechanism for the regulation of its translation",
        "Background":"['In mammalian systems, controlled progression through the cell cycle is essential for normal proliferation and its loss is a hallmark of malignancy. p16INK4a inhibits the cyclin-dependent kinases CDK4 and CDK6, thereby keeping the retinoblastoma protein (pRB) in a hypo-phosphorylated state, which can lead to G1/S checkpoint activation. In addition p16INK4a plays a crucial role in the process of replicative senescence. p16INK4a loss or inactivation is associated with predisposition to melanoma, pancreatic cancer and other malignancies, highlighting its recognized function as a tumor suppressor. Given its critical role in cell homeostasis, there is much interest in understanding the molecular regulators of p16INK4a expression.Here we report that p16 belongs to the expanding group of proteins whose translation is influenced by sequence/structural features of the 5UTR mRNA that are endowed of cellular Internal Ribosome Entry Site (IRES) activity. To study the potential for p16INK4a 5UTR to drive cap-independent translation we developed a dual-luciferase assay using a bicistronic vector (named pRuF), where wild type or deletion mutants of the p16INK4a 5UTRs were cloned as intervening sequence between Renilla and Firefly luciferase cDNAs. The p16INK4a 5UTR sequence in inverted orientation was included as additional control. Results of reporters relative activity coupled to control analyses of actual bicistronic mRNA transcription, indicated that the wild type p16INK4a 5UTR could stimulate Firefly luciferase translation. The IRES-like activity could not be mapped to a specific region of the 5UTR based on results with deletion constructs, and was two-fold stronger compared to the cMYC 5UTR, a known cellular IRES used as a control. Notably, hypoxic stress in particular, but also the treatment with mTOR inhibitors, enhanced the translation-stimulating property of the p16INK4a 5UTR. RNA immuno-precipitation (RIP) assays performed in the p16-positive melanoma-derived cell line SK-Mel-28 suggest that the RNA-binding protein YBX-1, known to act in translation control, can participate in p16 INK4a translation. Experiments were YBX-1 was over-expressed or knocked-down by si-RNA confirmed its involvement in p16INK4a cap-independent translational regulation. Taken collectively, our results suggest that the 5UTR region can modulate p16INK4a mRNA translation efficiency.']",
        "Doc_id":"AACR_2014-3384",
        "Doc_title":" An internal ribosomal entry site in the 5-untranslated region of p16INK4a mRNA provides a novel mechanism for the regulation of its translation",
        "_version_":1606188983280205824},
      {
        "Meeting_name":" MUC4 knockdown induces cellular senescence in head and neck cancer cells.",
        "Background":"['The limited effectiveness of therapy for patients with advanced stage Head and Neck Squamous Cell Carcinoma (HNSCC) or recurrent disease is a reflection of an incomplete understanding of the molecular basis of HNSCC pathogenesis. Cellular senescence is an extremely stable form of cell cycle arrest that limits the proliferation of damaged cells and may act as a natural barrier to cancer progression. MUC4, a high molecular weight glycoprotein, is overexpressed in many cancers and is implicated in cell proliferation, adhesion, anti-apoptosis, cell cycle regulation, migration and invasion of various carcinomas, but nothing is known about its clinical relevance and the mechanism through which it regulates cancer progression in HNSCC. Therefore, the present study was aimed to investigate clinical relevance and a potential role of MUC4 in cellular senescence in HNSCCs.Using immunohistochemical analysis, we observed a significant up regulation of MUC4 in 79% (68/86) of HNSCC tissue samples compared to only 10% (1/10) of benign tissues. Further, we observed high expression of MUC4 in a majority of HNSCC cell lines tested. Knockdown (KD) of MUC4 with specific shRNA in HNSCC cells markedly decreased cell proliferation. The doubling time increased from 26 h to 36 h and 34 h to 42 h in MUC4 silenced UMSCC-1 and SCC-10B cells, respectively as compared to their control counterparts. MUC4 KD in UMSCC-1 and UMSCC-10B cells resulted in accumulation of cells at the G0/G1 phase with concomitant decrease in the expression of cell cycle regulating proteins like Cyclin-E and Cyclin-D1, and decrease in BrDU incorporation. More importantly, MUC4 KD resulted in the induction of cellular senescence in both cell lines as indicated by an increase in the number of flat, enlarged and senescence-associated -galactosidase (SA--Gal) positive cells. Further,MUC4 KD resulted in the inhibition of FAK signaling, and decreased motility and invasive behavior in both UMSCC-1 and UMSCC-10B cells. Mechanistic dissection of senescent response to MUC4 silencing indicated decreased acetylated histone enrichment at Cyclin-E/Cyclin-D1 promoters, leading to their downregulation. Further, both cell lines UMSCC-1 and UMSCC-10B underwent a P16 and P21 dependent cellular senescence in response to MUC4 KD that requires inactivation of Akt and ERK signaling. In conclusions, these findings suggest a novel role of MUC4 in regulating cellular senescence and provide evidence of the functional role of MUC4 in the proliferation, motility and invasion of HNSCC cells. Therefore, downregulation of MUC4 may be a promising therapeutic approach for Head and Neck cancer treatment.']",
        "Doc_id":"AACR_2013-4044",
        "Doc_title":" MUC4 knockdown induces cellular senescence in head and neck cancer cells.",
        "_version_":1606188979394183168},
      {
        "Meeting_name":" Cell cycle regulators p16INK4a in metaplasia, dysplasia, and adenocarcinoma of Barrett's esophagus.",
        "Background":"['Background', ' p16INK4a is a cyclin-dependent kinase inhibitor, together with p21, p53 and p63 playing an important role in the regulation of the cell cycle and histomorphology in embryology, regeneration and in tumours. The variety of neoplastic and non-neoplastic types of epithelia and their architecture in Barrett esophagus may be associated with structural and functional proteins such as cell-cycle regulators. Loss of heterozygosity in p16INK4a/CDKN2A occurs in 75% of Barrett-carcinomas and is a amrker of better prognosis. Methods', ' Twenty formalin-fixed, paraffine embeded biopsies of Barrett esophagus with epithelia of specialised (colonic) type, twenty cases with metaplastic gastric foveolar type/cardiac type and ten cases of Barrett-associated adenocarcinoma (diffuse, intestinal and exophytic papillary type) were analysed for the expression and distribution of p16INK4a (Antibodies', ' mtm Heidelberg).All cases histologically and endopscopically confirmed (Munic Type C patients). Results', ' Nonneoplastic Barrett', ' Strong,expression of p16INK4a in the stratum spinosum cells of regenerative hyperplastic squamous epithelium', ' mostly coherent cells in columnar or reticulated arrangement. No expression in the foveolar cells of esophageal gastric heterotopia. Crypts and intestinal- metaplastic cardia-glands show slight to moderate nuclear and cytoplasmic expreession. Dysplasia and neoplasia in Barrett', ' Low p16INK4a positivity in colon-type specialized epithelium of low grade dysplasia. Moderarte positivity in high grade dysplasia. Most cases indeterminate for dysplasia are negative. Two different patterns of p16INK4a expression in invasive adenocarcinomas of Barrett epithelia', ' well-differentiated papillary and tubuloglandular cancers highly positive for p16INK4a; carcinomas of macroglandular or diffuse pattern or signet-cell-type no or low expression. Conclusions', ' Inactivation of CDKN2A /p16 and is an early event in Barrett\"s carcinogenesis correlated with abnormal deposition in tumor cells; it is a marker of dysplasia and good diffferentiated carcinomas and is not found in normal and highly malignant carcinoma cells.']",
        "Doc_id":"ASCO_49985-74",
        "Doc_title":" Cell cycle regulators p16INK4a in metaplasia, dysplasia, and adenocarcinoma of Barrett's esophagus.",
        "_version_":1606188985439223808},
      {
        "Meeting_name":" Risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.",
        "Background":"['Background', '   Germline mutations in the tumor suppressor gene CDKN2A occur in 5-20% of familial melanoma cases. A single founder mutation, p.Arg112dup, accounts for the majority of CDKN2A mutations in Swedish carriers. This mutation alters the peptide sequences of tumor suppressors p16-INK4A and p14-ARF. The aim of this study was to assess cancer risks in CDKN2A p.Arg112dup carriers and their first (FDRs) and second degree relatives (SDRS).  Methods', '  In this prospective cohort study, cancer diagnoses in CDKN2A p.Arg112dup mutation carriers (n=120), non-carriers (n=111), carriers FDRs (n=275) and SDRs (n=321) and controls (n=3976) were obtained from the Swedish Cancer Registry. Relative risks (RR) for cancers were calculated (number of cancers/person years). Due to the finding of high risks in mutation carriers of cancers that are normally associated with tobacco smoking, data was retrospectively collected on smoking history in carriers.  Odds ratios were calculated to compare smoking (ever-smoker/never-smoker) in carriers with or without a diagnosis of non-melanoma cancer. Two-sided 95% confidence intervals (95% CI) were calculated for all RRs.  Results', '  In carriers prospective RR for non-melanoma cancers was 5.0 (95% CI=3.7-7.3), for pancreatic cancer 43.8 (95% CI=13.8-139.0), for cancers in upper digestive tissues 17.1 (95% CI=6.3-46.5), and in respiratory tissues 15.6 (5.4-46.0). In FDRs and SDRs, RRs were significantly elevated for cancers in pancreas, respiratory and upper digestive tissues. In ever-smoking carriers compared with never-smoking carriers, the odds ratio of cancers in pancreas, respiratory or upper digestive tissues was 9.3 (95% CI= 1.9-44.7).   Conclusions', '  CDKN2A p.Arg112dup mutation carriers from melanoma-prone families and their FDRs and SDRs have elevated risk for pancreatic, lung, head and neck and gastro-esophageal carcinomas. These cancers were mainly seen in ever-smoking carriers. This is the first study that shows association between smoking history and cancer diagnoses in CDKN2A mutation carriers. Germline CDKN2A mutations may confer an increased sensitivity to carcinogens in tobacco smoke. CDKN2A mutation carriers should be counseled to abstain from smoking.']",
        "Doc_id":"ASCO_125956-144",
        "Doc_title":" Risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.",
        "_version_":1606189039338127360},
      {
        "Meeting_name":" A prospective study to evaluate the efficacy of curcumin in the management of advanced carcinoma cervix.",
        "Background":"['Background', ' Cervical cancer is the most common gynecologic cancer in India accounting for 132,082 new cases annually with a mortality of 74,118. Most cases present at an advanced stage of disease. Human papilloma virus (HPV) is the causative factor of cervical cancer. Curcumin (Diferuloylmethane) is obtained from curcuma longa. It acts as a chemo preventive agent with antioxidant, anti-inflammatory and antitumorogenic properties with low/nil pharmacological toxicity. In this study we elucidate the role of curcumin as an Objectives', ' Primary', ' To determine the efficacy of curcumin with radiotherapy and chemotherapy in improving the 5-year survival rate in advanced cases of cervical cancer. Secondary', 'To determine whether curcumin supplementation affects HPV, PCNA and P16 INK4a levels in exfoliated cervical cancer cells.adjuvant to chemo and radiotherapy in advanced cervical cancer patients. Curcumin is supplied as capsules of 500 mg each. The total daily dose of curcumin is 4 gram (8 capsules). Methods', ' Patient eligibility criteria', ' Invasive squamous cell carcinoma cervix, stages II-IIIB, ages 19 to 64 years, no history of prior malignancy, an ECOG 2, normal hematological and biochemical parameters, no evidence of HIV/AIDS. After informed consent, patients are treated with concurrent chemoradiation (radiotherapy 50 Gy/25 fractions over 5 weeks + intracavitory HDR brachytherapy 7Gy to point A three times, interdigitated starting at the end of 4 th week of treatment). Curcumin capsules are given for 42 days starting from first day of radiotherapy. Adverse events are recorded according to CTCAE V3. Study started after institute ethics committee approval. Of total planned 375 patients, 85 are accrued till date. Cervical scrapes are collected at baseline, 6 weeks (1st follow-up), 3 months (2nd follow-up), 6 months (3rd follow-upp) and 1 year (4th follow-up) post-treatment. HPV status, PCNA and P16INK4A protein expression are evaluated by immunocytochemistry. CT scan is done at 6 months to see the response. Primary endpoint', ' 5-year disease-free survival rate. The secondary endpoint', ' response rate by clinical examination and CT scan and to estimate down regulation of HPV, PCNA and P16 INK 4a with treatment.']",
        "Doc_id":"ASCO_54003-74",
        "Doc_title":" A prospective study to evaluate the efficacy of curcumin in the management of advanced carcinoma cervix.",
        "_version_":1606189013758115840},
      {
        "Meeting_name":" Correlation of PD-L1 expression with p16INK4A expression in nonoropharyngeal head and neck squamous cell carcinoma.",
        "Background":"['Background', ' The expression of PD-L1 expression is important for tumor cells to evade the immune system. The level of its expression and its correlation to disease prognosis is unclear in non-oropharyngeal head and neck squamous cell carcinoma (non-OPHNSCC). Methods', ' A retrospective clinicopathologic analysis was performed for 106 non-OPHNSCC patients diagnosed during the period from 2007 to 2014. We made tissue arrays from the paraffin-embedded non-OPHNSCC samples obtained from the patients, and studied PD-L1 and p16INK4A expression by immunohistochemistry. Systemic inflammatory factors including C-reactive protein, serum white blood cell, neutrophil, monocyte, and lymphocyte count were also analyzed to study the correlation. Results', ' We found that PD-L1 was overexpressed in 32.1% (34/106) and p16INK4A in 20.8% (22/106) of the patients who were studied. The expression of PD-L1 was associated with p16INK4A expression (p< 0.01), but was not associated with the level of systemic inflammatory factors. No significant prognostic values of PD-L1, p16INK4A, or other clinicopathologic factors were found except tumor stage (stage I/II vs. III/IV, p=0.03). Conclusions', ' This study demonstrates the correlation between PD-L1 and p16INK4A in non-OPHNSCC, which may provide important information for designing the clinical trials of anti-PD1/PDL1 treatment in head and neck cancer patients. Association between PD-L1 expression and clinicopathological characteristics.PD-L1 negative N = 72PD-L1 expression N = 34p valueAge (mean  SD)57.0  11.762.5  10.40.01a*StageI/II22 (30.6%)11 (32.4%)0.85III/IV50 (69.4%)23 (67.6%)HabitsBetel quid chewing41 (59.4%)16 (48.5%)0.30Tobacco use60 (87.0%)26 (78.8%)0.28Alcohol consumption45 (67.2%)22 (66.7%)0.96SitesOral47 (65.3%)20 (58.8%)0.44Hypopharynx20 (27.8%)9 (26.5%)Larynx5 (6.9%)5 (14.7%)Pathologic characteristicsp16INK4A expression9 (12.5%)13 (38.2%)<0.01*PNI21 (41.2%)18 (58.1%)0.14LVI29 (58.0%)19 (61.3%)0.77Tumor emboli15 (31.9%)15 (48.4%)0.14ECS11 (59.4%)8 (61.5%)0.83PNI, perineural invasion; LVI, lymphovascular invasion; ECS, extra-capsular spread aMann-Whitney test *p< 0.05']",
        "Doc_id":"ASCO_177992-194",
        "Doc_title":" Correlation of PD-L1 expression with p16INK4A expression in nonoropharyngeal head and neck squamous cell carcinoma.",
        "_version_":1606189035909283840},
      {
        "Meeting_name":" Racial differences in epigenetic modifications of head and neck squamous cell carcinomas",
        "Background":"['Disparities in incidence, mortality and survival are present among head and neck squamous cell carcinoma (HNSCC) patients, with males and African Americans disproportionately affected. Etiologic risk factors for HNSCC include tobacco and alcohol use and human papillomavirus (HPV) infection. Epidemiologically, HPV(+) tumors appreciate a prognostic advantage and have a distinct risk profile compared to HPV(-) HNSCCs. HPV(+) HNSCCs also have a different molecular profile than HPV(-) HNSCCs, specifically a higher somatic mutation rate among HPV(-) tumors and a higher degree of epigenetic modifications among HPV(+) tumors. Although disparities in epigenetic modifications by race have been described for breast, liver and colon cancer, these changes are not well understood among HNSCCs. Here, we described epigenetic modification of candidate genes affecting HNSCC carcinogenesis to understand potential molecular differences in tumor phenotype that may be associated with a distinct racial risk profile in HNSCC patients. We identified formalin-fixed paraffin-embedded (FFPE) HNSCC tissue blocks archived by the Louisiana Cancer Research Consortium Biospecimen Repository for Caucasian and African American patients. Information on site, sex and age was also available. DNA was extracted from tissue collected from areas of >70% cellularity. Using bisulfite sequencing (pyrosequencing), we quantified methylation levels for a panel of candidate genes that have been previously identified as significant in methylation of HNSCCs', ' CCNA1, CD1A, p16, DCC, GADD45 and NDN. Samples were also tested for HPV status. Using a Mann-Whitney-U test, we compared methylation levels by race, HPV status, sex and age. A total of 24 tissue blocks were retrieved, and we excluded five samples due to inadequate tissue, low DNA concentrations or ambiguous site definitions. The mean age at diagnosis was 56.7  6.5 years and the majority were male (79%). The race distribution was fairly even, with 47.4% African American and 52.6% White. Three HNSCCs were HPV(+), 15 were HPV(-) and one was inconclusive for HPV status. Overall, mean methylation levels were 54.9% for CD1A, 33.9% for CCNA1, 33.5% for DCC, 25.2% for NDN, 6.6% for p16, and 3.4% for GADD45. We noted a significant difference in mean methylation levels of CCNA1 by race (46.8% in African Americans and 19.1% in Whites, p < 0.02). We also found higher methylation levels for CD1A among HPV(+) tumors, 70.7%, compared to HPV(-) tumors, 55.6% (p < 0.04). DCC showed higher methylation levels in males compared to females (38.2% vs. 16.7% respectively; p < 0.04). Our preliminary results suggest that many factors, including race, may be associated with epigenetic modification in HNSCCs, and attention to the somatic profile of HNSCCs may indicate novel avenues for prevention and treatment of this disease.']",
        "Doc_id":"AACR_2013-3645",
        "Doc_title":" Racial differences in epigenetic modifications of head and neck squamous cell carcinomas",
        "_version_":1606189002637967360},
      {
        "Meeting_name":" Poor prognostic factors in human papilloma virus-positive head and neck cancer",
        "Background":"['Background', ' Human papilloma virus (HPV)-associated locally advanced head and neck squamous carcinoma (LA HNSCC) shows favorable treatment outcome, and treatment de-escalation is actively under-investigated. However, not all the HPV+ LA HNSCCs are curable, and some of them shows poor prognosis. The purpose of this study is to identify poor prognostic factors in HPV+ LA HNSCC patients. Methods', ' Patients who were diagnosed as LA HNSCC and tested for HPV status from 2000 to 2015 were included in this retrospective analysis. Demographic data (age, gender), smoking status, comorbidity, and clinical information about stage, pathology, type of definite treatment were obtained. HPV typing was conducted using HPV DNA genotyping chip or liquid bead microarray. Expression of p16 was assessed by immunohistochemistry. Univariate and multivariate analyses were done with factors associated with overall survival (OS) by Cox regression analysis. Results', ' One hundred fifty two HPV+ LA HNSCC patients were included in this study. Male patients were 82.2% and 43.4% were current or ex-smoker. Oropharyngeal cancer was 84.2%. In univariate analysis, old age, poor performance, non-oropharynx, advanced T stage (T3, 4), N0 stage, HPV genotype 18 were significantly associated with poor OS. Smoking was not associated with OS. In multivariate analysis, poor performance (ECOG PS1), non-oropharyngeal location were independently associated with shorter overall survival (HR 4.82, p = 0.003; HR 7.36, p = 0.001, respectively). Furthermore, HPV genotype 18 positivity was also independent poor prognostic factor for OS in HPV+ LA HNSCC (HR 11.41, p < 0.001). Conclusions', ' Non-oropharyngeal cancer, poor performance status, HPV genotype 18 were independent poor prognostic factors in HPV+ LA HNSCC. These patients should not be candidate of de-escalated treatment.']",
        "Doc_id":"ASCO_167377-176",
        "Doc_title":" Poor prognostic factors in human papilloma virus-positive head and neck cancer",
        "_version_":1606188984778620929},
      {
        "Meeting_name":" Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer",
        "Background":"['Objective', ' To validate a panel of methylation-based salivary rinse biomarkers (P16, CCNA1, DCC, TIMP3, MGMT, DAPK, and MINT31) previously shown to be independently associated with poor overall survival and local recurrence in a larger, separate cohort of patients with head and neck squamous cell carcinoma (HNSCC). Methods', ' One hundred ninety-seven patients were included. All pre-treatment saliva DNA samples were evaluated for the methylation status of the gene promoters by quantitative methylation-specific PCR. The main outcome measures were overall survival, local recurrence-free survival and disease-free survival. Results', ' In univariate analyses, the detection of hypermethylation of CCNA1, MGMT, and MINT31 was significantly associated with poor overall survival; the detection of hypermethylation of TIMP3 was significantly associated with local recurrence-free survival; and the detection of hypermethylation of MINT31 was significantly associated with poor disease-free survival. In multivariate analyses, detection of hypermethylation at any single marker was not predictive of overall survival in patients with HNSCC; detection of hypermethylation of TIMP3 in salivary rinse had an independent, significant association with local recurrence-free survival (Hazard Ratio, 2.51, 95% CI, 1.10 to 5.68); and none of the studied markers was significantly associated with disease-free survival. Conclusions', ' The detection of promoter hypermethylation of the seven genes in salivary rinse as an independent prognostic indicator of overall survival in patients with HNSCC was not validated. Detection of promoter hypermethylation of TIMP3 in pretreatment salivary rinse is independently associated with local recurrence-free survival in patients with HNSCC and may be a valuable salivary rinse biomarker for HNSCC recurrence. Such a test could potentially refine our ability to identify HNSCC patients at a high risk for recurrence.']",
        "Doc_id":"AACR_2012-723",
        "Doc_title":" Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer",
        "_version_":1606189041308401664},
      {
        "Meeting_name":" Is there an interaction between epidermal growth factor receptor (EGFR) inhibition and p16-status in patients (pts) with oropharyngeal squamous cell cancer",
        "Background":"['Background', '    Conflicting data exists about whether EGFR inhibition is more or less effective in pts with p16 positive or negative oropharynx cancer (OPC). We update results from two institutional clinical trials in pts with locoregionally advanced head and neck squamous cell carcinoma (LRA HNSCC) given chemoradiotherapy either with or without the oral EGFR inhibitor gefitinib (G), with specific attention to the subset of pts with p16-defined OPC.  Methods', '   Between 1996-2000, 44 pts with LRA HNSCC were treated on a Cleveland Clinic IRB-approved protocol using concurrent cisplatin, fluorouracil and radiation without G (G- cohort). Between 2003-2007, 60 similar pts were treated using the same chemoradiotherapy regimen with the addition of G 250 mg daily for 2 years beginning on day 1 of radiation (G+ cohort). Available biopsy material from 64 OPC pts (23 G-, 41 G+) was retrieved and tested by immunohistochemistry for p16 (as a surrogate for human papillomavirus) positivity. Kaplan-Meier outcome projections were compared using the log-rank test.    Results', '    With a median follow-up in excess of 7 years for all pts, survival and patterns of failure did not differ between the two trials. The 5-year overall survivals (OS) were 68% vs. 64% (p=0.73) and relapse-free survivals (RFS) 65% vs. 63% (p=0.85) in the G+ and G- cohorts respectively. OPC was more frequent in the more recently treated G+ cohort (68% vs. 53%). Excluding 14 pts for whom tumor was unavailable, OPC p16-positivity was also more frequent in the G+ cohort (74% vs. 63%). As expected, outcomes in the p16+ OPC pts were significantly better than in the p16- OPC pts including OS (66% vs. 58%, p=0.049) and RFS (69% vs. 56% p=0.027). However, in comparing the G+ and G- cohorts, the use of G did not significantly alter any survival outcome or pattern of failure in either the p16+ or p16- OPC pts.   Conclusions', '    Although the retrospective nature of this analysis limits the strength of our conclusions, in the definitive management of LRA HNSCC, we could identify no effect of oral EGFR inhibition on any outcome. In subset analysis there was also no differential impact found in either the p16+ or p16- OPC pts. Clinical trial information', ' NCT00352105.']",
        "Doc_id":"ASCO_113477-132",
        "Doc_title":" Is there an interaction between epidermal growth factor receptor (EGFR) inhibition and p16-status in patients (pts) with oropharyngeal squamous cell cancer",
        "_version_":1606189006322663424},
      {
        "Meeting_name":" p16INK4A down-regulation activates breast stromal adipocytes.",
        "Background":"['Obesity, a disease linked to increased number of adipocytes in various tissues, is now recognized as a risk factor for the development of breast cancer. Importantly, obesity has been reported to be associated with the occurrence of larger, more advanced tumors and aggressive cancer pathological features, including lymph node metastasis, advanced tumor stage, and high grade. Cancer-associated adipocytes (CAAs), the most abundant cellular component of breast cancer-associated stroma, promote carcinogenesis through paracrine effects. However, the molecular basis of adipocytes implication in breast carcinogenesis remains elusive. To shed light on this important phenomenon, we established and characterized normal adipocytes from post-plastic surgery of breast tissues. We have shown that these cells express various adipocyte biomarkers, including Leptin, TNF- and FABP4. Furthermore, we investigated the role of the tumor suppressor p16 INK4A protein in adipocytes activation. We have found that specific down-regulation of p16INK4A by shRNA increased the expression/secretion levels of various adipokines including leptin, activated breast adipocyte and enhanced their migration/invasion abilities. Consequently, media conditioned with these cells stimulated the proliferation and the migration/invasion of breast cancer cells and enhanced endothelial cell differentiation into capillary-like structures. In addition, we have also shown that media conditioned with breast cancer cells decrease the expression of p16INK4A and increase the expression of leptin in adipocytes.These results provide the first indication that p16INK4A down-regulation in breast stromal adipocytes is an important step toward their activation.']",
        "Doc_id":"AACR_2013-512",
        "Doc_title":" p16INK4A down-regulation activates breast stromal adipocytes.",
        "_version_":1606189015134896128},
      {
        "Meeting_name":" MicroRNA profiling reveals miR-205 upregulation is associated with head and neck squamous cell carcinoma and modulates E2F1 signaling.",
        "Background":"['Introduction', ' Based on our previous screen of miRNAs in head and neck squamous cell carcinoma (HNSCC), we sought to functionally evaluate candidate transcripts that could modify Rb/E2F signaling. Thus, we chose to investigate miR-205 as a putative HNSCC oncogene and regulator of E2F1 protein expression.Methods', ' miRNAs were isolated from 29 newly diagnosed HNSCC tumors (HPV-positive', ' 14, HPV-negative', ' 15) and 4 normal mucosa samples using the PureLink RNA Isolation Kit (Invitrogen). miRNA was analyzed using the ABI Megaplex protocol without pre-amplification (Applied Biosystems). Reactions were run using the miRNA Reverse Transcription Kit and Megaplex RT Human Pool A primers, then analyzed by TaqMan Low-Density Array (TLDA) cards. miRNA data was normalized to MammU6 expression, with undetectable transcripts assigned a Ct value of 40. Empirical Bayes moderated t-statistics were used to assess miRNA differential expression and the Benjamini-Hotchberg correction was applied to these p-values to account for multiple hypothesis testing. miR-205 expression was then transiently modified (Dharmacon) in an HPV-positive and -negative HNSCC cell line. These cells were characterized by Western blot and assayed for changes in proliferation utilizing two- and three-dimensional growth assays.Results', ' HNSCC miRNA expression was characterized by a general upregulation of individual transcripts and miRNA families compared to normal mucosa. This difference in expression was independent of HPV-status, with only two miRNAs demonstrating differential expression between HPV-positive and -negative tumors', ' miR-449a and miR-129-3p. miR-205, a transcript upregulated in both subtypes, was able to modulate proliferation and E2F1 expression levels in 93VU147T (HPV+), but not UM-SCC-15 (HPV-). Further Western blot analysis concluded modulations in Rb-phosphorylation status and apoptotic signaling factors may explain these E2F1-mediated effects. Conclusions', ' While significant differences are evident in the miRNA profiles of HNSCC compared to normal mucosa, a striking degree of similarity exists between HPV-positive and -negative miRNA deregulation. A functional evaluation of miR-205 determined this transcript is capable of modulating HNSCC growth in the genetic context of p16 expression and proapoptotic signaling.']",
        "Doc_id":"AACR_2013-3100",
        "Doc_title":" MicroRNA profiling reveals miR-205 upregulation is associated with head and neck squamous cell carcinoma and modulates E2F1 signaling.",
        "_version_":1606188985191759872},
      {
        "Meeting_name":" Prognosis of HPV-positive squamous cell carcinoma of tonsil-expressing high level of p16 and low level of EGFR.",
        "Background":"['Background', ' HPV infection has been known to be one of the important risk factors for carcinogenesis of head and neck squamous cell carcinoma (HNSCC). The over-expression of epidermal growth factor receptor (EGFR) correlates with a poor prognosis in HNSCC. We investigated the relationship between HPV status and EGFR expression and the prognostic impact of these markers in tonsil cancer. Methods', ' Eligibility criteria was the patients diagnosed as SCC of tonsil and received curative radical resection with available tumor tissue samples. In situ hybridization for HPV and immunohistochemistry for p16, EGFR, and p53 were performed. Results', ' Among 66 tonsil cancer patients, 24 (36.3%) patients showed HPV positivity. There were no statistically significant differences in clinical characteristics including sex, age, smoking history, TNM stage and treatment modalities between HPV-positive and -negative patients. The over-expression and high intensity of p16 had significant correlation with HPV positivity (p=0.003, 0.017). However, no correlation was found between p53 and HPV infection. There was a trend that the proportion of EGFR over-expression was greater in HPV-negative than in HPV-positive patients (p=0.082), and no or low EGFR intensity was observed in the patients showing p16 over-expression (p=0.015). Among the HPV-positive patients, the frequency of EGFR over-expression was significantly higher in ex- or current smokers (p=0.005). There was meaningful difference of three years disease-free survival between never smokers showing both over-expression of p16 and low expression of EGFR and the others (90.0% and 73.5%, respectively, p=0.082). On univariate analysis, the significant clinicopathologic factors affecting disease-free survival were smoking history and EGFR intensity (p=0.020 and 0.017, respectively). Conclusions', ' Taken together, p16 was a good surrogate marker for HPV infection. The expression of EGFR was inversely correlated with HPV positivity, but HPV-positive patients with smoking history showed EGFR over-expression. In the HPV-positive tonsil cancers, high p16 and low EGFR expression should be considered as favorable prognostic markers.']",
        "Doc_id":"ASCO_43735-74",
        "Doc_title":" Prognosis of HPV-positive squamous cell carcinoma of tonsil-expressing high level of p16 and low level of EGFR.",
        "_version_":1606189038710030336},
      {
        "Meeting_name":" The long non-coding RNA CAI2 is a tumor suppressor gene",
        "Background":"['We have recently reported on the discovery of a long non-coding RNA imbedded in intron 2 of the p16/ARF (CDKN2A) locus at 9p21. CAI2 is a non-conserved, RNA pol II regulated gene with whose expression is highly correlated with parent genes p16 and ARF. However, CAI2 is expressed in cell lines deleted for p16, ARF and even p15, and is expressed cell lines epigenetically silenced for p16 and/or ARF. Furthermore, treatment of p16 and/or ARF epigenetically silenced cell lines with 5-aza-2-deoxycytidin allows p16 and/or ARF re-expression while having no influence on CAI2, confirming independent regulation. Speculating, therefore, that the regulatory region of CAI2 lies imbedded in the non-transcribed portion of intron 2, we created expression constructs of the immediate 5 region of CAI2. However, consistent with a bioinformatical analysis, no regulatory activity was detected. This suggests that this non-coding RNA is non-traditionally controlled by remote but yet to be identified regulatory element(s) and/or mechanisms. By colony formation assay, CAI2 overexpression can inhibit cell growth in the p16 intact HEK293T and SK-BR-3 breast cancer cell lines. RNA Immunoprecipitation has revealed that CAI2 interacts with H3K27me3, a recruiter of Polycomb Repressive Complex 1 (PRC1) that modulates chromatin structure and gene expression, and BMI1, a PRC1 complex protein that is a negative regulator of p16. Consistent with this effect, CAI2 can induce p16 expression in HEK293T cells, and this was hypothesized to be the mechanism by which CAI2 inhibits cell growth. However, we now show that CAI2 can also inhibit colony formation in the p16/ARF deleted MCF7 and MDA-MB-231 breast cancer cell lines. Interestingly however, CAI2 overexpression had little to no effect on 2D cultures of HEK293T or MCF7 cells including DNA synthesis, XTT metabolic activity or cell count.As CAI2 is imbedded in the p16/ARF gene, standard siRNAs may inadvertently influence p16 and/or ARF expression due to actions on their pre-mRNAs. Therefore, we created a series of partial CAI2 knockouts using CRISPR technology and compared their growth by colony formation assay. Notably, clones containing a partial knockout of the 5 region of CAI2 proliferated faster than mock transfected clones, consistent with the growth suppressive properties observed with CAI2 overexpression. In 2D cultures, a small increase in DNA synthesis was also observed in the partial deletions. The HEK293T clones containing partial deletions of CAI2 also exhibited small increases in expression of the remaining intact portions of the gene with a concomitant decrease in p16 expression, all consistent with an influence of CAI2 on p16 expression and cell growth; no influence on ARF expression was observed.Taken together, the data demonstrate that CAI2 is capable of influencing p16 expression, but this influence is insufficient to fully account for the ability of CAI2 to regulate growth, and we conclude that CAI2 is a bona fide tumor suppressor gene in its own right.']",
        "Doc_id":"AACR_2016-980",
        "Doc_title":" The long non-coding RNA CAI2 is a tumor suppressor gene",
        "_version_":1606189020303327232},
      {
        "Meeting_name":" P16 DNA methylation inactivates transcription of IncRNA ANRIL",
        "Background":"['The exonic ANRIL (P15AS) is a 3.8-kb lncRNA transcribed from the antisense strand of the P14 promoter and flanking regions. Recently, we have constructed a P16 promoter DNA methyltransferase (P16-Dnmt) using the pTRIPZ vector that can specifically methylate human P16 CpG islands and found that P16 methylation directly leads to gene transcription silence [Cui et al. Genome Biology 2015, 16', '252]. However, whether ANRIL transcription is affected by P16 DNA methylation has not previously been reported. In the present study, correlation between endogenous P16, P15, P14 mRNA and ANRIL levels in a panel of cell lines were determined using quantitative RT-PCR. Unexpectedly, the results showed that ANRIL transcriptional level was positively and significantly correlated with the P16 mRNA level (r = 0.774, P = 0.003), but not correlated with the P15 or P14 mRNA levels (r = 0.09 or 0.30, P = 0.78 or 0.35). These phenomena were confirmed using the public available transcriptome data in the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE). Furthermore, transcription of both ANRIL and P16 mRNA were observed only in cancer cell lines in which the P16 alleles are unmethylated (Caski, SGC7901, BGC823, GES1, Siha and HeLa), but not in these cell lines in which the P16 alleles are fully methylated (Colo205, PC3, MHCC97H, RKO, SW480 and AGS). These suggest the possibility that methylation of the P16 promoter may inactivate transcription of ANRIL as well as P16. To study the possible causality between P16 DNA methylation and transcriptional silence of ANRIL, we employed P16-Dnmt to induce P16-specific DNA methylation in gastric cancer BGC823 cells, and found that transcription levels of both P16 and ANRIL were significantly decreased by the induced P16 DNA methylation (P<0.001 and 0.024, respectively). Besides, transcription level of P14 was also reduced (P = 0.043) while the P14 promoter CpG islands remained to be unmethylated. In contrast, P16 DNA demethylation induced by an artificial P16-specific transcription factor [Zhang et al. Human Gene Therapy 2012, 23', '1071-81] re-activated transcription of both ANRIL and P16 in H1299 cells (P<0.001). The mechanism of inactivation of ANRIL expression by P16 DNA methylation is under investigation. In conclusion, transcription of ANRIL is regulated by P16 DNA methylation.']",
        "Doc_id":"AACR_2016-999",
        "Doc_title":" P16 DNA methylation inactivates transcription of IncRNA ANRIL",
        "_version_":1606189013730852864},
      {
        "Meeting_name":" Differential effects of antiangiogenesis treatments on betel-nuts-related head and neck squamous cell carcinoma in Taiwan",
        "Background":"['Background', 'The treatment of head and neck squamous cell carcinoma(HNSCC) in Taiwan is very challenging and might be related to betel-nuts use. Betel-nuts chewing might contribute to (1)strong inflammation, invasion, and angiogenesis; (2)easy recurrence or metastasis; (3) poor response to chemotherapy, radiation, and epidermal growth factor receptor(EGFR) inhibitors.Purpose', 'We try to prove different kinds of anti-angiogenesis treatments will lead to different response on betel-nuts related HNSCC in Taiwan.Methods', 'Different anti-angiogenesis treatments, such as axitinib(VEGFR2 inhibitor), nintedanib(VEGFR2/FGFR inhibitor), and regorafenib(VEGFR2/FGFR/ more other signals inhibitor) were first used to treat (1)HUVEC; (2)HNSCC cell lines(SCC4, SCC9, SCC15, SCC25, FaDu, SAS, KB, Cal27, and TW2.6, betel-nuts related) to evaluate (a) invasion capacity by wound healing; (b) drug sensitivity by MTT assay; (c)synergistic effect with chemotherapy, EGFR inhibitor, and polo-like kinase inhibitor. Western blotting was also used to test signal change by treatments. TW2.6 had already been proved to possess defective p53, p16 loss, and increased Bcl2.Results', 'In our previous study, TW2.6 was resistant to chemotherapy, radiation, EGFR inhibitors, and ani-angiogenesis treamtents, such as axitinib and sunitinib. Axitinib, pure VEGFR2 inhibitor, was found to suppress HUVEC more prominently than nintedanib or regorafenib did. Invasion capacity of all HNSCC cell lines were all blocked by the three drugs but regorafenib did mostly well. However, axitinib had no effect on TW2.6; but nintedanb and regorafenib had moderate response on TW2.6. Besides, nintedanib and regorafenib both would resensitize TW2.6 to respond to chemotherapy, EGFR inhibitor, and polo-like kinase inhibitor again. Western blotting showed mesenchaml differentiation markers(slug, Twist, snail, Axl, c-MET, Vimentin) decreased after nintedanib and regorafenib use, too.Conclusion', 'TW2.6 might reflect treatment refractoriness of betel-nuts related HNSCC in Taiwan. In addition to PI3K/mTOR dual inhibition and polo-like kinase inhibitor with radiation(our studies shown in AACR and ESMO2015), VEGFR2/FGFR dual blockage might be effective on TW2,6 and resensitize TW2.6 to EGFR inhibitor, polo-like kinase inhibitor, & chemotherapy, maybe through the inhibition of mesenchymal transformation. VEGFR2/FGFR dual blockage will be one future combination backbone of betel-nuts related HNSCC.']",
        "Doc_id":"AACR_2016-3260",
        "Doc_title":" Differential effects of antiangiogenesis treatments on betel-nuts-related head and neck squamous cell carcinoma in Taiwan",
        "_version_":1606189035243438080},
      {
        "Meeting_name":" Differences in immune escape in HPV+ versus HPV- head and neck squamous cell carcinoma",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide and has not seen an improvement in survival in decades. Current standard-of-care treatments including surgical resection, chemotherapy and radiation still lead to high rates of recurrence and loco-regional metastasis contributing to the poor prognosis in these patients. It is well established that HNSCC are highly immune-modulatory tumors and may therefore benefit from immunotherapy treatment regimens. Better methods are therefore needed to match patients with the appropriate immunotherapy. Recently, human papillomavirus (HPV) was implicated in the etiology of a subset of HNSCC arising in younger patients without a history of alcohol and tobacco use. Approximately 30% of HNSCC tumors are HPV+ and despite late stage presentation, often have a better prognosis and response to therapy. This study examines how host immune recognition and response varies between HPV+ and HPV- HNSCC, with the goal of identifying new targets for immunotherapy. The immune profile and HPV infection status of 41 HNSCC patient tumor samples obtained from surgical resection was characterized by qRT-PCR, PCR, and IHC techniques. Tumor samples were analyzed for the expression of 40 genes involved in immune activation and suppression in the tumor microenvironment to generate an immune profile. Gene expression levels were normalized to GAPDH and compared across HPV+, HPV- and normal tissue groups by ANOVA and post-test pairwise analysis. HPV infectivity of tumor biopsies was determined using HPV consensus primers (MY09/MY11 and GP5+/GP6+) and confirmed with p16 immunohistochemistry. From these studies, eight of 41 (20%) HNSCC biopsies were HPV+ by PCR and IHC analysis. HPV+ tumors demonstrated statistically significant increased expression of genes related to immunosuppression including regulatory T (CD4, FoxP3, CTLA-4, and FasL) and myeloid suppressor cell markers (CD11b and IL-6, an inducer of these suppressor cells), as well as negative-regulators (SOCS1) (p<0.05). These tumors also demonstrated an increase in markers of immune activation and infiltration, including evidence of T cells (CD4, Fas-L), antigen presenting cells (CD80, CD83, CD1c), and inflammatory cytokines and co-stimulatory molecules (IL-2, IL-12, IFN- , and OX40L) (p<0.05). There were no statistically significant differences in gene expression found between normal tissue and HPV- HNSCC tumors. These studies demonstrate a general pattern of increased immunogenicity and concurrent immunosuppression in patients with HPV+ versus HPV- HNSCC that could potentially be used to inform immunotherapy treatment of HNSCC patients. HPV+ tumors may be more effectively treated with a regimen that employs a combination of immune stimulation and reversal of immune tolerance mechanisms, while HPV- tumors may require greater immune stimulation to activate endogenous anti-tumor immune responses.']",
        "Doc_id":"AACR_2012-3550",
        "Doc_title":" Differences in immune escape in HPV+ versus HPV- head and neck squamous cell carcinoma",
        "_version_":1606189026736340992},
      {
        "Meeting_name":" Landscape of genetic alterations in oropharyngeal squamous cell carcinoma (OPSCC) based on RNA-seq and WES analysis of FFPE samples and correlation with data from TCGA.",
        "Background":"['Background', ' Whole human exome sequencing (WES) has identified well characterized somatic mutations (such as TP53, CDKN2A, PIK3CA and HRAS) in patients with squamous cell carcinoma of the head and neck (SCCHN). We sought to optimize a combined RNA-seq and WES approach for identifying actionable mutations and gene expression signatures in p16 + versus - OPSCC. Methods', ' Relying on formalin fixed and paraffin embedded (FFPE) samples we applied a minimal mutation and copy number content (151 genes) on DNA and an extensive RNA panel on a total of 27 OPSCC (22 p16 +, and 5 p16 -). SAMSeq was used to identify the differentially expressed genes. Unsupervised hierarchical clustering of the TCGA OPSCC samples with available p16 status (n = 31) was performed for external validation of the results. Statistical significance was further tested by Fishers exact test. Results', ' We identified a gene signature differentially expressed in p16+ and p16- OPSCC. External validation showed a significant association between gene expression and p16 status (P = 0.00033). We did not however find an association with mutation burden and smoking history. A number of pathways associated with this gene signature such as NCAM1 may have relevant biologic implications in OPSCC. Conclusions', ' Our results underscore the reliability of integrating data from FFPE samples in distinguishing gene signatures characteristic of p16 + versus p16- OPSCC; these signatures need to be further explored for their biologic relevance in OPSCC (This research was supported by a grant NCI R21 CA182661-01A1to NFS and GZC).']",
        "Doc_id":"ASCO_184446-199",
        "Doc_title":" Landscape of genetic alterations in oropharyngeal squamous cell carcinoma (OPSCC) based on RNA-seq and WES analysis of FFPE samples and correlation with data from TCGA.",
        "_version_":1606188989583196160},
      {
        "Meeting_name":" Androgen receptor-mediated regulation of p14ARF transcription in prostate tumor cells",
        "Background":"['The p14ARF tumor suppressor is often deleted or silenced in malignancies. Prostate tumors are an exception, where p14 expression is elevated. To understand this phenomenon, we assessed the expression of p53 pathway members, which are most effected by p14ARF. The expression of androgen receptor (AR), a pivotal prostate cancer regulator, which is also affected by p14arf and MDM2 was analyzed as well. The studies used archival prostate tumor tissues obtained from prostatectomies performed at the Veterans Affairs-Northern California Health Care System in Mather California between 1996 and 2002 to better define the relationship between these interrelated networks. A prostate tumor tissue array consisting of 78 tumors of differing stages and grades was constructed to evaluate correlations between multiple parameters. Immunohistochemical studies assessed expression of the proliferation marker Ki67, p53, MDM2, MDM4, p14ARF, and the AR in the nuclear and cytoplasmic compartments of tumor and adjacent cells. p53, MDM4, p14ARF and AR were detected in nuclear and cytoplasmic compartments of tumor and non-tumor cells, but were predominantly nuclear. MDM2 expression was primarily cytoplasmic in tumor cells. Multivariate analysis of the immunohistochemical markers identified a strong correlation between expression of p14ARF and AR. Studies utilizing the prostate CWR22 xenograft and LNCaP cell line models revealed that castration or androgen deprivation resulted in reduced p14arf levels and that this effect correlated with a precipitous decline in E2F1-3a levels. In a reciprocal analysis, RB ablation enhanced p14ARF transcription, arguing that the E2F/RB pathway mediates AR-dependent p14ARF expression. However, we also identified an AR binding site located 40 KB upstream of the p14ARF gene. Chromatin immunoprecipitation (ChIP) studies showed that in prostate cells this site was bound by AR. ChIP studies also revealed E2F1 and E2F3 were present at the p14ARF promoter. Together, the studies argue p14ARF is a direct transcriptional target of AR and that AR and E2F collaborate to promote p14ARF expression..']",
        "Doc_id":"AACR_2015-5051",
        "Doc_title":" Androgen receptor-mediated regulation of p14ARF transcription in prostate tumor cells",
        "_version_":1606189030602440704},
      {
        "Meeting_name":" Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level",
        "Background":"['Spontaneous canine head and neck squamous cell carcinoma (HNSCC) represents an excellent model of human HNSCC but is greatly understudied. To better utilize this valuable resource, we performed its first genome-wide characterization by investigating 12 canine HNSCC cases, of which 9 are oral, via high density array comparative genomic hybridization and RNA-seq. The analyses reveal that these canine cancers faithfully recapitulate many key molecular features of human HNSCC. These include similar genomic copy number abnormality landscapes, analogous sequence mutation patterns, and recurrent alteration of known HNSCC genes (e.g., MYC, CDKN2A) and pathways (e.g., cell cycle, mitogenic signaling, TGF signaling). Amplification or overexpression of protein kinase genes, matrix metalloproteinase genes, and epithelial-mesenchymal transition genes TWIST1 and SNAI are also prominent in these canine tumors.The strong dog-human molecular homology fundamentally justifies the use of our novel dog-human comparison strategy for driver-passenger discrimination for HNSCC. This cross-species comparison will significantly advance beyond the current findings with the massive genomic data of the cancer genome atlas (TCGA), as exemplified by our pilot study on human 8q, a recurrently amplified site in human HNSCC.HNSCC represents the sixth leading cancer by incidence in humans; thus developing effective therapeutic interventions is important. While our understanding of the biology of HNSCC has been greatly advanced over past decades, translating these findings into clinical success has been frustratingly slow. A significant obstacle is the lack of translational model that can bridge the gap between preclinical research and human clinical trials. Our study indicates that spontaneous canine HSCC can effectively bridge this gap, significantly accelerating anti-HNSCC drug discovery.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-5147",
        "Doc_title":" Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level",
        "_version_":1606189040606904321},
      {
        "Meeting_name":" Direct down-regulation of eEF1A2 by Tumor suppressor p16INK4a inhibits cancer cell growth",
        "Background":"['The tumor suppressor protein p16INK4a is a member of the INK4 family of cyclin-dependent kinase (Cdk) inhibitors, which are involved in the regulation of the eukaryotic cell cycle. However, the mechanisms underlying the anti-proliferative effects of p16INK4a have not been fully elucidated. Using yeast two-hybrid screening, we identified the eukaryotic elongation factor (eEF)1A2 as a novel interacting partner of p16INK4a. eEF1A2 is thought to function as an oncogene in cancers. The p16INK4a protein interacted with all but the D2 (250-327 aa) domain of eEF1A2. Computational docking study predicted that D24/D131 residues of p16INK4a interacted with eEF1A2 and it was confirmed by pull-down assay with mutant p16INK4a (D24A/D131E). Ectopic expression of p16INK4a decreased the expression of eEF1A2 and inhibited cancer cell growth. Furthermore, suppression of protein synthesis by expression of p16INK4a ex vivo was verified by luciferase reporter activity. Microinjection of p16INK4a mRNA into the cytoplasm of Xenopus embryos suppressed the luciferase mRNA translation, whereas the combination of p16INK4a and morpholino-eEF1A2 resulted in a further reduction in translational activity. We conclude that the interaction of p16INK4a with eEF1A2, and subsequent downregulation of the expression and function of eEF1A2 is a novel mechanism explaining the anti-proliferative effects of p16INK4a.']",
        "Doc_id":"AACR_2014-2471",
        "Doc_title":" Direct down-regulation of eEF1A2 by Tumor suppressor p16INK4a inhibits cancer cell growth",
        "_version_":1606188973436174336},
      {
        "Meeting_name":" Promoter methylation of tumor suppressor genes in convalescent saliva samples from patients with head and neck squamous cell carcinoma",
        "Background":"['Purpose', ' Silencing of tumor suppressor genes (TSGs) plays an important role in head and neck carcinogenesis. Methylation of CpG islands in the promoter regions of genes acts as a significant mechanism of epigenetic gene silencing. In this study, we assessed the feasibility of epigenetic alterations in TSGs in post-treatment DNA shed from the oral mucosa as a prognostic marker for persistent/recurrent head and neck cancer. A panel of four genes (KIF1A, EDNRB, p16, DCC) was evaluated in this study.Experimental Design', ' Hypermethylation of the promoter regions was investigated by bisulfite modification and quantitative methylation-specific PCR (Q-MSP) which provides more objective and rapid estimation of gene methylation status. Fresh tumor samples and pre- and post-treatment salivary rinses were collected from 83 patients with HNSCC. Post-treatment saliva samples were collected once in every 3 months. In addition, 46 normal saliva and 16 normal mucosal samples from healthy individuals were obtained. Then we evaluated the correlation of the results with the clinical parameters.Results', ' KIF1A, EDNRB, p16 and DCC genes were methylated in 94%, 95%, 37% and 84% of primary HNSCC tissues, respectively and were only methylated in 2%, 6.8%, 5% and 10% of the salivary rinses from normal subjects. In addition, KIF1A, EDNRB, p16 and DCC were methylated in 35%, 69%, 8.4% and 38.6% of pre-treatment salivary rinses from HNSCC patients, respectively. We evaluated whether methylation levels of these genes in the post treatment saliva may predict the recurrence/prognosis or the chance of cure after treatment. Our data indicate that these genes may be potential biomarkers for HNSCC detection and follow up. Sixteen of 83 patients had recurrent tumors and KIF1A+EDNRB+p16+DCC methylation was observed in 37.5% of the patients in this group. The three gene panel (KIF1A, EDNRB and DCC) was also observed in 37.5% of the recurrent group and 46% of the overall patients, respectively.Conclusion', ' Methylation of the KIF1A, EDNRB and DCC gene promoters is a frequent event in HNSCC and these genes are not methylated in normal salivary rinses, demonstrating potential that they may act as biomarkers in detection strategies. Patients with presence of methylation in surveillance salivary rinses are at significant risk for recurrence. Quantitative measurement of salivary methylated DNA may have promise for surveillance and early detection of recurrence.']",
        "Doc_id":"AACR_2014-1384",
        "Doc_title":" Promoter methylation of tumor suppressor genes in convalescent saliva samples from patients with head and neck squamous cell carcinoma",
        "_version_":1606189024708395008},
      {
        "Meeting_name":" BMI1 and dominant negative p53 cooperate to suppress AKT-mediated oncogene-induced senescence and promote transformation in human neural stem cells.",
        "Background":"['Purpose', ' BMI-1 is required for the maintenance of normal brain stem cells and is associated with aggressive brain tumors such as glioblastoma multiforme (GBM). BMI1 is a polycomb group protein that can modify chromatin to silence the pro-senescence tumor suppressor p16INK4a. The PI3K/AKT pathway is also associated with clinically aggressive brain tumors. Interestingly, persistent activation of AKT can cause oncogene-induced senescence. Dominant negative R248W p53 mutation blocks induction of the tumor suppressor p21CIP1 and is found in aggressive brain tumors such as GBM. Telomere maintenance through telomerase enzyme activity is also found in aggressive brain tumors. We investigated if constitutively active AKT, dominant negative p53, BMI1, and hTERT can cooperate to bring about the transformation of human neural stem and progenitor cells, and in particular if BMI1 can suppress AKT induced senescence.Experimental Design', ' We used lentivirus to introduce singly and in combination BMI1, R248W p53, hTERT and constitutively active AKT into human cortex derived stem and progenitor cells. We assayed the effects of one, two, three or four oncogenes on the proliferation and induction of cellular senescence. We measured proliferation using bromodeoxyurine (BrdU) and senescence by western blotting for p16INK4a and p21 CIP1.Results', ' Increased expression of BMI1 alone did not have a significant effect on human neural stem cell proliferation, but did lead to the suppression of p16INK4a. AKT alone transduced cells showed no increased proliferation compared to control cells, but did show upregulation of p16INK4a. AKT alone expressing cells stopped growing after several passages in culture, in association with increased p16 INK4a expression. Cells transduced with BMI1 and AKT initially grew at a similar rate to control cells, but after several passages, similar to AKT alone transduced cells, BMI1/AKT cells stopped proliferating and expressed p21CIP1and p16INK4a. Control cells continued to proliferate for multiple additional passages. Cells transduced with R248W p53/hTERT/BMI1/AKT proliferated at an increased rate compared to control cells (17% BrdU positive for pBABE control cells compared to 37% for R248W p53/hTERT/BMI1/AKT p=0.0003, t-test). These cells did not undergo senescence, did not induce p16INK4a or p21CIP1 and continued proliferating more than control or single oncogene transduced cells long after other cells had senesced. Human neural stem cells transduced with R248W p53/hTERT/BMI1/AKT formed aggressive orthotopic xenograft glial tumors, while control cells did not form tumors.Conclusions', ' BMI1 alone cannot suppress AKT induced senescence in human cortex derived neural stem cells. But BMI1 combined with R248W p53 and hTERT caused suppression of AKT induced senescence, and resulting cells showed signs of oncogenic transformation']",
        "Doc_id":"AACR_2013-2607",
        "Doc_title":" BMI1 and dominant negative p53 cooperate to suppress AKT-mediated oncogene-induced senescence and promote transformation in human neural stem cells.",
        "_version_":1606189039845638144},
      {
        "Meeting_name":" Complex DNA damage cooperates with Ink4a/Ink4b/Arf loss to generate high grade gliomas in transgenic mouse models",
        "Background":"['Glioblastoma multiforme (GBM) are highly lethal brain tumors for which exposure to ionizing radiation is the only known risk factor. GBMs are characterized by alterations in three core signaling pathways', ' 1) RTK-PI3K-Akt, 2) ARF-MDM2-p53, and 3) Ink4a-RB1. In order to objectively evaluate the risk of developing malignant gliomas from exposure to ionizing radiation, we have developed mouse models with brain-specific deletions of Ink4a, Ink4b, Arf, or PTEN in logical combinations representing the progression of primary or secondary GBMs. Specifically, we examined whether complex, unrepairable DNA lesions, such as those induced by charged particles, are more tumorigenic compared to simple breaks that are efficiently repaired, such as those induced by gamma-rays. Using CDKN2A knockout murine astrocytes in which the tumor suppressors Ink4a and Arf have been deleted (abrogating RB1 and p53 pathways, respectively), we have previously shown that Fe ions are highly tumorigenic compared to gamma-rays. Importantly, we find that loss of a third tumor suppressor, Ink4b, is a critical event in tumorigenesis triggered by charged particles. Based on our in vitro results, we are now using transgenic mouse models with brain-specific deletions of these three key tumor suppressors (Ink4a/b, Arf) to evaluate radiation-induced gliomagenesis in vivo. Nestin-Cre; Ink4ab-/-; Arf f/f mice were irradiated with a single dose of 1 Gy Fe ions or 4 Gy gamma-rays. While gamma-induced damage is efficiently repaired by 1 day, unrepaired DNA lesions are evident up to 1 month following Fe irradiation. Most importantly, we find that combined loss of Ink4a/b and Arf cooperate with DNA damage by Fe ions resulting in a high incidence (25%) of malignant gliomas. These highly heterogeneous tumors arise with an average latency of 4.8 months and are classified as high grade (III and IV) glial tumors. Although tumors arising after gamma irradiation are also classified as high grade, they arise with a longer latency (5.6 months) and occur at a lower frequency (15%). To identify key genetic alterations involved in radiation-induced gliomagenesis, tumors are being analyzed by array CGH and microarray platforms. Strikingly, a 20- to 40-fold amplification of the MET proto-oncogene is observed in a high percentage of tumors. As MET is frequently amplified in human GBMs, it is likely that MET activation may be an important event in tumorigenesis triggered by charged particles in these mouse models. We are hopeful that a global and accurate picture of the genetic changes underlying radiation-induced gliomagenesis will emerge from this study. The data obtained will allow for comparison with changes recently identified in human gliomas by large scale genomic analyses and will allow us to understand whether radiation-induced gliomas are fundamentally similar to those occurring spontaneously, both in mouse models and in human patients.']",
        "Doc_id":"AACR_2012-2360",
        "Doc_title":" Complex DNA damage cooperates with Ink4a/Ink4b/Arf loss to generate high grade gliomas in transgenic mouse models",
        "_version_":1606189009922424833},
      {
        "Meeting_name":" Subcellular translocation of -catenin and its relationship with EGFR activation in HPV16 positive OPSCC.",
        "Background":"['Background', ' The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has increased in recent years. HPV-associated OPSCC follows a distinct carcinogenic pathway from HPV-negative OPSCC. The molecular basis of the disease progression due to HPV remains to be elucidated. Clinical observations have revealed frequent and early lymph node metastasis and unusual distant metastasis in HPV-associated as compared with HPV-negative OPSCC. To understand the underlying molecular mechanism, we have studied whether -catenin, one of the major proteins in the Wnt pathway, is involved in HPV-associated OPSCC metastasis. Methods', ' The study samples (n = 210) were collected from formalin-fixed and paraffin-embedded OPSCC tissues obtained from the Surgical Pathology files in the Department of Pathology at Emory University following the regulations of the Health Insurance Portability and Accountability Act (HIPAA). Expression levels of p16 as a surrogate marker for HPV-associated cancer, -catenin, and epidermal growth factor receptor (EGFR) were determined by immunohistochemistry (IHC) analyses. Membrane expression of -catenin and total EGFR level were scored as a weight index [WI = intensity (0, 1+, 2+, and 3+) x % of positive staining]. Nuclear -catenin and p16 were recorded as positive and negative. Expression and subcellular localization of -catenin as well as EGFR expression and activation were also studied in both HPV-positive and -negative head and neck SCC (HNSCC) cell lines (n =7) by Western blot analysis. SiRNA against HPV E6 was used to elucidate the effect of HPV on -catenin translocation. Results', ' Our results showed that membrane WI of -catenin was inversely correlated with p16 positivity (p < 0.0001), while nuclear staining of -catenin was associated with p16 positive OPSCC (p = 0.007) and positive lymph nodes (p = 0.0304). A low level of membrane -catenin (cut-off by the median value) was significantly associated with disease free survival and overall survival (p < 0.05 in both cases). Furthermore, WI EGFR was positively correlated with nuclear -catenin (p = 0.0001). Our in vitro study showed that nuclear -catenin level was higher in HPV16-positive HNSCC cell lines than in HPV16-negative cell lines. Furthermore, HPV16-positive cells showed higher EGFR activation than HPV16-negative cells. Reduction of HPV16 E6 led to the de-activation of EGFR and decreased level of -catenin in the nucleus. Conclusion', ' Our findings suggest that HPV16 E6 mediates the translocation of -catenin to the nucleus, which may be regulated by activated EGFR. The underlying mechanism deserves further investigation. (This study was supported by US National Institutes of Health (NIH/NCI) grant HHSN2610201000125C, R33 CA134392-01, and Georgia Cancer Coalition Distinguished Cancer Scholar Award to ZGC).']",
        "Doc_id":"AACR_2013-4798",
        "Doc_title":" Subcellular translocation of -catenin and its relationship with EGFR activation in HPV16 positive OPSCC.",
        "_version_":1606188972211437568},
      {
        "Meeting_name":" Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.",
        "Background":"['Background', '  Head and neck squamous cell carcinoma (HNSCC) is characterized by epidermal growth factor receptor (EGFR) overexpression but treatments targeting EGFR have met with limited clinical success. We hypothesized that everolimus (EV), an mTOR inhibitor, potentiates the activity of erlotinib (ER), an EGFR tyrosine kinase inhibitor, in platinum-resistant recurrent and/or metastatic HNSCC.  Methods', ' This single-arm two-stage phase II clinical trial evaluated EV 5 mg and ER 150 mg orally daily in patients (pts) with platinum-resistant recurrent and/or metastatic HNSCC. Primary endpoints were response rate and 12-week progression-free survival (PFS). Plasma biomarkers by multianalyte profiling (Luminex Corp) and ELISA at baseline (20 pts), 4 weeks (18 pts) and 12 weeks (16 pts) as well as p16 expression in baseline tumor tissue (29 pts) were assessed in correlation with clinical results.  Results', '  Of the 36 evaluable pts (median age 61 years, 29 males, 19 with oropharynx primaries, 15 with 2 lines of chemotherapy, 17 with prior cetuximab), 3 (8%) achieved partial response at 4 weeks, one of which was confirmed at 12 weeks, while 27 (75%) pts achieved disease stabilization at 4 weeks, 11 of which were confirmed at 12 weeks. The 12-week PFS was 49%, median PFS was 11.9 weeks and median overall survival (OS) was 10.25 months. Grade 3 toxicities included mucositis (17%), fatigue (14%), skin (8%), diarrhea (8%), and 5 pts withdrew from trial secondary to toxicity. High neutrophil gelatinase-associated lipocalin(NGAL) levels at baseline were associated with worse OS (HR 4.59; 95%CI 1.36, 15.46; p=0.014) and at 4 weeks with worse PFS (HR=12.29; 95% CI 1.26, 119.87; p=0.03) and OS (HR=6.21; 95% CI 0.95, 40.62; p=0.057). High carbonic anhydrase-9 (CA-9) levels at 4 weeks were associated with worse OS (HR=1.18; 95% CI 1.001, 1.41; p=0.049), while decreased CA-9 levels at 4 weeks were associated with better PFS (p=0.77).  Conclusions', '  Efficacy for the combination ofEV and ER is reasonable however plasma markers of tumor invasion and hypoxia are associated with worse outcomes, and further biomarker analysis may define subsets of pts with significant therapeutic benefit.  Clinical trial information', ' NCT00942734.']",
        "Doc_id":"ASCO_114057-132",
        "Doc_title":" Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.",
        "_version_":1606189012148551680},
      {
        "Meeting_name":" Actionable somatic mutations in head and neck cancer prognosis",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC) is a devastating illness with racial/ethnic disparities in survival. Using a retrospective study design, we evaluated 210 somatic mutation sties of 10 cancer genes (i.e., CDKN2A, EGFR, FGFR3, HRAS, KRAS, MET, NOTCH1, PIK3CA, STK11, and TP53) in 214 HNSCC patients', ' 98 Non-Hispanic Whites (NHW; 46%), 72 Hispanic Whites (HW; 34%), and 44 African Americans (AA; 20%). HW and AA had significantly higher mutation rates for EGFR, HRAS, KRAS, and TP53 compared to that in NHW. Significantly higher proportions of HW (30%) and AA (18%) had at least 3 mutations compared to that in NHW (p<0.001). In logistic regression models using 2-year as the cut-off for early death, we evaluated the overall and racial/ethnic-specific somatic mutations that are associated with early death. Although there was no significant association between somatic mutation and early death in the total population, NOTCH1 mutations were significantly associated with early death in NHW (odds ratio [OR] = 5.51, 95% confidence internal [CI] = 1.22, 24.83). More importantly, the NOTCH1 mutation C6814T (P2272S) within the PEST domain was associated with early death (OR = 13.13 (95%CI = 1.61, 107.36). TP53 mutations were significantly associated with early death in HW (OR = 3.84; 95%CI = 1.08, 13.68) in multivariate analysis after adjustment for age, gender, tumor site, and tumor stage. With limited sample size, no association was observed in AA. This is the first pilot study evaluating the association between somatic mutations and HNSCC early death in a tri-racial/ethnic population. Our data suggest that HW and AA have higher EGFR mutations and these patients may benefit from mutation-targeted precision medicine to improve survival.']",
        "Doc_id":"AACR_2015-3876",
        "Doc_title":" Actionable somatic mutations in head and neck cancer prognosis",
        "_version_":1606189006839611392},
      {
        "Meeting_name":" CDK4 inhibition enhances anti-melanoma effects of BRAF/MEK inhibition.",
        "Background":"['Introduction', ' Targeted therapy against BRAF-mutated melanoma has shown clinical efficacy. However, resistance to therapy often occurs. CDK4 (INK4)-retinoblastoma (RB) pathway controls cell cycle progression by regulating the G1-S checkpoint. Defect in the p16INK4A', ' cycling D-CDK4/6', ' RB pathway is also detected in melanoma. We study the effect of combining CDK4-RB pathway inhibition with BRAF/MEK inhibition as a possible strategy to overcome resistance to therapy.']",
        "Doc_id":"AACR_2017-2345",
        "Doc_title":" CDK4 inhibition enhances anti-melanoma effects of BRAF/MEK inhibition.",
        "_version_":1606188991445467136},
      {
        "Meeting_name":" Identification of new treatment options for platinum-resistant head and neck cancer in a panel of broadly characterized patient-derived xenografts.",
        "Background":"['Background-Aims', ' Cell lines and thereof established xenografts have a limited value for preclinical drug evaluation and biomarker analysis due to clonal selection and cellular dedifferentiation. We started establishing a large panel of patient derived xenografts from head and neck squamous cell carcinomas displaying the heterogeneity of this disease. Using these models we evaluate sensitivity to standard treatment, search for predictive biomarkers and test the sensitivity of experimental drugs and new treatment approaches.Methods', ' Specimens from head and neck tumor surgery were transplanted subcutaneously to immunodeficient mice within 24 hours. In case of engraftment, after 3rd passage, groups of 6 mice were treated with 5-FU, MTX, Cetuximab, Carboplatin, Docetaxel and in addition with the not yet approved drug Everolimus. Treatment was applied for 3 weeks. Response to treatment was evaluated by comparing growth inhibition of treated tumors in relation to a control group. Patient tumors and derived xenografts were evaluated for HPV status by immunohistochemical staining of p16INK4A and detection of HPV-16 E6 and E7 viral DNA by PCR. Primary tumor and the derived xenografts are screened for common oncogenic mutations using the Illumina TruSeq Amplicon - Cancer Panel. In addition transcription of mTOR pathway members were analyzed in more detail using RT-PCR and protein expression analysis.Results', ' In total, 70 tumor samples were transplanted resulting in 26 stably growing patient derived xenografts, 23 failed and 21 remain presently ongoing. Tumors remained histologically similar through several passages. Response to treatment varied considerably. We observed a remarkably large number of platin resistant tumors (9/11) in our study group. With our approach to identify alternative treatment options, we observed with the mTOR inhibitor everolimus a significant growth inhibition in 7 of 9 platin resistant tumors. Correlation of response with mutations in common oncogenes will be evaluated by sequencing and gene expression studies.Conclusion', ' Using newly developed patient derived xenografts of head and neck squamous cell carcinomas we identified a high sensitivity to the mTOR inhibitor everolimus. These results demonstrate that these models provide an excellent tool for preclinical drug and biomarker evaluation, systems biology and provide rationale hypotheses for further clinical trials.']",
        "Doc_id":"AACR_2013-2434",
        "Doc_title":" Identification of new treatment options for platinum-resistant head and neck cancer in a panel of broadly characterized patient-derived xenografts.",
        "_version_":1606189035817009152},
      {
        "Meeting_name":" Evaluation of stool melting curve analysis of methylated CpG island promoters as an alternative for early noninvasive diagnosis of colorectal tumors.",
        "Background":"['Background', ' Previous studies have shown that assessment of promoter hypermethylation of a limited number of genes in tumor biopsies may identify all colorectal tumors analyzed. The aim of the present study was to assess the clinical usefulness of a panel of methylation biomarkers in stool DNA in the diagnosis of colorectal tumors using Methylation Curve (MC) analyses, a technique that simultaneously analyze all CpG residues within a promoter. Methods', ' Promoter methylation status of 5 tumor-related genes (RARB2, p16INK4a, MGMT, p14ARF and APC) was analyzed in DNA stool samples and corresponding tissues in an initial set of 12 newly diagnosed patients with primary colorectal carcinomas and 20 with colorectal adenomas using Methylation-specific PCR (MSP). Results were validated in a set of 88 patients (20 healthy subjects, 17 inflammatory bowel disease, 23 adenomas, 28 carcinomas) using MC analyses. Median age for every group was 63, 51, 66 and 67 y respectively. Results', ' In the initial set, the majority [10 of 12 (83%) carcinomas and 18 of 20 (90%) adenomas] of biopsies were positive for at least one marker. In stool DNA prevalence was 75% for carcinomas (9 of 12) and 60% for adenomas (12 of 20) with no false positive in stools. In the validation set MC was used. Analytical sensitivity of MC was 5% of methylated alleles for p16INK4a, p14ARF, RARB2 and APC and 10% for MGMT. In the validation set MC analyses of biopsies showed that at least one marker was positive in 22 of 28 (79%) carcinomas and 16 of 23 (70%) adenomas. In stool DNA, these percentages were 64% (18 of 28) for carcinomas and 42% (9 of 23) for adenomas. No aberrant methylation was observed in healthy subjects and in 2 of 15 (13%) of IBD patients aberrant RARB2 methylation was detected. Conclusions', ' Melting Curve analysis of a panel of methylation markers in stool DNA is a good alternative for the early non-invasive diagnosis of colorectal tumors.']",
        "Doc_id":"ASCO_33663-65",
        "Doc_title":" Evaluation of stool melting curve analysis of methylated CpG island promoters as an alternative for early noninvasive diagnosis of colorectal tumors.",
        "_version_":1606189006528184320},
      {
        "Meeting_name":" Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype.",
        "Background":"['Background', ' We have previously demonstrated that p16 expression defines a biologically distinct subgroup of oropharyngeal squamous cell cancers (OSCC). Thus, OSCC can be Class I', ' human papillomavirus (HPV)-, Class II', ' HPV16+/p16-, or Class III', ' HPV16+/p16+. Tumors bearing a high p16 phenotype were associated with superior outcome. Using in situ automated quantitative protein expression analysis (AQUA) to explore the biomarker signatures of these 3 classes we found that beta-catenin, epidermal growth factor receptor (EGFR) and Met were upregulated in class III tumors. Our aim was to validate these findings using an independent cohort. Methods', ' A tissue microarray composed of 122 specimens from primary HNSCC cases treated with either external beam radiotherapy (EBRT) or gross total surgical resection and EBRT was constructed. Protein expression levels for a panel of 13 markers (EGFR, MET, STAT 3, ERK 1/2, pAkt, PI3Kp85, PI3Kp110, PTEN, p53, Bcl-2, E-cadherin, -catenin, NFB) were analyzed using AQUA. P16 protein levels were correlated with progression-free (PFS) and overall survival (OS). Survival analysis was performed by Kaplan-Meier method with log-rank test for assessing statistical significance.Comparison of expression between the p16 positive and p16 negative groups was done using unpaired t-tests. Results', ' Mean follow-up time for the cohort was 40 months. AQUA scores were divided into quartiles. Survival analysis showed that patients in the top quartile had a significantly better DFS (p = 0.01) and OS (p = 0.002). In multivariable analysis, adjusting for well-characterized prognostic variables, p16 expression retained its prognostic significance. Expression of E-cadherin and -catenin was significantly higher in the p16 positive versus the p16 negative group (p = 0.014 and p = 0.006, respectively). p16 positive tumors also expressed higher levels of PTEN (p = 0.0009), PI3Kp110 (p = 0.03), NFB (p = 0.007), and Bcl-2 (p = 0.005). Conclusions', ' These results validate p16 as a favorable prognostic marker in HNSCC. They also validate beta-catenin as a distinct biomarker in HNSCC bearing high p16 phenotype. Given that HPV+ tumors are p16+, beta-catenin is a candidate biomarker that distinguishes HPV+ versus HPV- HNSCC.']",
        "Doc_id":"ASCO_32628-65",
        "Doc_title":" Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype.",
        "_version_":1606189013922742273},
      {
        "Meeting_name":" FGFR3 correlation with mutant p53 and its prognostic value in oropharyngeal squamous cell carcinoma (OPSCC).",
        "Background":"['Background', ' Fibroblast growth factor receptor 3 (FGFR3) is expressed in squamous cell carcinoma of the head and neck (SCCHN) including oropharyngeal squamous cell carcinoma (OPSCC) and is a potential therapeutic target. Information on its prognostic value and its correlation with other relevant cancer related proteins is limited. Methods', ' We performed immunohistochemistry (IHC) analyses of p16, mutant p53 (mp53), and FGFR3 on 221 retrospectively collected OPSCC tissue samples. mp53, and FGFR3 were semi-quantified as weighted index [WI = % positive x intensity (0. 1+, 2+, and 3+)]. Correlations of FGFR3 WI with p16 status, and mp53 WI were analyzed. Association of FGFR3 with disease-free survival (DFS) or overall survival (OS) was assessed. Results', ' A total of 144/221 (65%) were p16 +, 93/172 (54%) had mp53, and 140/221 (63%) expressed FGFR3. FGFR3 was highly correlated with mp53 (p < 0.001), which was true in both p16 + and  OPSCC (p < 0.0001 and p = 0.0006, respectively).mp53 level was significantly lower in p16 positive versus p16 negative group (p < 0.0001). Univariate analysis revealed an association of p16 negative and high mp53 with worse OS (p < 0.001 and p < 0.001, respectively) and DFS (p < 0.001 and p = 0.004, respectively). FGFR3 was associated with worse OS and DFS (p = 0.014 and p = 0.047, respectively). On multivariable analysis FGFR3 was associated with worse DFS (p = 0.005), but not OS. Kaplan-Meier plot using medians of both FGFR3 and mp53 as the cut-off values showed that higher FGFR3 and mp53 correlated to worst DFS (p = 0.025) and OS (p = 0.009). Conclusions', ' Our results suggest that FGFR3 is associated with mp53 and p16  OPSCC and correlates with worse clinical outcome. The biologic relation of FGFR3 and mp53 in OPSCC deserves further investigation. (This research was supported by a grant NCI R21 CA182661-01A1to NFS and GZC).']",
        "Doc_id":"ASCO_185406-199",
        "Doc_title":" FGFR3 correlation with mutant p53 and its prognostic value in oropharyngeal squamous cell carcinoma (OPSCC).",
        "_version_":1606189030680035328},
      {
        "Meeting_name":" Expression of Aurora A and Phospho-Aurora-A is predictive of survival in patients with head and neck cancer",
        "Background":"['Introduction', ' The Aurora kinases represent a family of serine/threonine kinases important in regulating cell cycle progression. Aurora-A is required for centrosome function and mitotic spindle assembly. Aurora-A phosphosphorylation supports the activity of many proteins involved in cell proliferation and survival, including important EGFR effectors such as AKT and RAS. High expression of Aurora A has been shown in patients with breast, lung, gastrointestinal, genitourinary, and gynecological cancers. The Aurora kinases are known to promote tumor formation and progression, which has led investigators to develop multiple inhibitors of Aurora kinases for clinical use. The expression of Aurora-A kinase in head and neck cancers is not well understood. We assessed the overall survival (OS) for a cohort of patients with squamous cell carcinoma of the head and neck (SCCHN) based upon Aurora-A and phospho-Aurora-A kinase expression (reflecting active Aurora-A). We also related this to SCCHN subtype, using p16 expression as a surrogate for human papillomavirus association, because of the recognition that p16 + cancers have far superior prognosis. Methods', ' Tumor tissue from 89 patients with SCCHN operated on at the Fox Chase Cancer Center was analyzed for Aurora-A and phospho-Aurora-A expression. Aurora kinase expression was determined using AQUATM, with the median values used to distinguish over-expressers. Aurora-A and phospho-Aurora-A expression was correlated with T and N stage and OS, in p16+ versus p16- tumors The p16 status was determined by immunohistochemistry. Results', \" T stage was inversely related to Aurora-A expression when adjusted for p16 status (Spearman's rho -0.24, p = 0.04). Aurora-A expression was not related to N stage (Spearman's rho -0.03, p = 0.79). OS was 36 months for over-expressers of Aurora-A and 92 months for patients with low levels of Aurora-A expression (HR 1.9, 95% CI 1.05-3.46). 20 patients were positive for p16 by IHC. There was no difference in survival amongst p16 positive patients based on Aurora-A expression (53.3 months vs 57.2 months, p = 0.679). Amongst the 69 p16 negative patients, OS was 93.6 months for patients with low levels of Aurora-A expression and 35.9 months for those with elevated levels of Aurora-A (HR 1.84, 95% CI 0.89-3.79). There was a trend towards improved survival in patients with lower levels of phospho-Aurora-A expression (63.9 vs 57.6 months, p = 0.129). Conclusions\", ' Increased expression of Aurora-A in this cohort of SCCHN patients is associated with a significant decrease in OS. Increased expression of Aurora-A in patients with p16 positive tumors does not seem to impact survival, though the number of patients was small. Aurora-A represents a possible therapeutic target in patients with SCCHN.']",
        "Doc_id":"AACR_2012-721",
        "Doc_title":" Expression of Aurora A and Phospho-Aurora-A is predictive of survival in patients with head and neck cancer",
        "_version_":1606188973681541120},
      {
        "Meeting_name":" KEYNOTE-040",
        "Background":"['Background', '   Prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, with limited treatment options and survival rates of 6-9 months following standard-of-care (SOC) therapies. Pembrolizumab, a humanized IgG4 monoclonal antibody against PD-1 designed to block the interaction between PD-1 and its ligands PD-L1 and PD-L2, has demonstrated clinical efficacy by investigator review (confirmed and unconfirmed responses) in a phase I study of R/M HNSCC. Preliminary PD-L1 biomarker data suggest that response rate may be greater in PD-L1positive patients. Methods', '   In this global open-label, phase III KEYNOTE-040 (NCT02252042) trial, 466 subjects with recurrent or metastatic HNSCC that have failed prior platinum therapy will be randomized (1', '1) to pembrolizumab (200 mg Q3W) vs investigators choice SOC (single-agent methotrexate, docetaxel, or cetuximab). Randomization will be stratified by ECOG PS (0 vs 1), human papillomavirus (HPV) status in oropharyngeal cancer by p16 immunohistochemistry testing (positive vs negative), and centralized PD-L1 status (positive vs negative). Pembrolizumab will be given for  24 months or until disease progression, unacceptable toxicity, or investigator decision. AEs will be assessed according to NCI CTCAE, v4.0. Imaging will occur per RECIST v1.1 at 9 weeks and every 6 weeks thereafter. Modified RECIST, which allows for continued treatment after initial radiographic progression until confirmation imaging  4 weeks, will be used to account for unique responses seen with pembrolizumab. Radiographic responses will be confirmed by independent central review by RECIST v1.1 and modified RECIST and analyzed in real time for verification of progressive disease by RECIST v1.1. Survival follow-up will occur every 12 weeks. Primary end points are progression free survival (PFS) and overall survival (OS); secondary end points include ORR, DOR and PFS, OS, and ORR in PD-L1+ patients. Treatment differences in PFS and OS will be assessed using stratified log-rank test; Hazard ratios with 95% confidence intervals will be estimated using stratified Cox proportional hazard models. Clinical trial information', ' NCT02252042']",
        "Doc_id":"ASCO_146762-156",
        "Doc_title":" KEYNOTE-040",
        "_version_":1606188997240946689},
      {
        "Meeting_name":" Bcl-xL and IL-6 act independently and synergistically to accelerate plasmacytopoiesis and plasma cell tumor formation in Balb/c mice.",
        "Background":"[\"Accelerated development of spontaneous plasma cell tumors (PCT) occurs in mucosal-associated lymphoid tissues of mice bearing both IL-6 and BCL-XL transgenes (double transgenic (dTg)). 91% of dTG mice developed PCTs at a mean age of 89 days. In contrast, 53% of the IL-6 Tg mice developed PCTs at a mean age of 301 days and 12% BCL-XL Tg mice developed PCTs with a mean age of 433 days. The PCTs formed primarily in Peyer's Patches, medullary cords of the mesenteric lymph node and/or the lamina propria of small intestinal villi where they were preceded by massive plasma cell hyperplasia. To investigate the molecular basis of the cooperation between IL-6 and BCL-xL transgenes to accelerate PCT development we performed detailed analysis of cell lines developed from dTG mice and and spontaneous or pristane-induced tumors of Bcl-xL TG mice. All the tumors carry Ig/Myc-deregulating chromosomal translocations, which are thought to be the initiating event of PCT development. Therefore we focused on finding possible differences in secondary alterations. Although the subsets were poorly distinguished by microarray-based gene expression profiling, there were significant differences in the expression of p21, p19ARF, p53, HUWE1 and pRb as determined by western blotting and qPCR. DTG tumors were characterized by alterations in pathways governing expression of pRb that included increased expression of INK4A and down regulation of pRb itself as well as down regulation of p19ARF. Most notably we discovered discordance between protein and mRNA levels for pRb and p19Arf. Efforts to understand the molecular basis for these distinctions and their contributions to the biology of these PCT subsets are in progress.\"]",
        "Doc_id":"AACR_2013-3852",
        "Doc_title":" Bcl-xL and IL-6 act independently and synergistically to accelerate plasmacytopoiesis and plasma cell tumor formation in Balb/c mice.",
        "_version_":1606188994969731072},
      {
        "Meeting_name":" Investigation of the spatial interrelations among multiple types of immune and immune related cells in head and neck squamous cell carcinoma",
        "Background":"[\"Cancer immunotherapy is rapidly changing the landscape of medical oncology and research. The rise of immunomodulatory therapies such as CTLA-4 inhibitors and the durable effects seen in many tumor types are exciting. Despite huge success in this area, positive effects are only observed in a percentage of treated subjects, and it is still not clear why this is the case or how to differentiate responder from non-responder a priori. To this end, a great deal of research is being directed towards the development of in-situ immune profile analyses of tumor-infiltrating lymphocytes (TILs) in solid tumors that includes investigation of interdistributions of multiple immune cells and other markers important for immunotherapy (e.g., PD-1 and PD-L1). We present a combined method for the simultaneous IHC staining of up to 7 antigens, multispectral imaging (MSI), a per-cell quantitative analysis, cellular phenotyping and multivariate hypothesized interaction distribution (HID) analysis of the spatial interrelations among the cells within sections of standard clinical biopsies to search for patterns correlated with clinical outcome and therapeutic response. Whole sections of FFPE archival head and neck squamous cell carcinoma (HNSCC) biopsies from 130 subjects (96 male, 34 female, median 58 years, median follow up 60 months) were stained simultaneously for CD3, CD8, CD68, FOXP3, PD-1, PD-L1 using tyramide-conjugated fluorophores based on an Opal multiplexed IHC method. Each section was imaged in its entirety at 4x. Using an automated region selection method, approximately 20 multispectral images were acquired from regions of tumor and tumor margin at 20x. Each image was segmented into tumor, stromal and blank compartments. Cellular locations were found using the DAPI staining. The multimarker stain intensities of each cell were used to delineate each cell's phenotype. Patients are stratified based on human papillomavirus (HPV) status (P16 IHC, HPV DNA PCR, HPV DNA ISH). The phenotype, staining intensity pattern and spatial location for each TIL was then used as input into the HID analysis for an exploration of cellular patterns associated with good and poor clinical outcome in HPV positive or negative HNSCC. The complexity of tumor-immune interactions is driving the requirement for highly multiplexed in-situ cellular analyses. It is therefore even more relevant that a method such as exhibited here, capable of defining and measuring the effect on patient outcome of the spatial patterns of multiple cellular phenotypes in the tumor microenvironment is available.\"]",
        "Doc_id":"AACR_2015-2352",
        "Doc_title":" Investigation of the spatial interrelations among multiple types of immune and immune related cells in head and neck squamous cell carcinoma",
        "_version_":1606189008269869056},
      {
        "Meeting_name":" Analysis of genetic aberrations in squamous cell carcinoma of the oral tongue.",
        "Background":"['Squamous cell carcinoma of the oral tongue (SCCOT) is a common form of head and neck squamous cell carcinoma (HNSCC). In the last few decades, a steady increase in incidence rates of SCCOT has been reported across the world including India. SCCOT is known to be an age related disease and tobacco consumption is implicated as the main etiological agent, like other HNSCC subtypes. Recent reports have indicated an increase in incidence of SCCOT in the young and in nonsmokers. Among HNSCC, SCCOT appears to be more aggressive with respect to its clinical and biological behavior. Molecular genetic studies on SCCOT are scarce and most studies have been conducted on a small cohort of patients and/or restricted to a single/few molecular marker(s). We have conducted a multipronged molecular genetic study of SCCOT and analyzed the status of known tumorigenesis pathways including TP53, epidermal growth factor receptor (EGFR), microsatellite instability (MSI), CDKN2A, FHIT and human papilloma virus (HPV) infection in surgically resected primary tumor samples and correlated with clinocopathological variables. 67% (67/100) of SCCOT samples exhibited p53 nuclear stabilization whereas a greater proportion (87/100; 87%) exhibited elevated EGFR expression, in accordance with existing literature. Interestingly, p53 nuclear stabilization was found to be more common in young (31/39; 79.5%) than in older (35/59; 59.3%) patients (p = 0.0481). As expected, patients with p53 nuclear stabilization exhibited poorer survival. Further, PCR based mutation screening of exons 5-8 of TP53 (encoding the DNA binding domain) revealed mutations in 50% of samples exhibiting nuclear stabilization. HPV infection was observed in 11/82 (13.4%) tumors while the frequencies of MSI (12/86; 14%) and loss of heterozygosity (LoH) in CDKN2A (32.6%) and FHIT (28.4%) loci were significantly higher than previous studies. In addition, LoH at FHIT locus was significantly associated with p53 nuclear stabilization (p=0.047). Analysis of genome-wide DNA copy number alterations (CNA) using array based comparative genomic hybridization revealed unique copy number alterations validated by quantitative PCR. Exome sequencing and transcriptome profiling are currently underway to understand the pathways/genes deregulated in SCCOT, especially in samples not exhibiting p53 nuclear stabilization.']",
        "Doc_id":"AACR_2013-1216",
        "Doc_title":" Analysis of genetic aberrations in squamous cell carcinoma of the oral tongue.",
        "_version_":1606189023185862657},
      {
        "Meeting_name":" Should age affect our treatment decisions for head and neck cancer-",
        "Background":"['Background', '  Current opinion suggests elderly patients (pts) with head and neck cancer, those 65 or older, do not tolerate surgery, chemotherapy, or radiation as well as their younger counterparts. If this holds true, elderly pts may not be offered standard treatments to prevent assumed complications.   Methods', '  A retrospective cohort study at our comprehensive cancer center was conducted of newly diagnosed pts with head and neck squamous cell carcinoma to explore differences in treatment-related complications between older and younger groups. We included data from the first 199 eligible pts (99 younger than 65 year old and 100 older than 65) evaluated between April 2009 and June 2010.  Results', '   79% of pts receiving treatment were male with a mean age of 54.9 and 71.6 years for the younger and older groups respectively. The older group had significantly more comorbidities (p < 0.001). The majority of older pts presented with oral cavity tumors (46%) while the oropharynx was the predominant site in the younger group (45%). 55% of younger and 49% of older pts presented with stage 4 disease across all sites. A total of 51 pts were p16 positive with no statistical differences between the groups. Surgery was the initial treatment for 57% of older pts (p < 0.008) while 46% of younger pts received concurrent chemotherapy and radiation as the primary treatment (p < 0.008). There was no statistically significant difference in surgical or radiation complications between the groups. Although most pts receiving chemotherapy experienced complications, older pts had slightly more (93% vs. 78%; p<0.031). The mean survival was 24.8 months with no statistical difference between groups.  Significantly more pts in the older group, at last follow-up, were disease free (p < 0.012). Conclusions', '  The treatment of elderly pts with head and neck squamous cell carcinoma in our experience was congruent with that of younger pts. Elderly pts did not suffer more complications with surgery or radiation, however chemotherapy produced somewhat more complications in the elderly pts. Elderly pts did display less evidence of disease on follow-up. Age is always a consideration when treating individuals, but should not preclude the curative standard.']",
        "Doc_id":"ASCO_97187-114",
        "Doc_title":" Should age affect our treatment decisions for head and neck cancer-",
        "_version_":1606189012984266752},
      {
        "Meeting_name":" Establishing quality indicators for neck dissection",
        "Background":"['Background', '  Quality of head and neck surgery has thus far focused on adherence to clinical national guidelines and margin status.  For other solid tumors, an association has been found between lymph node counts from regional nodal dissection and overall survival; as such, lymph node counts have been proposed as measure of quality.  Yet, for neck dissection, no prospective metrics for surgical quality have been established for mucosal squamous cell carcinoma.  The purpose of this study is to investigate the association between lymph node counts from primary neck dissection, local-regional recurrence, and overall survival (OS).  Methods', '   Secondary analysis of patients in RTOG trials 9501 and 0234 was performed.  The number of lymph nodes counted from regional nodal dissection was evaluated for its prognostic impact on overall survival using a multivariate Cox model adjusted for demographic, tumor, and lymph node data, and stratified by postoperative treatment group', ' (1) radiation or (2) chemoradiation on RTOG 9501 or (3) chemoradiation and cetuximab on RTOG 0234. Models were compared by Akaike Information Criterion (AIC).  Results', '   Five hundred and seventy-two patients were analyzed.  Median follow-up for surviving patients was eight years. Median number of lymph nodes recorded on the left and right sides were 24 and 25.  Fewer than 18 nodes was associated with significantly worse OS relative to  18 nodes (hazard ratio 1.38, 95%CI 1.09-1.74, p = 0.007). The model with this cut point had minimum AIC of all possible models. The difference appears to be driven by local-regional failure (HR 1.46, 95%CI 1.02-2.08, p = 0.04) but not distant metastasis (HR 1.08, 95%CI 0.77-1.53, p = 0.65).  Limited to RTOG 0234, adding p16 status to the model does not affect the hazard ratio for sampled nodes and the effect of nodes is not different by p16 status (p-value for interaction 0.99).  Conclusions', '   Identifying 18 or more lymph nodes was associated with improved overall survival and lower rates of local-regional failure.  The benefit is seen in both p16-positive and p16-negative patients. The removal and identification of at least 18 lymph nodes should be considered as a measure of quality in neck dissections for mucosal squamous cell carcinoma.']",
        "Doc_id":"ASCO_147862-156",
        "Doc_title":" Establishing quality indicators for neck dissection",
        "_version_":1606189027179888640},
      {
        "Meeting_name":" P16INK4A, a surrogate marker of HPV infection and prognosis for head and neck cancer, delays DNA damage repair and enhances radiation response",
        "Background":"['Human papillomavirus (HPV) type 16 is a major cause of oropharyngeal carcinoma (OPC). P16INK4A has been suggested to be a reliable surrogate marker of HPV-associated OPC with 100% sensitivity and about 80% specificity. Increasing data showed tumor HPV positivity or p16 expression was strongly associated with significantly better prognosis in patients with OPC. As a tumor suppressor gene, p16 has biological functions including regulation of cell cycle progression at the G1/S boundary, angiogenesis, cell senescence, tumor invasion, cell spreading, apoptosis and anoikis. The present study was undertaken to assess the role of p16 in regulating tumor radioresponse and the underlying mechanisms in OPC cell lines.OPC cell lines HN-5 (HPV and p16 negative) and UMSCC-47 (HPV and p16 positive) were used. P16 overexpressing HN-5 cells and shRNA p16 knockdown UMSCC-47 cells were generated using lentivirus vectors. Treatment endpoint was clonogenic cell survival (CSA) determined 10-12 days (for HN5) or 17-20 days (for UMSCC-47) after exposing the cells to 2-10 Gy single doses of -radiation (IR). Compared with the control (scramble) cells, p16-overexpressing HN5 cells had significantly higher radiosensitivity (by a factor of 1.56 at 0.1 cell survival fraction); whereas, p16-knockingdown UMSCC-47 cells had less radiosensitivity (by a factor of 1.23 at 0.1 cell survival fraction). Overexpressing P16 in HN-5 cells significantly prolonged the presence of radiation-induced double-strand breaks detected on the basis of 53BP1 foci at 24h after 4 Gy IR. To directly gauge damaged DNA, an alkaline comet assay to detect both single- and double-strand DNA breaks was performed. P16 overexpressing HN-5 cells exhibited a 2.09-fold increase in the comet tail moment 48 hours after IR. This finding was supported by increased expression of 53BP1 analyzed by Western blot.In conclusion, other than being a robust surrogate marker for tumor control and survival outcome, our findings demonstrated that p16 also functions as a potent radiation sensitizer. The major underlying mechanism of p16 regulating radiosensitivity is by inhibition of DNA damage repair.']",
        "Doc_id":"AACR_2014-4895",
        "Doc_title":" P16INK4A, a surrogate marker of HPV infection and prognosis for head and neck cancer, delays DNA damage repair and enhances radiation response",
        "_version_":1606189008821420032},
      {
        "Meeting_name":" Genomic profiling of squamous malignancies across anatomic sites.",
        "Background":"['Background', ' Primary squamous cell carcinomas (SCCs) have diverse etiologies, but can share genomic features. We reviewed the genomic profiles of a series of SCC cases of differing anatomic origin. Methods', ' Hybrid-capture based genomic profiling of 182 or 236 or 315 genes was performed on 4783 squamous malignancies in the course of clinical care, with baits for HPV6, 11, 16, and 18, and assessment of tumor mutation burden (TMB; mutations/Mb) and microsatellite instability. Results', ' Sites of origin were head and neck (HNSCC, n = 1300), cervical (cSCC; n = 318), anal (aSCC, n = 248), esophageal (n = 242), lung (lSCC, n = 2386), and cutaneous (sSCC, n = 289) SCC cases. For HNSCC, cSCC, and aSCC (collectively termed HCA SCC), 395 (30%), 215 (68%), and 211 (83%) were HPV positive, respectively. For HCA SCC, the most common GA were in TP53 (45%), CDKN2A (29%), PIK3CA (24%), TERT (21%), and FAT1 (14%). The most frequent GA differentially associated with HPV status were in PIK3CA (34.9% versus 16.0%), CYLD (11.4% versus 1.4%) and PTEN (14.8% versus 6.1%) for HPV+ cases, and TP53 (3.8% versus 76.5%), CDKN2A ()1.4% versus 49.8%), and TERT (4.3% versus 33.0%) for HPV- cases. Mean TMB for HPV+ and HPV- cases were 6.6 (STDEV 7.3) and 13.7 (STDEV 29.7), respectively. TMB of all SCC cases was significantly different (p < 10-12) when stratified by HPV status. For lSCC and eSCC, the most common GA were found in TP53 (86%) CDKN2A (40%), and PIK3CA (26%) and mean TMB was 11.6 with HPV found in 3.1% of cases. In sSCC, the most common GA were in TP53 (85.5%), CDKN2A (54.3%), and TERT(44.0%), and mean TMB was 59.5 with HPV in 3.1% of cases. Subsets of SCC cases had defining and targetable GA including bi-allelic deletion of SMARCB1 ( < 0.3%), amplification of PD-L1 (~2%), and various kinase fusions. Cases demonstrating radiologic response to immunotherapy and matched targeted therapies, as well as subsequent development of multiple mechanisms of acquired resistance, will be presented. Conclusions', ' HPV driven SCC have similar genomic profiles regardless of of site origin, and have a significantly lower median TMB than HPV negative SCC. Early consistency of responses of SCC to matched therapies may strengthen the case for site independent genomic predictors of therapy response.']",
        "Doc_id":"ASCO_195000-199",
        "Doc_title":" Genomic profiling of squamous malignancies across anatomic sites.",
        "_version_":1606189027154722816},
      {
        "Meeting_name":" Molecular signatures of class II HLA and p-16 status as an immune-based classification of OPSCC relying on known predictors of sensitivity to PD-1 blockade.",
        "Background":"['Background', ' PD-1 inhibitors are known to have significant clinical activity in head and neck squamous cell cancer (SCCHN); there is, however, no selection criterion for SCCHN patients who may benefit from PD-1 inhibition. Utilizing RNA-seq analysis we explored a set of human genes encoding leukocyte antigens (HLAs) as part of a 37-gene panel predictive of response in melanoma patients to PD-1 inhibitors (Chen et al, Cancer Discov. 2016 Aug;6(8)', '827-37).We investigated whether this panel could define an immune-based classification of oropharyngeal squamous cell carcinoma (OPSCC). Methods', ' We have applied a minimal mutation and copy number content (151 genes) using an Agilent Clearseq DNA and an extensive Illumina Truseq RNA panel providing key information on gene fusions, differential gene expression, coding mutation and metagenomics on 47 SCCHN FFPE samples including 27 OPSCC. We performed an unsupervised hierarchical clustering of the samples. Two clusters with high and low expression were noted. Fishers exact test was performed to determine if the samples in each clusters were associated with p16 as a surrogate marker for HPV status. The same procedure was repeated on Level 3 transcriptome data from the TCGA via GDC data portal. Results', ' A set of fourteen immune related HLA antigen genes were identified within the 37-gene panel predictive to response to PD-1 inhibitors in p16+ versus - OPSCC (p = 0.015).We applied the same set of immune related HLA genes on the 103 patient samples from TCGA with known p16 status. When applied on all samples, there was no correlation between the HLA gene expression and p16 status (p = 0.1366); however, when restricted to OPSCC patients there was a high correlation with p16 status (p = 0.0047). Conclusions', ' We have identified a set of immune related HLA type II genes that are over-expressed in p16 positive OPSCC. This opens the door for further evaluation of these genes to better understand the immune related factors affecting the biology of HPV-associated OPSCC and its response to PD-1 inhibitors. (This research was supported by a grant NCI R21 CA182661-01A1to NFS and GZC).']",
        "Doc_id":"ASCO_183551-199",
        "Doc_title":" Molecular signatures of class II HLA and p-16 status as an immune-based classification of OPSCC relying on known predictors of sensitivity to PD-1 blockade.",
        "_version_":1606188985860751360},
      {
        "Meeting_name":" Epigenetic regulation by SET protein in HNSCC",
        "Background":"['Background', ' Epigenetic regulation is essential in the control of both normal cellular processes and cancer development. DNA methylation and histone acetylation are involved in chromatin remodeling and gene transcription control. Recently, we reported that SET protein, a member of the acetyltransferase inhibitor complex, is strongly accumulated in HNSCC. However, SET action in gene expression is unknown, so we assessed SET role in the control of epigenetic modifications.Materials and Methods', ' HNSCC (HN6, HN12 and HN13), HEK293 and NOK-SI cell lines were used. SET overexpression was obtained in HEK293 and NOK-SI cells using pcDNA3.1 with SET cDNA, and SET knockdown in HNSCC cells using siRNA or shRNA. Human transcription factors RT Profiler PCR Array profile (TF) and human tumor suppressor genes (TSG) EpiTect DNA Methyl qPCR Array System (SABioscience-Qiagen) were used to determine the SET action in gene transcription and DNA methylation. Quantitative real time PCR (qPCR), chromatin immunoprecipitation (ChIP), immunofluorescence, Western blotting and DNA methyltransferases (DNMT) activities (EpiSeeker DNMT Activity Quantification Kit; Abcam) assays were used. Trichostatin A (TSA, 100 ng/mL), which increases histone acetylation, or 5-aza-2-deoxycytidine (5-aza, 1ug/mL), which decreases DNA methylation, were used for epigenetic modifications.Results', ' TFs mRNA analysis showed only 15 genes up-regulated and 65 down-regulated in HEK293/SET cells. Eight down-regulated (ATF2, CTNNB1, HIF-1A, NFATC3, RELA and STAT1) and two up-regulated (ATF3 and MYB) genes were also assessed by qPCR and similar mRNA profile was obtained. HNSCC SET knockdown cells presented opposite mRNA profile. ChIP analysis was performed for nine genes and HIF-1A, NFATC3 and STAT1 promoters showed interaction with SET. However, NFATC3 and STAT1 protein levels were not altered. DNA methylation profile of TSG showed that SET overexpression in HEK293 and NOK-SI cells promoted hypomethylation whereas SET knockdown in HN12 and HN13 cells promoted hypermethylation. HN6, HN12 and HN13 control cells, which present constitutive SET accumulation, presented a methylation loss pattern similar to the observed in HEK293 and NOK-SI cells with SET overexpression. GSTP1, PTEN and TP16 mRNAs levels decreased in SET-overexpressing cells despite the DNA demethylation status. To assess which modification is the main SET mechanism in the gene expression regulation, we performed qPCR in cell lines treated with TSA or 5-aza. TSA treatment reversed the SET overexpression effect in GSTP1, HIF-1A, NFATC3, PTEN, TP16 and STAT1 mRNA whereas 5-aza did not reverse. SET overexpression promoted increase in DNMT activities accompanied by increase in DNMT-1 protein.Conclusions', ' SET accumulation promotes transcriptional repression through histone hypoacetylation regulation and DNA demethylation is not associated with loss of DNMTs activities.']",
        "Doc_id":"AACR_2013-4244",
        "Doc_title":" Epigenetic regulation by SET protein in HNSCC",
        "_version_":1606188989231923201},
      {
        "Meeting_name":" Establishment and characterization of patient-derived xenografts of head and neck tumors.",
        "Background":"['Background-Aims', ' The introduction of first targeted therapy with Cetuximab has improved survival of head and neck cancer. However there is still a large population with intrinsic resistance. To evaluate the mechanisms and find alternative treatments we started establishing a large panel of patient derived xenografts from head and neck squamous cell carcinomas displaying the heterogeneity of this disease, as cell lines and thereof established xenografts have only a limited value for preclinical drug evaluation and biomarker analysis due to clonal selection and cellular dedifferentiation. Using these models we evaluate new treatment options, identify predictive biomarkers and test the sensitivity of experimental drugs and treatment approaches.Methods', ' Specimen from head and neck tumor samples were transplanted subcutaneously to immunodeficient mice within 24 hours. In case of engraftment groups of 5-6 mice were treated after 3rd passage with 5-FU, MTX, Cetuximab, Carboplatin, Docetaxel and Everolimus. Treatment was applied for 3 weeks. Response to treatment was evaluated by comparing growth inhibition of treated tumors in relation to a control group. Patient tumors and xenografts were evaluated for HPV status by immunohistochemical staining of p16INK4A and detection of HPV-16 E6 and E7 viral DNA by PCR. Primary tumor and the derived xenografts are screened for common oncogenic mutations using the Illumina TruSeq Amplicon - Cancer Panel and for genetic expression profiles by Affymetrix analysisResults', ' In total, 70 tumor samples were transplanted resulting in 26 stably growing patient derived xenografts and 21 remain presently ongoing. So far only 23 xenotransplanted tumors did not grow. This results in an engraftment rate of >60%. Tumors remained histologically similar through several passages. Engraftment was not related to growth fraction of the primary tumor, ranging from 10 to 90% evaluated by Ki67 staining. In a few cases we were able to establish xenografts from primary tumors and synchronous metastases. These showed high similarity concerning growth rate and drug sensitivity. Response to treatment varied considerably. Significant growth inhibition in relation to the control group was observed in 8 of 11 (72%) treated tumors for Everolimus, in 4/11 (36%) for 5-FU, 3/11 (27%) for MTX, in 3/11 (27%) for Carboplatin, in 3/11 (27%) for Cetuximab and in 6/11 (54%) for Docetaxel. Out of the established xenografts four primary tumors were classified as HPV positive but only one of them remained positive after several passages in mice.Conclusion', ' Our newly established head and neck cancer panel provides an excellent tool for preclinical drug and biomarker research. Together with the molecular genetic characterization, these patient derived xenografts can be used for modeling the systemic biology of the tumor and can help to develop new rational hypotheses for further clinical trials.']",
        "Doc_id":"AACR_2013-2783",
        "Doc_title":" Establishment and characterization of patient-derived xenografts of head and neck tumors.",
        "_version_":1606188990669520896},
      {
        "Meeting_name":" The p16/ARF intron 2 imbedded long non-coding RNA CAI2 is highly expressed in tumor cells and modulates chromatin structure",
        "Background":"['Over the last several years it has become apparent that the majority of the genome is transcribed with the number of non-coding RNA (ncRNA) genes significantly higher than the number of protein-encoding genes. The 9p21 locus harbors a number of tumor suppressor genes including p15, p10, ARF, chARF, p16, p16, p12 and p16-ACT, and the long ncRNAs ANRIL and p15AS. The abundance of regulatory genes in such a short span perhaps accounts for why this region is frequently inactivated in many cancers. We report on the novel lncRNA CAI2, a non-conserved gene imbedded in p16/ARF intron 2 with homology that is limited to the upper primates. CAI2 is a single exon, RNA pol II regulated gene with a poly A signal localized in p16/ARF exon 3, yet independent of the p16/ARF poly A signal. The expression levels of CAI2, p16 and ARF genes are highly correlated, being low in normal tissue but high in most tumor cell lines with an intact 9p21 locus. Notably, high levels of CAI2 expression are associated with advanced-stage of neuroblastoma, one of the few tumor types where 9p21 alterations are infrequent and where p16 is paradoxically overexpressed. CAI2 expression was associated with a poor outcome in neuroblastoma, suggesting value as a biomarker of tumor cell stage and patient outcome. Despite the strong correlation between CAI2 and p16 expression, CAI2 is independently regulated and is expressed in cell lines deleted or epigenetically silenced for p16, ARF and even p15. In response to serum deprivation, CAI2 levels rise rapidly in normal mononuclear cells, but slowly in tumor cell lines, suggesting that CAI2 is also a stress-response gene. CAI2 levels also rise in response to chemotherapeutic insult such as etoposide treatment. The NMB7 neuroblastoma cell line is one of very few neuroblastoma cell lines to express CAI2 at low levels. During passage, this cell line undergoes morphological changes, proliferates faster and exhibits an increase of more than 100-fold in CAI2 expression, though a concomitant decrease in Tyrosine Hydroxylase expression suggests the changes are not due to differentiation. Consistent with this, Retinoic Acid treatment, part of standard neuroblastoma therapeutic regimen known to induce neuroblastoma cell differentiation, slightly decreased CAI2 expression. As many lncRNAs regulate chromatin states, we considered epigenetic roles for CAI2 in gene regulation. RNA Immunoprecipitation revealed that CAI2 interacts with H3K27me3, a recruiter of Polycomb Repressive Complex 1 (PRC1) that modulates chromatin structure and gene expression. As many advanced stage neuroblastomas and neuroblastoma cell lines highly express p16, we speculate that CAI2 binding to H3K27me3 may modulate chromatin structure and regulate expression at the 9p21 locus.']",
        "Doc_id":"AACR_2015-158",
        "Doc_title":" The p16/ARF intron 2 imbedded long non-coding RNA CAI2 is highly expressed in tumor cells and modulates chromatin structure",
        "_version_":1606189000896282624},
      {
        "Meeting_name":" Human papillomavirus (HPV) induced malignancies and markers of immunogenicity.",
        "Background":"['Background', ' Approximately 5% of all cancers result from HPV, commonly leading to head and neck (HN) and anogenital (AG) cancers. Immune therapy is used in many cancers including HN. Positive PDL1 and high tumor mutation load (TML) have been proposed as potential markers of immunogenicity among many tumors, but little is known specifically among HPV driven cancers. Methods', ' A retrospective analysis of patients with HPV related cancers was performed based on tissue availability. TP53 wild type status was used as a surrogate for HPV positivity. Among oropharynx cases with TP53 wt, p16 testing was performed for confirmation. Next generation Sequencing (NGS Sanger) was used for tumor mutation load (TML) calculation. High TML cut off was defined as 17 mutations/megabase based on prior publications. PDL1 status was reported based on IHC 5%. A 2-tail Fishers exact test was utilized for statistical analysis. Results', ' A total of 737 patients with HN and AG (cervical, anal, vulvar, penile) squamous cell carcinoma were identified. Of these, 251 had complete 592 gene panel NGS data. HPV + TP53 Wt disease was detected in oropharynx (70%), cervical (88%), and anal (82%) cancer. HPV+ HNSCC had a trend to a higher PDL1 compared to HPV neg (50% vs 31%, p = 0.16) but there were no significant differences among PDL1 between HPV+ and neg patients across the entire combined disease cohorts (41% vs 36%, p = 0.56). TML-high patients showed a trend to increased PDL1 positivity (60% vs 38%, p = 0.09). However, high TML was less common in HPV+ HNSCC vs HPV neg (2.2 vs. % 9.7% p = 0.19). Unlike some other malignancies, high TML was uncommon across HPV+ tumors in general (8%). Conclusions', ' Despite fewer TML high cases among HPV + patients, there was no difference among PDL1 expression. It is possible that a lower threshold may need to be used when determining TML high vs. low in viral-driven cancers. It is also possible that in view of viral immunogenicity, certain genomic alterations contribute more to higher PDL1 expression rather than the sum of total genomic alterations. We are currently pursuing both lines of investigation. These findings are hypothesis generating for future trial design rather than treatment decision-making, and need to be confirmed in large prospective cohorts.']",
        "Doc_id":"ASCO_191394-199",
        "Doc_title":" Human papillomavirus (HPV) induced malignancies and markers of immunogenicity.",
        "_version_":1606189027056156673},
      {
        "Meeting_name":" IL-6/Stat3 signaling is an indispensable modulator of oncogene-induced cellular senescence",
        "Background":"['IL-6/Stat3 signaling plays a role as a proto-oncogene in various tumors including prostate cancer, where IL-6 has been explored as therapeutic target. Deficiency of Pten, one of the most commonly mutated genes in cancer, directly triggers a senescence program critically depending on the p19Arf-p53 fail-safe pathway. We identified a novel and unexpected tumor suppressive role of IL-6/Stat3 signaling in a Pten-deficient murine prostate cancer model. Our data provide evidence that activation of IL-6/Stat3 signaling axis is implicated in oncogene-induced senescence (OIS). Strikingly, genetic ablation of IL-6 strongly promoted prostate cancer initiation, progression and metastasis in Pten-deficient mice. Mechanistically, IL6/Stat3 signaling regulates p19Arf-p53-induced senescence by modulating expression of the ubiquitin ligase MDM2 in pre-neoplastic cells. Critically, in prostate cancer patients low expression of Stat3 or p14Arf, the human homologue of p19Arf, correlates with poor survival. Therefore, the IL-6/Stat3 signaling axis may represent a novel molecular target for senescence-based cancer therapies.']",
        "Doc_id":"AACR_2014-3138",
        "Doc_title":" IL-6/Stat3 signaling is an indispensable modulator of oncogene-induced cellular senescence",
        "_version_":1606189024552157184},
      {
        "Meeting_name":" Wolf-Hirschhorn syndrome candidate 1 plays an important role in the pathogenesis of head and neck cancer.",
        "Background":"['Wolf-Hirschhorn syndrome candidate 1 (WHSC1) is a histone lysine methyltransferase (HMT) which was initially found to be deregulated in a subset of multiple myeloma cells with the t(4;14) (p16;q32) translocation and poor prognosis. Recently, our group as well as others found that WHSC1 was overexpressed in a variety of tumors, including lung and esophageal squamous cell carcinomas, with low or no expression in normal tissues except the testis. Long-term survival of patients with squamous cell carcinoma of the head and neck (SCCHN) remains poor and thus new therapeutic strategies are urgently needed. Epigenetic alterations have mainly been studied as a potential mechanism of progression from dysplasia to squamous cell carcinoma. Given the promising potential of HMTs as novel drug targets and the aforementioned interesting expression patterns, we further investigated the role of WHSC1 in carcinogenesis through immunohistochemical analysis (IHC) using tissue microarrays of 123 locoregionally advanced SCCHN patients, and 6 samples of fibroepithelial hyperplasia lesions obtained from oral biopsies. We classified its expression levels with a scoring scale of 0 (no expression), +1 (mild), +2 (moderate) or +3 (strong). WHSC1 expression in the nucleus and cytoplasm was moderate (score +2, 37%) or strong (score +3, 38%) in 75% of SCCHN samples, while 25% showed mild (score +1, 24%) or no (score 0, 1%) expression. WHSC1 staining of normal epithelial regions revealed an exclusively nuclear expression pattern in the basal and parabasal layers. This is consistent with reports suggesting a physiologic role of the Wnt-pathway, which was recently found to be induced by WHSC1, in the differentiation process of the squamous epithelium. We also performed Western blot analysis of WHSC1 in 8 SCCHN cells lines, 3 control fibroblast cell lines and 1 keratinocyte cell line. We observed moderate to strong overexpression of WHSC1 in 4 of 8 SCCHN cell lines, while no expression was detected in the normal keratinocytes or the fibroblast cell lines. These findings support a potential role of the WHSC1 pathway in the pathogenesis of SCCHN and provides a new therapeutic avenue for drug discovery in this fatal disease.']",
        "Doc_id":"AACR_2013-2979",
        "Doc_title":" Wolf-Hirschhorn syndrome candidate 1 plays an important role in the pathogenesis of head and neck cancer.",
        "_version_":1606189037938278400},
      {
        "Meeting_name":" Integrated analysis of squamous tumors identifies novel targets and dissects gene regulation",
        "Background":"['Background', ' Studies by The Cancer Genome Atlas (TCGA) and others have identified regions of somatic copy number alteration (SCNA) in head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC). Both tumor types exhibit frequent SCNAs in chromosomes 3q, 9p, and 11q. Although CDKN2A is the putative target of 9p deletions, numerous targets have been proposed in the 3q amplicon, including SOX2, PIK3CA, and TP63. Because expression levels are affected by underlying genomic events, we hypothesized that an integrated analysis of multiple genomic data types would provide increased ability to identify target genes in SCNA regions when compared to methods based on copy number alone while providing insight into mechanisms regulating expression. Findings may be subsequently validated by examining multiple tumor types or performing training/testing analyses.Techniques', ' Gene expression (GE), DNA copy number (CN), DNA methylation (ME), and microRNA expression (miR) data were obtained from the TCGA studies of HNSCC and LUSC. Linear models were constructed for each gene to investigate the effect of changes in CN, ME, and miR on GE. Analysis of model output provided an approach to identify target genes in SCNA regions and assess the effect of genomic alterations on expression.Results', ' Genome-wide GE, CN, ME, and miR data were available for n = 279 (HNSCC) and n = 159 (LUSC) tumor samples. Univariate modeling detected a strong overall association between GE and CN, as measured by the coefficient of determination (model R2). Although some genes found in SCNA studies produced large model R2 e.g. SOX2 a number of genes with large model R2 are relatively unknown. Notable examples include DVL3, and SENP2, which were implicated as driver genes in the 3q amplicon by a recent study of LUSC but not identified in the TCGA report. Remarkably, the model R2 for DVL3 and SENP2 was also high in HNSCC, and such a finding in a distinct tumor type provides validation and merits additional study. Output from models additionally including ME and miR as covariates contributes insight into the diversity of regulation of gene expression, but the strength of the association between GE and CN could mask other effects. Thus we constructed linear models in which the response variable was the residuals from the GE/CN model and the covariates were ME or miR. The TCGA study of glioblastoma noted frequent methylation of MGMT. When modeling MGMT we detected a highly significant association between ME and the GE/CN residuals in both HNSCC and LUSC. These results illustrate a pronounced effect of ME on GE conditional on CN.Conclusion', ' Linear modeling techniques provide a flexible and powerful basis for performing integrated analysis of genomic data. Our approach produces predicted results when analyzing known cancer genes, highlights lesser known genes for future study, provides insight into gene regulation, and draws attention to genes relevant in multiple tumor types.']",
        "Doc_id":"AACR_2014-5334",
        "Doc_title":" Integrated analysis of squamous tumors identifies novel targets and dissects gene regulation",
        "_version_":1606189025601781760},
      {
        "Meeting_name":" CDKN2B loss promotes progression from benign melanocytic nevus to melanoma",
        "Background":"['The CDKN2A locus on chromosome 9p21 encodes two tumor suppressors', ' the cyclin dependent kinase inhibitor p16INK4a and the MDM2 regulator p14ARF. Homozygous deletion of this locus is among the most common genetic events in human cancer across tissues, with the resultant selective advantage to cancer cells generally attributed to the loss of CDKN2A proteins, which help maintain functional Rb and p53. However, in greater than 90% of cancer tissues harboring CDKN2A deletion, the adjacent CDKN2B gene encoding the p15 cyclin dependent kinase inhibitor, is also deleted. The degree to which CDKN2B-encoded p15 loss contributes to human tumorigenesis is unclear. Here we show that CDKN2B is highly upregulated in common, benign melanocytic nevi (moles) expressing the constitutively active BRAF(V600E) oncogene. A large percentage of melanomas develop in continuity with these pre-existing nevi, suggesting that nevus melanocytes are not permanently senescent, and can serve as tumor-initiating cells upon acquisition of additional genetic changes. By examining primary melanocytes isolated directly from freshly excised benign human nevi, as well as normal primary melanocytes engineered to inducibly express BRAF(V600E), we link BRAF activation to a TGF-dependent p15 induction that arrests nevi in their pre-malignant state. We also use the primary nevus cells to establish a new genetically-defined, human in vivo melanoma xenograft model, which maximizes medical relevance by utilizing the naturally occurring melanoma precursor cells in a native 3-dimensional environment. With this approach, we show that p15 depletion in benign nevi promotes progression to melanoma, establishing the reversibility of nevus melanocyte growth arrest, and the functional importance of CDKN2B loss in human cancer.']",
        "Doc_id":"AACR_2015-1239",
        "Doc_title":" CDKN2B loss promotes progression from benign melanocytic nevus to melanoma",
        "_version_":1606189020591685632},
      {
        "Meeting_name":" Senescence induced of smooth muscel protein 22-alpha (SM22) and Radiation patients change human-link genes expression level",
        "Background":"[\"P53 and RB protein is famous for its capacity to suppress tumor senescence pathway member. Senescence is a leading cause of cancer-related death, considerable uncertainty still remains about their effectiveness. However, each marker in an increased risk that experience genomic data with a cancer-specific mutations. So, senescence marker that techniques can't develop patient-specific treatment for particular about experimental study-conditions and result-analysis. This study was undertaken to evaluate the sm22 (smooth muscel protein 22-alpha) protein relation of senescence marker and changes condition of the radiation at human-link senescence marker genes. We were determined the expression of senescence-associated -galactosidase and western-blot assay. It was performed in colon cancers that were 17 patients each of normal and adenoma, 16 patients each of normal and adenocarcinoma. To conformed enzyme efficiency is -galactosidase, senescence pathway using of p16, p21 and p53. On the other hand, sm22 use of senescence marker in study. we have decided to micro-array analysis that 3 patients each of normal and adenoma, 2 patients each of normal and adenocarcinoma, 2 patients each of normal and irradiation-adenocarcinoma (2 weeks after) available miRNA sequences on the Agilent Human whole genome 8x60K array chip. Gene expression levels were calculated with Feature Extraction v10.7.3.1 (Agilent technologies, CA) Relative signal intensities for each gene were generated using the Robust Multi-Array Average algorithm. Senescence induced p16 expression in dependent -galactosidase assay results, sm22 protein suppressed cellular senescence levels as well as p16 protein. The expression of p16 and sm22 was analyzed that not involved each normals, adenomas and adenocarcinomas tissue by western blot analysis. In addition, it found that these results were similar to those of micro array. The three groups (adenoma, adeno-carcinoma and irradiation-adeno-carcinoma) can be compared in terms of total 2-fold changed gene (least 200% of controls for up-regulated and lower than 50% of controls for down-regulated genes). We found this integrative data analysis tool to the LCN2, LYPD5 and LOC100132051 genes as well as CDKN2 (p16) and TAGLN2 (sm22) gene expression. Irradiation groups was much less than the adenoma (45.3 %) and adenocarcinoma (71.1 %) 2-fold changed gene expression. The LCN2, LYPD5 and LOC100132051 genes lower than adeno-carcinoma group level. Our observations suggest that shared gene and protein expression profiles may contribute to sm22 and p16 of senescence marker, irradiation induces cellular senescence of colon cancer.\"]",
        "Doc_id":"AACR_2012-3953",
        "Doc_title":" Senescence induced of smooth muscel protein 22-alpha (SM22) and Radiation patients change human-link genes expression level",
        "_version_":1606189040763142144},
      {
        "Meeting_name":" Study of induction docetaxel, cisplatin, cetuximab and bevacizumab (TPE-A) followed by concurrent radiotherapy, cisplatin, cetuximab and bevacizumab (XPE-A) in patients with high-risk locally advanced head and neck cancer.",
        "Background":"['TITTLE', ' A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer.  Background', '  The role of induction chemotherapy in the management of locally advanced squamous cell carcinoma of the head and neck (SCCHN) has long been debated. The incorporation of novel agents in the induction setting remains of interest. We sought to investigate dual inhibition of EGFR and VEGF along with chemotherapy in locally advanced SCCHN in a phase II clinical trial  Methods', '  Eligibility included ECOG status 0-1, adequate laboratory parameters, no bleeding history or taking anticoagulation; p16+ with 10 pack-years or less were excluded. Patients (pts) received induction therapy with bevacizumab 15 mg/Kg, docetaxel 75 mg/m2, cetuximab (250 mg/m2 after loading dose of 400 mg/m2 on cycle 1, day 1) and cisplatin 75 mg/m2 (TPE-A) IV once a week repeated every 21 days for 3 cycles, with G-CSF support, with optional surgery for non-responders in the primary, followed by radiotherapy to a total dose of 70 Gy in 35 fractions/7 weeks concurrently w/bevacizumab 15 mg/Kg every 3 weeks, cetuximab weekly and cisplatin 30 mg/m2weekly (XPE-A). Primary end point was complete response rate after induction with a planned sample size of 33. The study was closed due to slow accrual.  Results', '  Three pts were enrolled, all males, ages 51, 53, 67;  stages T4aN2B-C all p16 negative. One of three pts had a complete response and remains progression-free more than 12 months. The two other pts relapsed at 6 and 12 months, respectively. Grade 3 drug-related adverse events (AEs) were grade 3 neutropenic fever (N = 1),  hyponatremia (1), hypokalemia (1), hypophosphatemia (1), XRT dermatitis (1) and mucositis (1). There were no grade 4 AEs or serious bleeding.  Conclusions', '  In this small number of pts we could provide evidence supporting the feasibility and safety of this multiagent regimen. However, it remains unclear whether bevacizumab and/or cetuximab add to the efficacy of chemoradiotherapy Clinical trial information', ' NCT01588431']",
        "Doc_id":"ASCO_150303-156",
        "Doc_title":" Study of induction docetaxel, cisplatin, cetuximab and bevacizumab (TPE-A) followed by concurrent radiotherapy, cisplatin, cetuximab and bevacizumab (XPE-A) in patients with high-risk locally advanced head and neck cancer.",
        "_version_":1606188989841145856},
      {
        "Meeting_name":" Impact of human papillomavirus (HPV) E6/E7 gene silencing on the expression of biomarkers that distinguish HPV+ versus HPV16- head and neck squamous cell carcinomas (HNSCC).",
        "Background":"['Background', ' Three studies (Pyeon et al, Slebos et al, and Schlecht et al) have identified biomarkers that distinguish HPV+ versus HPV- HNSCC using cDNA microarrays. We sought to determine whether the identified biomarker differences are a direct consequence of HPV16 E6 andE7 oncogene expression. Methods', ' We selected genes that were found to have altered expression in HPV16+ HNSCC compared to HPV16-. Short hairpin RNAs targeting HPV type 16 E6 and E7 genes were delivered by retrovirus infection to HPV16+ oropharyngeal cancer cell lines 147T and 090. cDNA microarray analysis was performed (slides represented approximately 35000 genes) to determine the transcriptional profile before and after E6/E7 silencing. Results', ' E6/E7 gene silencing affected the expression of the following genes', ' RFC4, CDKN2A, MCM6, NASP, EP300, E2F2, PCNA, KLK6, ANGPT1, DNAJCI, PRKCG (Table). Conclusions', ' Expression of several biomarkers that distinguish HPV16+ from HPV16- HNSCC is regulated by E6/E7 gene expression. Targeting E6/E7 will be an effective therapeutic strategy in HPV16+ HNSCC since alteration of key molecules that increase the malignant potential of these tumors is controlled by E6/E7 expression. HUGO ID DescriptionFold Change 147TFold Change 090 RFC4Replication factor C (activator 1)-1.36-2.51 CDKN2ACyclin-dependent kinase inhibitor 2A (p16INK4A)-1.3-1.25 MCM6Minichromosome maintenance deficient 6-1.32-1.23 NASPNuclear autoantigenic sperm protein (histone-binding)-1.24-1.31 EP300E1A binding protein p300-1.32-1.25 E2F2E2F transcription factor 2-1.69-1.97 PCNAProliferating cell nuclear antigen-1.42-1.47 KLK6Kallikrein 6 (neurosin, zyme); human protease M+1.66+1.4 ANGPT1Angiopoietin 1+1.37+1.42 DNAJC1DnaJ (Hsp40) homologue, subfamily C, member 1+1.69+1.46 PRKCGProtein kinase C, gamma+1.3+1.35']",
        "Doc_id":"ASCO_32701-65",
        "Doc_title":" Impact of human papillomavirus (HPV) E6/E7 gene silencing on the expression of biomarkers that distinguish HPV+ versus HPV16- head and neck squamous cell carcinomas (HNSCC).",
        "_version_":1606188997018648576},
      {
        "Meeting_name":" Distinct roles of p53 and p19ARF in MYC-dependent tumor oncogene addiction",
        "Background":"['Acute T-cell lymphoblastic leukemia (T-ALL) is a pediatric malignancy in which the MYC oncogene is frequently overexpressed. Although, T-ALL responds to standard therapies, in 20% of cases, treatment fails to induce sustained remission, resulting in reduced patient survival. Inhibition or restoration of the mutant gene products that drive tumorigenesis can reverse the aberrant cell growth and result in elimination of tumor cells through the phenomenon of oncogene addiction. In order to recapitulate tumor regression and recurrence, we have developed conditional mouse models of MYC-dependent T-ALL, thereby allowing for the investigation of therapeutic resistance. Recently, we have shown oncogene addiction in our MYC-driven murine model of T-ALL occurs through both tumor cell-intrinsic mechanisms, such as cellular senescence and apoptosis, and tumor cell-extrinsic, host-dependent mechanisms, including inhibition of angiogenesis, immune system-dependent tumor clearance, and autocrine/paracrine survival signaling. We now present evidence that loss of either p53 or p19ARF facilitates tumor recurrence through distinct mechanisms. p53 utilizes host-dependent mechanisms by allowing tumors to maintain angiogenesis, while p19ARF employs tumor-cell intrinsic mechanisms to circumvent senescence upon oncogene inactivation in vivo. To further interrogate the mechanisms that underlie p53- and p19ARF-dependent tumor recurrence, we performed gene expression analysis on MYC wild-type, MYC/p53-/-, and MYC/p19-/- tumors before and after MYC inactivation. Utilizing novel computational techniques to compare gene expression from our T-ALL cells to gene expression of normal hematopoietic differentiation from the Immunologic Genome Project, we have delineated the regulatory pathways underlying the effects of tumor suppressor loss in human MYC-driven lymphoma cells in the presence of targeted MYC-inactivation. We have also utilized expression analysis to establish gene signatures from unique to our MYC/p53-/- and MYC/p19-/- murine T-ALL models and shown them to be prognostic for specific human T-ALL subtypes, as well as patient relapse-free survival. Overall, we have utilized whole transcriptomic analysis to further define the underlying cell signaling by which loss of p53 and p19 facilitate tumor recurrence and demonstrated that loss of these tumor suppressors can predict outcome in human patients.']",
        "Doc_id":"AACR_2012-4879",
        "Doc_title":" Distinct roles of p53 and p19ARF in MYC-dependent tumor oncogene addiction",
        "_version_":1606189036988268544},
      {
        "Meeting_name":" Human papillomavirus (HPV)related, p16 positive head and neck squamous cell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solid organ transplantation (SOT).",
        "Background":"['Background', '   It is well-recognized that patients who undergo SCT or SOT are at risk for second malignancies, including HNSCC.  While viral oncogenes have a defined role in some post-transplant cancers, the link between HPV infection and HNSCC in immunosuppressed patients has not been well studied.   Methods', '   We reviewed the Cleveland Clinic SCT and SOT databases and identified patients who developed HNSCC after transplantation.  Demographics, primary site and stage were noted.  In situ hybridization for high risk HPV subtypes (HPV-ISH) and p16 immunohistochemistry results were recorded if available, or were performed in patients with sufficient pathologic material.  Results', '  Twenty-one patients with HNSCC after transplantation were identified; 9 (43%) after SCT and 12 (57%) after SOT.  Eighteen patients (86%) were male, and all were Caucasian, with a median age at HNSCC diagnosis of 57 (range 31-72) years, and a median time from transplantation to HNSCC diagnosis of 6.1 (range 0.4-16.4) years.   The primary site was in the oropharynx in 8 patients (38%), oral cavity in 6 (28%), larynx in 5 (24%), hypopharynx in 1 (5%), and unknown in 1 (5%). HNSCC stage was I in 4 (20%) patients, II in 4 (20%), III in 4 (20%), IVA in 5 (24%), and IVB in 1 (5%).  Data on disease stage was not available in 3 patients.     HPV-ISH and p16 status could be determined in 17 patients; 6 were both p16 and HPV-ISH positive, 1 was p16 positive but insufficient tissue was available for HPV-ISH testing, and 1 was p16 positive and HPV-ISH negative.  Five of the p16 positive HNSCCs occurred in SOT recipients, 3 were diagnosed after SCT.  The remaining 9 patients were both p16 and HPV negative.  Among the 8 p16 positive patients, primary sites were in the oropharynx in 4,  larynx in 2, and  oral cavity in 2.  Among the 9  p16 negative patients, primary sites included oral cavity in 3, oropharynx in 3, hypopharynx in 1, larynx in 1 and unknown in 1.  Conclusions', '  In this small retrospective study, the HNSCCs that developed after SCT and SOT were frequently positive for HPV-ISH and p16.  Unlike HPV-related HNSCCs in immunocompetent patients, HPV and p16 positivity was often identified outside of the oropharynx.']",
        "Doc_id":"ASCO_79591-102",
        "Doc_title":" Human papillomavirus (HPV)related, p16 positive head and neck squamous cell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solid organ transplantation (SOT).",
        "_version_":1606189002957783040},
      {
        "Meeting_name":" HPV status predicts therapy response in patients with locally advanced HNSCC receiving cetuximab-based radioimmunotherapy.",
        "Background":"['HPV+ HNSCC show better therapy responses and improved survival when compared to HPV- HNSCC. No data exist on the prognostic value of HPV and combined HPV/EGFR status in patients with locally advanced HNSCC (LAHNSCC) treated with radiotherapy and cetuximab. The HPV status defined by p16INK4A immunohistochemistry and PCR-based chip analysis was assessed in a clinically well-characterized cohort of patients with LAHNSCC. Outcome was estimated using Kaplan-Meier analysis. Additionally, the EGFR expression levels and the effect of radioimmunotherapy in HPV+ and HPV- HNSCC cell lines were determined. 34% of the cases were p16INK4A/HPV positive. p16INK4A significantly correlated with male sex, younger patients and oropharnygeal localization and was a powerful predictor of OS (p=0.001) and PFS (p0.001). The HRs for HPV+ tumors were 0.17 (95%CI', ' 0.056-0.524, p=0.002) for OS and 0.12 (95%CI', ' 0.033-0.438, p=0.001) for PFS. P16INK4A correlated well with the HPV status (p0.001). The HPV+ UD-SCC2 cells had higher EGFR levels when compared to HPV- FaDu cells and the efficacy of combined radioimmunotherapy was stronger. This is the first study that demonstrates the prognostic value of HPV in patients with LAHNSCC receiving cetuximab-based radioimmunotherapy.']",
        "Doc_id":"AACR_2013-2391",
        "Doc_title":" HPV status predicts therapy response in patients with locally advanced HNSCC receiving cetuximab-based radioimmunotherapy.",
        "_version_":1606188971981799424},
      {
        "Meeting_name":" CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma",
        "Background":"['The p16-CyclinD1-CDK4-RB pathway regulates G1-S cell cycle transition. This pathway is deregulated in 90% of melanomas, through amplification or increased expression of CDK4 or Cyclin D1 (CCND1), or reduced expression of the CDK inhibitor p16INK4A (CDKN2A).To explore if CDK4 may be a viable target for the treatment of human melanoma we screened a panel of melanoma cell lines with the highly selective CDK4/6 inhibitor PD-0332991 (PD-991). A majority of cell lines were found to be sensitive to PD-991, although there was a distinct population of resistant cell lines. In sensitive melanoma cell lines, treatment with PD-991 resulted in loss of hyperphosphorylated RB and a concomitant G0/G1 cell cycle arrest. Treated cells displayed an enlarged flattened morphology and an increase in SA--galactosidase staining compared to vehicle controls, indicative of cellular senescence. RB-null cell lines were resistant to CDK4/6 inhibition, and did not display cell cycle arrest or senescence. Expression and mutational analysis was performed to identify additional genomic predictors of sensitivity and resistance. Loss of CDKN2A/p16 correlated with sensitivity to PD-991 (p<0.02), and this was confirmed at the level of protein expression. Mutation of p53 and the corresponding low expression of p53 targets p21 and MDM2 correlated with resistance (p<0.0001). There was no increase in p53 transcriptional targets or evidence of apoptosis in response to PD-991 treatment of sensitive cells, and senescence occurs in both p53 WT and mutant cells, indicating that this response does not require functional p53. However, in p53 WT cells, combination treatment with PD-991 and the p53 pathway activator Nutlin3a results in increased sensitivity to PD-991 compared to treatment with PD-991 alone. This additive effect is not observed in p53 mutant cells, suggesting there is a functional role for WT p53 in the response to PD-991.Conclusions', ' These preliminary data identify RB, p16 and p53 as predictors of response to PD-991, and support further evaluation of CDK4/6 inhibitors in melanoma.']",
        "Doc_id":"AACR_2015-3089",
        "Doc_title":" CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma",
        "_version_":1606189010637553664},
      {
        "Meeting_name":" Semiquantitative detection of aberrant methylation as a tumor biomarker in the serum and plasma of patients with gastric cancer",
        "Background":"['Background', ' Epigenetic silencing of tumor-related genes, due to CpG island methylation, is considered to be an important mechanism for the development of many tumors, including gastric cancinoma (GC). DNA methylation of multiple CpG sites in promoter regions of several tumor related genes, such as hMLH1, p14, COX2, and APC has been analyzed in GC so for. Circulating tumor DNA in serum/plasma has been demonstrated to reflect the biological characteristics of tumors. Recently, the presence of gene promoter methylation in serum/plasma DNA has also been demonstrated in patients with cancers of lung, head and neck, liver, and breast. So, in the present study, we attempted to determine the feasibility and the clinical correlations of detecting tumor-associated aberrant methylation in the serum/plasma of patients with gastric cancer. Materials and Methods', ' We examined promoter methylation of 6 genes using methylation-specific PCR (MSP) and methylation-sensitive high-resolution melting (MS-HRM) in paired serum, plasma and tumor samples of 50 gastric cancer patients. The tumor and the paired serum/plasma were investigated for aberrant methylation in BLU, DAPK1, GADD45G, MGMT, p15 and p16. The sensitivity of the HRM analysis was tested by using dilutions of fully methylated DNA into unmethylated DNA. Results', ' MSP was used to assess gene methylation in tumor samples. Promoter methylation in BLU, DAPK1, GADD45G, MGMT, p15, and p16 were detected in 47%, 37%, 59%, 32%, 14%, and 43% of tumor tissues by MSP. MS-HRM was used to assess gene methylation in serum/plasma samples concurrently. In the serum/plasma of gastric cancer patients, BLU, DAPK1, GADD45G, MGMT, p15, and p16 were methylated at frequencies of 26%, 21%, 23%, 11%, 9%, and 17%, respectively. Nineteen (38%) gastric tumor samples displayed concurrent methylation in three or more tumor genes. Aberrant methylation in one or more genes was found in 74% (37/50) serum samples and 70% (35/50) plasma samples. However, there was not a significant relationship of gene methylation between gastric tumor tissues and serum/plasma samples.Conclusion', ' These results suggest that aberrant promoter methylation in serum/plasma can be detected in a substantial proportion of gastric cancer patients. Detection of DNA methylation in serum/plasma may be a biomarker for early detection of gastric cancer. MS-HRM is powerful technique for the analysis of promoter methylation. Application of HRM analysis to large amount of clinical samples proves to be a fast and high-throughput way to investigate the epigenetic status of genes.']",
        "Doc_id":"AACR_2012-4538",
        "Doc_title":" Semiquantitative detection of aberrant methylation as a tumor biomarker in the serum and plasma of patients with gastric cancer",
        "_version_":1606188980373553152},
      {
        "Meeting_name":" CD44, protein, demographics and risk factor data",
        "Background":"[\"Head and neck squamous cell carcinoma (HNSCC) is a debilitating and deadly disease. The main risk factors are tobacco and alcohol use and human papillomavirus (HPV) infection. Early detection tests are needed because the majority of patients present in late stage when cure rates reach only 40%. Our group has developed a simple, inexpensive, noninvasive diagnostic test based on soluble CD44 (solCD44) and total protein levels. We used a case-control design to evaluate soluble markers for HNSCC in 150 oropharyngeal (OP) and lip/oral cavity (Lip/OC) patients and 150 controls frequency matched for age, gender, race, ethnicity, tobacco use and socioeconomic status. We compared patient groups with respect to important covariates using the chi-square, Fisher's exact test, or t-test. Markers mean levels were compared either by t-test or ANOVA, followed by pairwise multiple comparisons. Logistic regression analysis was used to evaluate predictivity of the salivary markers univariately and multivariately with adjustment for demographics and risk factors. We report odds ratio (OR) estimates with corresponding 95% confidence interval (95% CI) and area under the curve (AUC) of the operating characteristic curve (ROC) for fitted models. The case-control groups did not differ in regards to age, gender, race, ethnicity, history of ever vs. never smoking, current alcohol use, number of teeth removed, or county vs. private hospital system. The mean log2CD44 and protein levels were elevated in cases (log2 CD44= 1.94 ng/ml, protein=0.93 mg/ml) compared to controls (log2 CD44= 1.28 ng/ml, protein= 0.76 mg/ml), (p<.0001; p=.003, respectively). Log2CD44 levels were significantly elevated in older vs. younger cases (p<0.05). There were no significant mean log2 CD44 level differences between Lip/OC and OP cases, TNM or HPV status in cancer patients. In the cases for which HPV status was available (as measured by the surrogate marker p16), log 2 CD44 levels varied by smoking status (lower in never smokers), by drinking status in HPV + cases (lower in non-drinkers) and N-stage (higher levels in N0, Nx vs. N1-N3 in HPV-positive and the opposite effect in HPV-negative tumors). For protein, there were no differences in either the case or the control group based on demographic or risk variables. When we stratified by HPV status, race/ethnicity and drinking status did have an effect (higher levels in blacks vs. WNH and higher in current vs. former and never/mild drinkers in HPV positive tumors only). A specific model was developed for each of the 3 race/ethnicity groups with the highest AUC for blacks (AUC= .835) and WNH (AUC= .831) followed by HW (AUC= .777). Models included log2CD44, protein, smoking, gender and age; strongly suggesting that these factors play an important role for HNSCC early detection studies.\"]",
        "Doc_id":"AACR_2013-3548",
        "Doc_title":" CD44, protein, demographics and risk factor data",
        "_version_":1606189011867533312},
      {
        "Meeting_name":" Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary",
        "Background":"['Background', ' Patients with advanced carcinoma of unknown primary (CUP) have limited effective therapeutic options given the challenges of phenotypic and genotypic diversity. To identify future novel therapeutic strategies we conduct an ongoing exploratory analysis of next-generation sequencing (NGS) of relapsed, refractory CUP.Methods', ' We identified CUP patients referred to our phase I clinic with adequate FFPE sections from archival tissue for a targeted CLIA-certified NGS assay (Foundation One, MA). Over 2000 exons of 186 cancer-related genes plus over 30 introns from 14 genes often rearranged in cancer were fully sequenced for point mutations, insertions/deletions, copy number alterations (CNAs) and select gene fusions.Results', ' Of 19 patients seen (10 male, 9 female; median age at diagnosis 49 years), 17 demonstrated genomic alterations (median 3 aberrations/tumor, range 0 - 10); two patients had no reportable genomic alterations. Of the 71 detected aberrations, 17 (24%) have been implicated in impaired cell cycle regulation and arrest; specifically in genes which encode the cyclin-dependent kinases (CDK12 Q570*, CDKN2A/B loss, CDKN2A p16INK4a loss and p14ARF exon 2-3 loss) or their associated proteins including amplification of CCND1 and CCNE1 (n = 3). Of these 8 patients with impaired cell cycle regulation, 5 (63%) demonstrated concurrent mutations associated with epigenetic deregulation and impaired DNA methylation, most commonly ARID1A Y1211fs*5 and S1929fs*25, which encodes the AT-rich interactive domain-containing protein 1A, Arid1a, a member of the SWI/SNF chromatin remodeling complex); other mutations observed are CREBBP S893L (encoding a ubiquitously expressed transcriptional coregulatory protein controlling chromatin remodeling via its histone acetyltransferase activity); MLL2 R4904* (encoding an H3K4-specific histone methyltransferase) and KDM6A S466* (encoding the histone H3 lysine 27 demethylase UTX). Overall 5 of 19 (26%) patients with advanced relapsed CUP demonstrated a profile of aberrations that concurrently impact cell cycle arrest and epigenetic regulation.Conclusion', ' Through NGS-based molecular profiling, we can a subset of patients with advanced carcinoma of unknown primary with coexisting mutations leading to impaired cell cycle arrest and epigenetic deregulation, highlighting a therapeutic combination with a cell cycle inhibitor (such as Cdk4/6 inhibitors currently in clinical trial) and histone deacetylase inhibitors.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-604",
        "Doc_title":" Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary",
        "_version_":1606188999208075265},
      {
        "Meeting_name":" Analysis of p16 expression by AQUA in non-small cell lung cancer (NSCLC) among non-smokers.",
        "Background":"['Background', '  The tumor suppressor p16 is a biomarker for HPV-related head and neck squamous cell cancer, especially in patients (pts) without prior tobacco use.  Retrospective analyses of NSCLC from unselected pts provide limited data regarding the role of p16 and incidence of HPV, but suggest that p16 expression is associated with a favorable prognosis.  Our goal is to estimate the proportion of never/light smoking (< 10 pack years) pts with NSCLC with p16+ tumors and correlate these data with outcomes.  We hypothesize that p16+ tumors will be HPV related.  Methods', \"  A tissue microarray was constructed with NSCLC surgical specimens from never/light smokers (1995-2009) available in the Fox Chase Cancer Center Biosample Repository.  Slides were incubated with anti-p16 antibody (E6H4, MTM Laboratories) and wide-spectrum screening rabbit cytokeratin antibody (Dako Z0622).  DAPI was used to define tissue nuclei.  p16 levels were measured with fluorescent immunohistochemistry (IHC) on the HistoRx PM-2000 platform (AQUA).  After image validation, scores from two nonoverlapping images were obtained per case.  p16 AQUA score was analyzed as a dichotomous variable (positive/negative) based on a naturally occurring cutpoint.  We used Wilcoxon rank-sum tests, Fisher's exact tests, and Kaplan-Meier estimators with log-rank tests for analyses.  Results\", '   33 pts were included (25 female, ages 47-84).  Histology', ' adenocarcinoma (28), adenosquamous (3), squamous (2).  TNM Stage', ' T1 (4), T2 (26), T3 (1), N0 (15), N1 (8), N2 (8), N3 (1), M1 (2). Perioperative treatment', ' chemotherapy (9), radiation (5).  AQUA score range', ' 91-7733.  A natural cutpoint occurred at 3000 with 25 low (p16-) and 8 high (p16+) expressors.  AQUA score correlated with standard IHC H score (p=0.0005).  There was no significant relationship between p16 level and gender, T or N stage.  When controlling for N stage and p16 level, p16+ was associated with inferior survival (HR 2.68, p=0.03).  Conclusions', '  In NSCLC among never/light smokers, p16 expression can be quantified with a natural cutpoint (high vs. low).  p16+ is associated with inferior survival.  Analysis of HPV status and EGFR/KRAS mutations in these tumors is ongoing and will be presented at the meeting. Funded by ACS-IRG grant.']",
        "Doc_id":"ASCO_85004-102",
        "Doc_title":" Analysis of p16 expression by AQUA in non-small cell lung cancer (NSCLC) among non-smokers.",
        "_version_":1606188995348267009},
      {
        "Meeting_name":" DNA methylation pattern predicts treatment response and survival in patients with metastatic or recurrent colorectal cancer.",
        "Background":"['Background', ' The epigenetic changes such as DNA methylation affect various steps in tumorigenesis of colorectal carcinoma. The aim of this study was to investigate whether DNA methylation pattern was associated with chemotherapeutic response and survival in patients with metastatic or recurrent colorectal cancer.Patients and method', ' We retrospectively collected tumor tissues of primary site from 236 patients with metastatic or recurrent colorectal cancer (mCRC). Pyrosequencing was used to examine the methylation of 7 CpG island loci (p16, p14, MINT1, MINT2, MINT31, hMLH1, DKK3) in DNA extracted from formalin-fixed paraffin-embedded specimens. To elucidate the predictive role of DNA methylation markers, Kaplan-Meier survival estimation and Cox regression were performed for time to progression (TTP) and overall survival (OS). KRAS and BRAF mutations were also analyzed.Result', ' The methylation frequencies of the 7 genes analyzed were 45.8% for p16, 14.0% for p14, 22.0% for MINT1, 14.4% for MINT2, 19.9% for MINT31, 2.1% for MLH1, and 33.9% for DKK3. As for mutation status, 28.8% (68 of 229) tumors harbored KRAS mutation and 2.5% (6 of 125) tumors harbored BRAF mutation. Both mutations were mutually exclusive. We devided patients into three groups on the basis of the number of methylated genes (group 1, 01 methylation n=117; group 2, 24 methylation n=73; group 3, 5-7 methylation n=9). Median OS of group 3 was significantly shorter than other groups (median OS 38.1m in group1 vs 19.4m in group 3, log rank P=0.003; median OS 38.0m in group2 vs 19.4m in group3, log rank P=0.012). In 129 patients with measurable lesions, group 3 (n=6) showed a trend toward lower disease control rate (DCR=66.7%) and shortend TTP (median 3.5m) than group 1 (n=76, 86.8%, 7.6m) or group 2 (n=47, 80.9%, 6.6m). In multivariate analysis for OS, initial tumor stage (AJCC 1-3 vs 4', ' HR=2.67; 95%CI, 1.82-3.93, P <0.0001), tumor differentiation (well/moderate vs poor/mucinous', ' HR=2.18; 95%CI, 1.41-3.37, P <0.0001), resectability (resectable vs unresectable', ' HR=2.55; 95%CI, 1.54-4.22, P <0.0001), and number of methylation (0-4 methylated vs 5-7 methylated', ' HR=2.26; 95%CI, 1.11-4.60, P=0.025) were independent prognostic factors.Conclusion', ' This study suggests that DNA methylation status may predict treatment outcome and survival in patients with metastatic or recurrent colorectal carcinoma.']",
        "Doc_id":"AACR_2013-670",
        "Doc_title":" DNA methylation pattern predicts treatment response and survival in patients with metastatic or recurrent colorectal cancer.",
        "_version_":1606188994798813184},
      {
        "Meeting_name":" Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination",
        "Background":"['In T-cell acute lymphoblastic leukemia (ALL), the genes CDKN2A (p16 and p14) and MTAP are homozygously co-deleted, with a frequency of 35 %. MTAP cleaves the natural substrate, 5-deoxy-5-methylthioadenosine, to adenine and 5-methylthioribose-1-phosphate, which are converted to adenine nucleotides and methionine. Cells lacking MTAP are unable to salvage adenine through this pathway and rely on the de novo pathway for purine synthesis. This variation between normal MTAP+ cells and tumor MTAP-/- cells led to several studies showing that MTAP -/- cells are more sensitive to inhibitors of de novo purine synthesis.Pralatrexate (PDX) is a second generation antifolate that targets dihydrofolate reductase and via conversion to polyglutamylates, inhibits de novo purine synthesis. 6-Thioguanine (6TG), an antimetabolite analog of guanine, also target de novo purine synthesis. MTAP-deficient ALL cells should be more sensitive to these agents, remarkably so in combination. We tested single agent PDX and 6TG as well as a combination treatment in MTAP+ (Molt4) and MTAP-/- (CEM) ALL xenografts. CEM xenografts were more sensitive to PDX treatment than MOLT4 xenografts. CEM xenografts were also much more sensitive to 6TG, while Molt4 xenografts were resistant to 6TG. Early results of the combination of PDX and 6TG in vivo show promise as an effective therapy of MTAP-/- T-cell ALL.']",
        "Doc_id":"AACR_2014-843",
        "Doc_title":" Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination",
        "_version_":1606188980732166144},
      {
        "Meeting_name":" Genotoxic effect and epigenetic alterations induced by the environmental carcinogen dibenzo[a, l]pyrene in oral tissues of mice",
        "Background":"['Oral cancer is the major form of head and neck squamous cell carcinoma, which is the fifth most common cancer worldwide. Tobacco smoking is one of the leading causes of oral cancer. Dibenzo[a, l]pyrene (DB[a, l]P) is the most potent carcinogenic polycyclic aromatic hydrocarbon found in tobacco smoke. Recently we developed a novel mouse model of oral cancer induced by DB[a, l]P; we also showed the remarkable carcinogenicity and specificity of the fjord region diol epoxide metabolite, ()-anti-11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a, l]pyrene (DB[a, l]PDE). Using immunohistochemistry (IHC), we have shown over-expression of p53 protein in mice oral squamous cell carcinoma and dysplastic tissues induced by DB[a, l]P and DB[a, l]PDE. Current understanding of molecular pathogenesis of oral cancer in humans suggests that both genetic and epigenetic alterations are crucial and complement each other. Our hypothesis is that both genetic and epigenetic alterations induced by DB[a, l]P can contribute to the development of oral cancer. P53 protein overexpression detected by IHC may result from p53 gene mutation or exposure to genotoxic stress. To determine whether p53 over-expression is in part due to p53 mutations, Exons 5 to 8 of p53 from 5 tumor tissues were analyzed by polymerase chain reaction single-strand conformation polymorphisms (PCR-SSCP) and direct sequencing. G to T transversion was detected in Exon 5, leading to mutation of codon 155 Arg to Leu; A to T transversion was detected in Exon 7, resulting in mutation of codon 232 Lys to stop codon. To test the epigenetic effect of DB[a, l]P, methylation specific PCR and bisulfate sequencing were used to detect methylation alteration of p16 and RAR- promoters. Promoter hypermethylation of both p16 and RAR- were detected in tumors induced by DB[a, l]PDE; also in oral tissues of mice treated with DB[a, l]P (24nmol, 3 times per week, for 5 weeks, sacrificed at 48 h, 1, 2 and 4 weeks after last dose). These results suggested that genotoxic DNA adducts derived from DB[a, l]P can induce mutations in critical genes, such as tumor suppressor gene p53; this environmental carcinogen also can induce p16 and RAR- promoter hypermethylation at early stage, which can contribute to the promotion and progression of oral carcinogenesis.']",
        "Doc_id":"AACR_2012-5470",
        "Doc_title":" Genotoxic effect and epigenetic alterations induced by the environmental carcinogen dibenzo[a, l]pyrene in oral tissues of mice",
        "_version_":1606189002833002496},
      {
        "Meeting_name":" p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC).",
        "Background":"['Background', '     p16 immunoexpression is considered a surrogate biomarker for the presence of functional Human Papillomavirus oncoprotein E7 in HNSCC. We sought to determine the association between p16 status and response/survival in a prospective phase II clinical trial in patients with HNSCC.  Methods', '     Sixty-three eligible patients with operable stage III/IV HNSCC participated in Eastern Cooperative Oncology Group (ECOG) phase II trial of induction chemotherapy with weekly cetuximab, paclitaxel and carboplatin x 6 followed by  chemoradiotherapy with weekly cetuximab. paclitaxel, carboplatin.  P16 protein expression status was assessed using automated quantitative protein analysis (AQUA). The objectives of this analysis were to determine whether p16 status was correlated with response to treatment, progression-free survival (PFS) and overall survival (OS). Fishers exact tests were used to compare response rates whereas survival distributions were estimated using the Kaplan-Meier method using  log rank test to compare survival curves between p16 categories.  Results', '     The median p16 tumor mask AQUA score was 42.9 (Range=6-491). Of the 63 tumors included in this study, 38 (60.3%) had sufficient tissue for analysis of p16.  Using a cut-off score of 80, 16 out of 38 eligible cases (i.e., 42%) were classified as p16+. Almost 58% of the responders had low p16 tumor mask AQUA scores. However, there was no significant association between p16 status and objective response (p-value=1.00). Moreover, 2-year PFS for p16 high and low categories were, respectively, 0.74 [95% CI (0.53, 0.96)] and 0.58 [95% CI (0.37, 0.79)]. The 2-year overall survival rates for p16 high and low categories were, respectively, 0.81 [95% CI (0.61, 1.00)] and 0.77 [95% CI (0.60, 0.95)].  Conclusions', '    There was no significant association between p16 AQUA status and response/ survival in this small subset of patients treated in the prospective E2303 study.  Large prospective studies will determine the association between p16 status and response to cetuximab in HNSCC.']",
        "Doc_id":"ASCO_83432-102",
        "Doc_title":" p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC).",
        "_version_":1606188974877966336},
      {
        "Meeting_name":" Obesity-induced destabilization of p16INK4A promotes the procarcinogenic effects of breast stromal adipocytes through miR-141/miR-146b-5p-dependent inhibition of leptin.",
        "Background":"['Obesity, a disease linked to increased number of adipocytes in various tissues, is increasingly recognized as a risk factor for the development of breast cancer. However, the molecular basis of adipocyte-related breast carcinogenesis remains elusive. In this study, we established and characterized normal stromal adipocytes from post-plastic surgery of breast tissues from obese and lean women. We have shown that adipocytes from obese women express low level of the tumor suppressor p16 protein, have higher secretion of various adipokines and higher invasion and migration capabilities as compared to adipocytes from lean women. In addition, down-regulation of p16INK4A by shRNA in adipocytes from lean women increased the expression/secretion levels of various adipokines including leptin, activated breast adipocytes and enhanced their migration/invasion abilities. Consequently, media conditioned with p16-deficient adipocytes or adipocytes from obese women promote epithelial-to-mesenchymal-transition in normal breast luminal cells in a leptin-dependent manner and induced tumor growth in vivo. Indeed, p16INK4A suppresses Leptin at the mRNA level through miR-141 and miR-146b-5p, which inhibits Leptin expression through a specific sequence at the Leptin 3UTR. These results show the existence of active adipocytes in the mammary gland of obese women in absence of breast cancer cells and provide the first indication that p16INK4A through targeting miR-141 and miR-146b-5p suppresses Leptin and its procarcinogenic effects. This indicates that p16 pathway has non-cell-autonomous tumor suppressor function in breast stromal adipocytes.']",
        "Doc_id":"AACR_2017-5937",
        "Doc_title":" Obesity-induced destabilization of p16INK4A promotes the procarcinogenic effects of breast stromal adipocytes through miR-141/miR-146b-5p-dependent inhibition of leptin.",
        "_version_":1606188970727702528},
      {
        "Meeting_name":" Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC).",
        "Background":"['Background', ' Human papilloma virus associated oropharyngeal SCC (HPV +ve OPSCC) is a clinically and molecularly distinct disease from HPV-negative HNSCC, with a better prognosis. We sought to determine the relationship between hypoxia, a known adverse prognostic factor in patients with locally advanced HNSCC, and HPV status. Methods', ' Eligible patients had', ' stage III and IV HNSCC treated on phase I and II chemoradiation trials with 70 Gy combined with  tirapazamine  and cisplatin (TPZ/CIS) or cisplatin and 5FU (CIS/5FU); pretreatment hypoxic imaging using FMISO-PET; and known HPV status as determined by p16 immunohistochemistry. Separate analyses were also conducted to consider the impact of TPZ on HPVnegative tumors in the randomized TROG 98.02 trial. Hypoxia was assessed by qualitative scoring of FMISO uptake in both primary tumors and nodes as previously described (J Clin Oncol 24', '2098-2104, 2006). Results', ' 63 patients were included in the analysis. Both p16 +ve OPSCC tumors and p16 -ve HNSCC tumors had a high prevalence of tumor hypoxia (74% and 80%). The distribution of hypoxia (primary, nodal) was also similar.  In patients treated with CIS/5FU there was a trend for worse locoregional control in p16 negative (-ve) hypoxic tumors compared to non-hypoxic tumors, HR= 5.1; 95% CI, 0.62  42.38; p=0.145.  In patients with p16 -ve hypoxic tumors treated on the randomized phase II trial, there was worse locoregional control on CIS/5FU compared to TPZ/CIS. (HR = 25; 95% CI, 3.01  208; p < 0.001) and worse failure-free survival (HR = 4.35, 95% CI, 1.71  11.24; p = 0.003). Only 1 out of 14 p16 +ve patients in either arm of the trial experienced locoregional failure. Conclusions', ' Hypoxia, as measured by FMISO-PET, is frequently present in both p16 +ve and -ve HNSCC.  The presence of hypoxia in p16 -ve patients was predictive of better locoregional control and failure-free survival in patients treated with tirapazamine. Supported by a NHMRC project grant.']",
        "Doc_id":"ASCO_84448-102",
        "Doc_title":" Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC).",
        "_version_":1606189027226025984}]
  }}
